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ABSTRACT 
 
The risk of cardiovascular-related death is several-fold higher in patients with 
chronic kidney disease (CKD) compared with the general population. Arterial 
calcification (AC) is extremely common in patients with CKD and strongly 
associates with cardiovascular-related mortality, however, there are currently no 
specific treatments to prevent its development and/or progression. Abundant 
evidence now suggests that AC is cell-mediated and actively-regulated, involving 
mechanisms linked to bone homeostasis, production of calcification inhibitors and 
vascular smooth muscle cell (VSMC) function.  
The P2X7 receptor (P2X7R) is an ATP-sensitive cation channel which has been 
implicated in several biological processes, in non-vascular contexts, thought to be 
important in the aetiology of AC. In addition, disruption to the normal function of 
some enzymes involved in ATP metabolism has been shown to contribute to AC, 
although little is known about their role in CKD-related arterial calcium deposition. 
The work in this thesis tested the primary hypothesis that P2X7R contributes to the 
pathogenesis of CKD-associated AC. Preliminary work was also conducted to 
examine the expression of components of the ATP-metabolising system in this 
clinical setting. 
P2X7R expression was confirmed in human and rodent vascular smooth muscle but 
was un-affected by calcification. In vitro, the P2X7R-specific antagonist, A438079, 
did not influence calcium deposition occurring in the presence of human VSMCs or 
segments of rat aorta exposed to ‘calcification-promoting’ medium. Calcification of 
cultured rat aorta was also not influenced by a second P2X7R-specific antagonist, 
A839977, or by BzATP (a receptor agonist). Aortic rings from mice deficient in 
P2X7R calcified to a similar extent to wild-type controls in vitro. 
A novel, adenine-based mouse model was developed to evaluate the effect of P2X7R 
gene deficiency on CKD-associated AC in vivo. However, the number of mice 
exhibiting AC in the final experiment was too low to draw any firm conclusion. 
Therefore, rats were fed an adenine-containing, high phosphate diet for 4 weeks (to 
iii 
  
induce CKD and AC) and administered a selective P2X7R antagonist, twice daily, 
throughout this period. Pharmacological blockade of P2X7R did not influence the 
magnitude of aortic calcification in this model. 
Quantification of mRNA performed on tissue obtained from the in vivo rat 
experiment suggested that VSMC-specific markers are down-regulated in calcified 
arteries, although VSMC osteogenic transformation, which is widely reported in the 
literature to occur in the context of AC, was not detected. Expression of the 
apoptosis marker, caspase-3, was increased in calcified arteries in vivo. P2X7R 
blockade did not influence any of these changes in mRNA expression. 
Expression of mRNA for ENPP-1, an ATP-metabolising enzyme responsible for the 
generation of the calcification inhibitor, pyrophosphate (PPi), was significantly 
increased in calcified arteries from CKD rats. Functional activity of ENPP-1 was 
also increased in these vessels. The expression of mRNA for other components of 
the ATP-metabolising system was also in keeping with an attempt by VSMCs to 
generate more PPi, possibly as an adaptive, defensive response to uraemic, 
calcification-promoting factors. Furthermore, an increase in ENPP-1 mRNA 
expression was detected in calcified inferior epigastric arteries from patients with 
end-stage renal disease (extracted at the time of kidney transplantation). 
In summary, P2X7R does not appear to contribute to the pathogenesis of CKD-
associated AC, although this should be confirmed in experimental models which 
more closely simulate human disease. Arterial expression of enzymes involved in the 
metabolism of ATP does seem to change in AC. Future work should therefore focus 
on gauging the clinical relevance of this in order to better understand the 
mechanisms underlying the disease and potentially develop new therapeutic 
interventions. 
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CHAPTER 1 – INTRODUCTION 
PART 1 - Chronic Kidney Disease-Associated Arterial Calcification 
1.1 Chronic Kidney Disease Is Associated With Increased Cardiovascular Risk 
Chronic Kidney Disease (CKD) is a global health problem with an estimated 
prevalence of 12% in developed countries (Levey et al 2011, Levey & Coresh 2012). 
Cardiovascular events are the leading cause of death in patients with CKD 
(Angelantonio et al 2010) and those on renal replacement therapy (RRT) (Pruthi et 
al 2014). Moreover, renal impairment is associated with a marked increase in 
cardiovascular risk compared with the general population (Tonelli et al 2006) and 
this risk continues to increase as glomerular filtration rate (GFR) declines (Go et al 
2004). Scoring systems which use traditional ‘Framingham’ risk factors (Dawber et 
al 1957, Dawber et al 1959) to predict the likelihood of a cardiovascular event 
consistently produce underestimates in patients with CKD (Weiner et al 2007) and 
accordingly the concept of ‘renal specific’ risk factors has emerged. A number of 
these non-traditional risk factors have been proposed (Baigent et al 2000) and 
include chronic inflammation, volume overload, elevated parathyroid hormone 
(PTH), anaemia, ‘uraemic toxins’, hyperhomocysteinaemia, hyperphosphataemia 
and, perhaps most importantly, arterial calcification (AC). 
1.2 Arterial Calcification In Patients With Chronic Kidney Disease 
AC is highly prevalent in patients with CKD and can occur in the intimal or medial 
layers of the vessel wall (Amann 2008). Intimal calcification occurs in the context of 
atherosclerotic disease in a fashion identical to that seen in the general population 
and is associated with the numerous, well-established risk factors known to promote 
this process (Dawber et al 1957, Dawber et al 1959). Calcification of the arterial 
media is much more specific, although not unique, to patients with CKD (Amann 
2008). 
AC is linked to adverse health outcomes and numerous studies have shown that the 
severity of AC predicts survival, with higher calcification scores associated with 
increased mortality in both dialysis (London et al 2003) and pre-dialysis patients 
(Chiu et al 2010). In the case of intimal calcification this observation is hardly 
surprising given that it is directly related to atherosclerotic disease. However, medial 
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AC leads to decreased arterial compliance, an increase in pulse-wave velocity 
(PWV) and an associated increase in cardiac afterload (London et al 2003, Sigrist et 
al 2007, Sutliff et al 2011), which may also contribute to this increase in 
cardiovascular risk.  
AC also contributes to profound morbidity in patients with end-stage renal disease 
(ESRD). AC of the iliac vessels frequently precludes successful kidney 
transplantation because of the difficulty posed in forming donor-recipient arterial 
anastomoses and, similarly, creation of arterio-venous fistulae can be complicated in 
patients requiring haemodialysis (HmD). In addition, AC contributes to the 
devastating and often fatal condition calciphylaxis (calcific uraemic arteriolopathy) 
(Adrogue et al 1981). 
1.3 The Aetiology Of Arterial Calcification 
Calcification of the arterial intima, as discussed above, is associated with 
atherosclerosis. The pathogenesis of this form of vascular disease is relatively well 
established and known to involve lipid accumulation, inflammatory cell infiltration 
and plaque formation (Weber & Noels 2011). In contrast, the mechanisms 
contributing to arterial medial calcification are much less well understood but seem 
to be different to those involved in atheroma because lipid and inflammation are 
consistently absent in these lesions and calcification can occur independently at this 
site (Shanahan et al 1999, Shroff et al 2008). This form of disease is the focus of this 
thesis and all subsequent reference to AC relates to calcium deposition within the 
medial layer of the vessel wall. 
1.3.1 AC is not simply the result of passive mineral deposition. 
The traditionally held view was that AC occurred in patients with CKD when the 
circulating concentrations of calcium and phosphate were elevated to such a degree 
so as to ‘supersaturate’ serum, with the consequent passive deposition of both in the 
walls of blood vessels. However, AC is frequently seen in patients with ‘normal’ 
circulating levels of these ions such as in the setting of diabetes (Shanahan et al 
1999) and/or aging (Allison et al 2004), and not all patients with 
hyperphosphataemia develop AC (Parfitt 1969, Amann 2008). Therefore intuitively 
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the pathogenesis must be more complex than the explanation offered by this simple 
‘passive-deposition’ model. 
The ‘passive-deposition’ theory also falls down when one considers the normal 
process of bone formation. In this tissue, on-going mineralisation manifesting as 
hydroxyapatite deposition (which is also the most common form of mineral detected 
in AC (Schliper et al 2010)), occurs in an organised fashion without the requirement 
of elevated serum calcium and phosphate concentrations. This suggests that 
conditions and/or adaptations in the local environment, rather than the absolute 
concentration of the relevant circulating ions, determine whether calcification 
develops.  In addition, there are now several described genetic disorders that result in 
abnormal calcification of the vasculature without disturbances in serum calcium and 
phosphate balance (Rutsch et al 2003, St Hilaire et al 2011, Nitschke et al 2012, 
Eytan et al 2013).  
The implication from these observations is that ‘non-passive’ factors must contribute 
to the pathogenesis of AC. As will now be reviewed, this concept has led to a recent 
explosion of research into the possible factors governing the development and 
progression of ectopic arterial calcium deposition. 
1.4 Methods Used To Study Arterial Calcification 
Before discussing the current theories pertaining to the pathogenesis of AC it is 
important to outline the various experimental systems employed to study the disease. 
In vitro and in vivo models have been developed, each with distinct advantages and 
drawbacks.  
1.4.1 Cell and tissue culture models. 
As expanded upon below, the vascular smooth muscle cell (VSMC) has emerged as 
a ‘key player’ in the development of AC and in vitro models used frequently involve 
the culture of this cell type. In culture, VSMCs are described to form nodules which 
spontaneously calcify over a number of weeks (Proudfoot et al 1998). When the 
concentration of phosphate and/or calcium of the culture medium is increased, 
calcification is reported to occur more rapidly and in association with matrix vesicles 
(MVs) released from the cell (Reynolds et al 2004).  
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Although VSMCs in culture can secrete matrix (Underwood & Whitelock 1998, 
Reynolds et al 2004), they lack their normal extracellular architecture. In particular, 
the elastic lamina is absent in vitro, which in vivo is the initial site of medial AC 
(Lanzer et al 2014). Ex vivo arterial ring culture models offer an alternative approach 
to overcome this issue (Lomashvili et al 2004, Shroff et al 2010). Here, segments of 
artery are removed from either animals or humans and cultured in a similar fashion 
to VSMCs. Owing to the fact that tissue is intact in this system, it is thought to better 
simulate ‘real life’ conditions. Furthermore, when VSMCs are placed in culture they 
lose their contractile properties usually present in vivo and simultaneously change 
expression profiles of some genes (Nakano-Kurimoto et al 2009). Ring culture 
models are thought to also minimise this effect (Lomashvili et al 2004). 
1.4.2 Rat models. 
In rats, AC can be induced by CKD-independent or -dependent mechanisms. For 
investigating CKD-associated AC there are 3 main rat models in common use – the 
5/6
th
 nephrectomy model, the Cy/+ rat and the adenine nephropathy model. A brief 
account of the non-CKD models will first be given before expanding upon these 
CKD-dependent systems. 
1.4.2.i Non-CKD rat models. 
In the absence of renal injury AC has successfully been induced by the 
administration of warfarin (Price et al 1998), owing to its antagonism of vitamin K, 
which is required to activate the calcification inhibitor matrix gla-protein (MGP) 
(Hao et al 1995) (see section 1.5.3.ii). High-dose vitamin D can also be injected into 
rats with the effect of causing widespread AC (Fleisch et al 1965). A more invasive 
method of producing AC was described by Basalyga et al (2004) whereby the aorta 
was surgically exposed and calcium chloride directly applied for 15 minutes using a 
pre-soaked gauze.  
1.4.2.ii The 5/6
th
 nephrectomy model. 
The 5/6
th
 nephrectomy model usually involves a two-stage surgical procedure 
whereby a partial nephrectomy of one kidney is performed, followed by a 
contralateral total nephrectomy some days later (Chauntin & Ferris 1932). This 
reduction in functional renal mass is enough to induce the serum biochemical 
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changes of CKD such as elevations in creatinine, urea and phosphate, but rarely 
leads to arterial calcium deposition (Shobeiri et al 2010). AC can be induced in this 
model by the addition of a high phosphate diet. The normal dietary phosphate 
content for rats is around 0.5% (Haut et al 1980). If this is increased to at least 0.9%, 
some rats, but not all, will develop AC over 3-6 months (Neven & D’Haese 2011). 
Additional daily administration of vitamin D to animals on this regime has been 
reported to bring calcification rates closer to 100% (Haffner et al 2005).  
1.4.2.iii The Cy/+ rat. 
The heterozygous Cy/+ rat develops autosomal dominant polycystic kidney disease 
(ADPKD) and by around 9 months of age displays all the biochemical features of 
advanced CKD (Kaspareit-Rittinghausen et al 1990). AC was induced in this model 
by Moe et al (2008). These investigators fed a 0.7% phosphate-containing diet to 
male Cy/+ rats and observed high-turnover bone disease and AC in 60% of these 
animals at 38 weeks. Interestingly, no calcification was observed at 34 weeks.  
1.4.2.iv The adenine nephropathy model. 
The third rat model involves the dietary administration of adenine. This model 
closely resembles the human disease, adenine phosphoribosyltransferase (APRT) 
deficiency - a rare, autosomal recessive disorder which can result in ESRD if 
untreated (Bollee et al 2010). Adenine is usually metabolised by the enzyme APRT 
to generate adenosine mono-phosphate (AMP) (Hori & Henderson 1966). As a 
consequence of this reaction the concentration of circulating adenine is usually 
maintained at a very low level. However, if present in sufficiently high amounts, (a 
diet containing 0.75% adenine is commonly administered), the excess load will 
cause the enzyme to become saturated. Under these circumstances adenine is 
metabolised by xanthine oxidase to yield the product 2,8-dihydroxyadenine which is 
relatively insoluble at urinary pH and therefore precipitates out in the tubular lumen 
causing obstruction, fibrosis and ultimately advanced renal impairment (Yokozawa 
et al 1986, Okada et al 1999). High-turnover bone disease is also a feature of this 
model (Katsumata et al 2003).  
If used in combination with a high phosphate diet, some rats fed this regime will 
develop AC over 4 weeks (Shobeiri et al 2010, Neven & D’Haese 2011). However, 
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many of the early studies that employed this model reported high variability with 
some animals developing extensive AC but calcium deposition undetectable in 
others. In this regard a major advance was made by Price et al (2006) who combined 
the 0.75% adenine/high phosphate regime with a low (2.5%) dietary protein content. 
This had the unexpected effect of inducing extensive aortic calcification in all 
animals. The mechanism underlying this observation is unclear but may involve a 
higher bioavailability of phosphate due to less of the ion being bound to protein 
(Neven & D’Haese 2011).  
1.4.3 Mouse models. 
1.4.3.i Non-CKD models. 
A number of murine models of AC are described in mice with targeted genetic 
deletions. Examples include animals with a specific knockout (KO) of genes 
encoding apolipoprotein E (apoE) (Jawein et al 2004), low-density lipoprotein 
receptor (LDLR) (Ishibashi et al 1994), MGP (Luo et al 1997), ecto-nucleotide 
pyrophosphatase/phosphodiesterase-1 (ENPP-1) (Sali et al 1999) and fetuin A 
(Schafer et al 2003). The apoE and LDLR KO animals actually develop 
atherosclerotic calcification and are therefore less useful for studying medial disease. 
The others have deletions in genes encoding calcification inhibitors (see section 
1.5.3). 
1.4.3.ii CKD model. 
To investigate AC due to CKD, only one mouse model has been described to date 
(El-Abbadi et al 2009). This involves a two-stage surgical reduction of renal mass 
(5/6
th
 nephrectomy) in adult, female, DBA/2 mice, followed by an extended period 
of high phosphate feeding. In the original report by El-Abbadi et al (2009) the 
majority of mice exhibited extensive medial aortic calcification with typical 
biochemical features of advanced renal disease after 3 months. Interestingly, these 
authors reported that female mice developed aortic calcification much more readily 
than males, hence the exclusive use of this gender. These investigators have also 
shown that high-turnover bone disease occurs in this model (Lau et al 2012a). 
The DBA/2 strain of mouse used in this model appears to be critical as it is prone to 
cardiovascular calcification whereas other commonly employed strains such as the 
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C57Bl/6 are reported to be resistant (Eaton et al 1978). The mechanism underlying 
this strain difference has been partially elucidated. Using quantitative trait locus 
analysis, a number of relevant loci have been mapped with the major contributor 
(Dyscalc1) located on chromosome 7 (Ivandic et al 2001). The causative gene was 
subsequently found to be Abcc6 (which encodes the ATP-binding cassette 
transporter ABCC-6).  Mice prone to calcification display reduced levels of this 
protein (Meng et al 2007). 
1.5 The Pathogenesis Of Arterial Calcification 
There is now overwhelming evidence to indicate that AC involves the non-passive 
deposition of mineral and that it is a cell-mediated and regulated process. A number 
of mechanisms have been implicated in the pathogenesis and those which have been 
consistently advanced in the literature are now discussed. It should be noted however 
that for the majority of these pathways much controversy and divided opinion still 
exists within the scientific community regarding their relevance and role in 
mediating AC. A summary of these mechanisms is shown in Figure 1.1. 
1.5.1 The role of the VSMC. 
1.5.1.i Links with bone formation. 
Although a number of cell types have been shown to contribute to AC (Shanahan et 
al 2011), the VSMC is now considered to be fundamentally important. VSMCs are 
of mesenchymal origin and display a continuum of plasticity in their phenotype, 
ranging from a contractile state at one end to a synthetic entity at the other. This 
latter state is characterised by the ability of the cell to proliferate and secrete growth 
factors and extracellular matrix (ECM) (Rensen et al 2007).  
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Techniques such as transmission electron microscopy (TEM) (Schlieper et al 2010) 
and magnetic resonance spectroscopy (MRS) (Duer et al 2008) have revealed that in 
man, arterial mineral deposits frequently take the form of hydroxyapatite in a 
structure that very closely resembles the architecture of bone. In keeping with these 
observations, a number of in vitro studies (reviewed in Shanahan et al 2011) have 
reported that, when cultured in calcification-promoting (high phosphate) conditions, 
VSMC phenotype switches from the contractile state to take on characteristics more 
typically associated with bone-forming, (i.e. synthetic and secretory), osteoblast-like 
cells. This so called ‘osteogenic transformation’ is usually inferred by detecting a 
decrease in messenger ribonucleic acid (mRNA) and/or protein for VSMC-specific 
markers such as alpha-smooth muscle actin (α-SMA) and smooth muscle-22 (SM-
22) (Proudfoot & Shanahan 2012) in association with an increase in osteogenic 
transcription factors such as runt-related transcription factor-2 (runx-2) (Komori et al 
1997, Ducy et al 1997) and osterix (Nakashima et al 2002) and/or other bone-related 
proteins including bone morphogenetic protein (BMP) -2 (Celil et al 2005). 
Similar findings have also been reported by some groups using in vivo models. For 
example, using immunohistochemistry to assess aortas taken from 5/6
th
 
nephrectomised mice, Pai et al (2011) reported decreased and increased staining in 
calcified vessels for SM-22 and runx-2, respectively. In humans, increased staining 
for runx-2 and other bone-related proteins has been reported in calcified vessels 
taken from patients with ESRD (Moe et al 2002, Shroff et al 2008). 
It is thought that phosphate plays a key role in mediating VSMC osteogenic 
transformation. In vitro studies have suggested that VSMCs up-regulate runx-2 when 
cultured in high phosphate conditions and that this occurs in a dose-dependent 
manner (Jono et al 2000). Intracellular uptake of phosphate through the sodium-
dependent co-transporters PiT-1 and PiT-2 is thought to be vital to this pathway 
because cell and animal studies in which these proteins were knocked-down showed 
suppression of both runx-2 expression and calcium deposition (Li et al 2006, 
Crouthamel et al 2013). 
How phosphate brings about these cellular changes is unknown. One group have 
implicated activation of extracellular-signal-regulated kinase (ERK) 1/2 as a possible 
mechanistic pathway because up-regulation of runx-2 occurred in parallel with 
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increased phosphorylation of this protein in murine VSMCs exposed to high 
phosphate in vitro. Inhibition of ERK1/2 phosphorylation prevented this effect 
(Speer et al 2009). Other potential phosphate-induced mechanisms include 
increasing SM-22 methylation (Montes de Oca et al 2010) and an elevation in 
reactive oxygen species (Zhao et al 2011). 
1.5.1.ii VSMC apoptosis and release of MVs. 
Some studies have implicated apoptosis as an important mechanism in driving the 
development of AC. Cultured VSMCs undergo apoptosis in calcification-promoting 
conditions and apoptotic bodies are thought to act as nucleation sites for mineral 
attachment and crystal expansion (Proudfoot et al 2000). Increased apoptosis has 
been demonstrated in calcified arteries taken from patients with CKD (Shroff et al 
2008) and apoptosis inhibitors have been shown to reduce AC in an ex vivo model 
(Shroff et al 2010).  
Elevated extracellular calcium is thought to be an important driver of apoptosis in 
this context. VSMCs undergo enhanced apoptosis when cultured in an elevated 
concentration of calcium and the apoptotic bodies formed calcify to a greater extent 
when the environment is rich in this ion (Proudfoot et al 2000). In this study by 
Proudfoot et al, phosphate appeared to exert a synergistic effect in mediating 
apoptosis. This may be due to phosphate-induced suppression of the anti-apoptotic 
factor, growth arrest-specific protein 6 (Son et al 2006). 
Another early event in the development of AC is thought to be the release of MVs by 
VSMCs. MVs are membrane-bound sacs containing pre-formed hydroxyapatite 
which, in a similar fashion to apoptotic bodies, can serve as nucleation sites for 
hydroxyapatite growth (Reynolds et al 2004). In non-calcified states VSMCs still 
seem to contain MVs but here the vesicles are loaded with calcification inhibitors 
such as fetuin A (Reynolds et al 2005). The combination of suppressed inhibitor 
levels (see section 1.5.3) and elevated extracellular calcium appear to confer the 
property of ‘calcification-competence’ on these MVs. 
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1.5.2 AC is related to bone health. 
Over recent years a number of studies have consistently reported an inverse 
relationship between bone health and AC. In both the general population and in those 
with osteoporosis, bone mineral density (BMD) has been shown to negatively 
correlate with extra-osseous mineralisation (see Persy & D’Haese 2009). A 
connection with rarer bone disorders such as Paget’s disease has also been suggested 
(Laroche & Delmotte 2005). A similar association seems to exist in CKD, although 
as detailed below, the spectrum of bone disease is more complex in this clinical 
setting, encompassing more than isolated alterations in BMD. 
In recognition of the fact that in a number of observational studies investigating 
patients with renal impairment, disturbances in mineral homeostasis were closely 
linked not only to bone health, but also to arterial disease in the form of ectopic 
calcification, in 2006 the Kidney Disease Improving Global Outcomes (KDIGO) 
group coined the term ‘Chronic Kidney Disease-Mineral Bone Disorder’ (CKD-
MBD) (Moe et al 2006). This is defined as the presence, in a patient with CKD, of at 
least one of the following: 
1. Abnormalities in serum phosphate, calcium, PTH or vitamin D. 
2. Abnormalities of bone turnover, mineralisation, volume, linear growth or 
strength. 
3. Vascular or other soft tissue calcification. 
Although the paradigm of CKD-MBD has now been adopted by the renal 
community it must be borne in mind that a definitive link between bone and AC has 
yet to be proven (Persy & D’Haese 2009).  
As implied by the second component of the CKD-MBD definition above, several 
elements of normal bone homeostasis can be disturbed in patients with renal 
dysfunction. Which of these processes is most closely related to AC is unknown. 
Low bone turnover has been found to associate with AC by some groups (London et 
al 2004, Tomiyama et al 2010) whilst others have found a link with both high- and 
low-turnover states (Barreto et al 2008, Asci et al 2011). Experimentally, correction 
of the low-turnover state in CKD mice, achieved by administration of BMP-7, 
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resulted in an attenuation of AC (Davies et al 2005). The study by Tomiyama et al 
(2010) also reported an inverse relationship between AC and bone density and 
volume. Other groups have also found AC to negatively correlate with bone volume 
(Barreto et al 2008, Adragao et al 2009). 
1.5.3 Inhibitors of calcification. 
A number of calcification inhibitors are produced in vivo to protect against unwanted 
ectopic mineral deposition in sites such as the cardiovascular system. Possibly the 
one that has received most attention is inorganic pyrophosphate (PPi) which is 
discussed in depth in Part 2 of this chapter. Other inhibitors that have been studied in 
some detail include fetuin A and MGP. 
1.5.3.i Fetuin A. 
Fetuin A is a protein synthesised in the liver and is present in extracellular tissue as 
well as in high concentrations in plasma. The molecule strongly binds calcium and 
phosphate and is thought to act as a scavenger of these ions to prevent calcification 
(Jahnen-Dechent et al 2011). In keeping with this theory, fetuin A KO mice display 
widespread extra-skeletal mineral deposits (Schafer et al 2003, Jahnen-Dechent et al 
2011).  
Serum fetuin A appears to be suppressed in patients with ESRD (Ketteler et al 2003) 
but not early stages of CKD (Ix et al 2006). In a cross-sectional study of dialysis 
patients Ketteler et al (2003), found an association between lower circulating fetuin 
A and cardiovascular mortality. Whether this finding is related to inhibition of 
calcification is not clear, however some studies have found an inverse correlation 
between plasma fetuin A levels and AC in patients with CKD (Moe et al 2005, Koos 
et al 2009).  
1.5.3.ii MGP. 
MGP is a vitamin K-dependent protein present in bone and the vasculature (Hao et al 
1995). As noted above, rodents treated with the vitamin K antagonist, warfarin, 
develop AC (Price et al 1998) and MGP KO mice exhibit widespread ectopic 
mineral deposition (Luo et al 1997). In humans, a mutated form of MGP occurs in 
Keutal’s syndrome (Munroe et al 1999), a rare autosomal recessive disorder in 
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which AC is a feature, albeit relatively mild (Meier et al 2001). MGP is reported to 
be up-regulated in calcified arteries taken from uraemic rats, possibly as a protective 
response, although the exact mechanism through which it inhibits AC remains 
uncertain (Lomashvili et al 2011). Patients with CKD are vitamin K-deficient 
(Holden et al 2010) and treatment with vitamin K reduces AC in uraemic rats 
(McCabe et al 2013). Together these findings suggest that CKD is, in effect, a state 
of functional MGP deficiency. 
1.5.4 Degradation and remodelling of the ECM. 
Microscopic evaluation of the early stages of AC has indicated that mineral 
deposition initially occurs on elastin fibres in the ECM (Lanzer et al 2014, O’Neill & 
Adams 2014). Elastin has a propensity to bind calcium and phosphate (Urry 1971) 
and increasing evidence suggests that integral and structural disruption of this 
molecule within the ECM contributes to AC (Pai & Giachelli 2010).  
Matrix metalloproteinases (MMPs) -2 and -9 and cathepsin S are enzymes capable of 
degrading elastin (Chow et al 2007). In vivo studies have indicated that genetic 
deficiency of any of these proteins can protect against arterial calcium deposition 
(Basalyga et al 2004, Aikawa et al 2009). Using the Cy/+ rat model, Chen et al 
(2011) showed an increase in activity of both MMP-2 and MMP-9 in CKD and that 
blocking enzyme activity pharmacologically reduced calcification in an ex vivo 
model. Up-regulation of MMP-2 was also detected in arteries taken from patients 
with CKD compared with controls (Ada et al 2009) and this correlated with both the 
degree of elastin fibre disorganisation and detectable calcification. In the murine 
model of CKD-associated AC, fragmentation and disruption of elastin were seen to 
occur prior to the onset of calcification (Pai et al 2011). 
Interestingly some authors have also shown that elastin fragments can induce VSMC 
osteogenic transformation in vitro even in the absence of increased phosphate 
(Simionescu et al 2005). When high phosphate conditions are present, calcification 
is accelerated in the presence of elastin degradation products (Hosaka et al 2009). 
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1.6 Current Treatment Options For Arterial Calcification 
At present there are no treatments available to specifically prevent or attenuate the 
progression of AC. Cholesterol-lowering agents are of proven efficacy for reducing 
atherosclerosis-related mortality in those at risk in the general population (Baigent et 
al 2005) and this benefit seems to be maintained in patients with CKD (Baigent et al 
2011) although probably not in those on dialysis (Wanner et al 2005, Fellstrom et al 
2009). The utility of these agents in kidney transplant (TP) recipients is currently 
uncertain (Palmer et al 2014). Beta-blockers and agents that inhibit the renin-
angiotensin-aldosterone system may also confer some cardiovascular protection in 
selected patients with CKD although large, randomised, prospective studies using 
patient-centred outcomes are lacking (Kidney Disease: Improving Global Outcomes 
(KDIGO) CKD Work Group 2013). 
Although AC is not simply a function of circulating concentrations of phosphate and 
calcium, as demonstrated experimentally in the studies discussed previously (section 
1.5), these ions are clearly able to contribute to ectopic mineralisation. These 
observations, coupled with the apparent link between bone health and AC, have led 
many to investigate whether correcting phosphate and calcium biochemistry in 
patients with CKD will influence the development and/or progression of arterial 
calcium deposition. 
Phosphate-binding agents are commonly prescribed to patients with ESRD in an 
attempt to limit intestinal absorption of this ion and a number of studies have 
evaluated the influence of these compounds on AC. Phosphate-binders can be either 
calcium-containing or non-calcium-containing and a major issue that has recently 
come to light is the excess calcium burden caused by administration of the former 
class of compound. Many studies have indicated that calcium-containing binders 
lead to a more rapid progression of AC compared with non-calcium-containing 
agents (Chertow et al 2002, Block et al 2005, Russo et al 2007) and moreover, a 
recent meta-analysis demonstrated that calcium-containing compounds were also 
associated with a higher mortality rate (Jamal et al 2013).  
In fact, whether phosphate-binders are beneficial at all is uncertain. No prospective 
trial has ever been performed to determine whether these agents confer a survival 
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benefit compared with placebo. A prospective trial which evaluated both calcium-
based and non-calcium-based phosphate binders in patients not yet on RRT 
suggested that whilst these agents do lower serum phosphate, they may actually lead 
to increased AC (Block et al 2012). It should be noted that progression of AC was 
not the primary outcome in this study and patient numbers were relatively small. In 
addition, the greatest risk for AC seemed to be in the group taking calcium-based 
drugs. However, the findings highlight the urgent need for trials addressing patient-
level outcomes. At present most clinicians would still advocate the use of phosphate-
binders for patients with hyperphosphataemia although it is likely that prescriptions 
of calcium-based agents will now fall. 
Calcimimetic drugs such as cinacalcet, effectively reduce serum PTH and also 
suppress calcium and phosphate levels (Quarles et al 2003, Block et al 2004). These 
agents have been shown to reduce AC in rats with CKD (Kawata et al 2008, Henley 
et al 2009). The ADVANCE trial (Raggi et al 2011) compared the effect of cinacalet 
plus low dose vitamin D with vitamin D therapy alone, on the progression of AC in 
patients on HmD. The primary outcome measure in this trial was progression in 
density of AC and this did not reach statistical significance. However, when AC was 
measured volumetrically, cinacalcet retarded progression. In the EVOLVE trial 
(Chertow et al 2012), cinacalcet led to a non-significant reduction in the primary 
composite end-point of cardiovascular events and death compared with placebo. The 
effect reached statistical significance after correcting for baseline characteristics. 
A number of other interventions which aim to minimise phosphate and/or calcium 
loading are currently recommended by KDIGO (Kidney Disease: Improving Global 
Outcomes (KDIGO) CKD–MBD Work Group 2009). Logically they would all seem 
to be beneficial, although none have been evaluated in long-term, randomised, 
controlled trials. Suggested measures include restricting dietary intake of phosphate, 
optimising dialytic phosphate removal, minimising dialysate calcium concentrations 
and avoiding excessive vitamin D therapy. 
Despite theoretical advantages of these interventions they remain non-specific to AC 
and whilst some may possibly slow progression of the disease, there is currently no 
way of inhibiting the process altogether.  Based on what is known about the 
pathogenesis of AC a number of potential therapeutic agents are currently in the 
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early stages of investigation. Examples of these include vitamin K (Krueger et al 
2013) and sodium thiosulphate (Adirekkiat et al 2010). As will now be discussed, 
there are a number of reasons to consider evaluating various components of the 
purinergic system as potential targets for therapy. 
PART 2 - Adenosine Tri-Phosphate And Arterial Calcification 
1.7 An Overview Of The Purinergic System 
The ability of adenosine tri-phosphate (ATP) to exert physiological effects in the 
mammalian heart, in addition to its role as the main cellular energy source, was first 
recognised almost a century ago in the seminal work of Drury and Szent-Gyorgi 
(1929). The extracellular ATP receptor system, known collectively as the purinergic 
system, was first predicted by Burnstock in the 1970s and is now well-characterised 
(Burnstock 2006, Burnstock 2012). It has been implicated in a number of biological 
processes and disease states, well illustrated by the therapeutic role of the P2Y12 
antagonist, clopidogrel, in the treatment of myocardial infarction (Sabatine et al 
2005). 
Two broad categories of purinergic receptors have been identified on a wide range of 
cells (see Burnstock 2012 for an in-depth review and historical perspective). P1 
receptors are G protein-coupled and respond primarily to adenosine.  Four subtypes 
have been described to date, A1, A2A, A2B and A3. P2 receptors are principally 
activated by tri- and di-nucleotides and are classified as either P2X or P2Y. P2X 
receptors are ion-gated channels consisting of 3 subunits, 7 subtypes are currently 
recognised (P2X1-7). P2Y receptors are G protein-coupled with 8 subtypes currently 
known (P2Y1, 2, 4, 6, 11-14). Receptors are numbered according to the order in 
which they were discovered. The dis-continuous P2Y numbering system is because 
some receptors were initially assigned to this group but subsequently identified as 
either species homologues or as belonging to an alternative receptor family.  
The availability of extracellular nucleotides for activation of these receptors is tightly 
regulated by a number of enzymes, the ecto-nucleotidases, which catalyse the 
metabolism of ATP and related molecules (Figure 1.2) (Zimmermann et al 2012). 
There are 4 broad categories of enzymes in this class. Ecto-nucleoside triphosphate 
diphosphohydrolases (NTPDases), of which there are 8, including CD39 (NTPDase-
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1), hydrolyse ATP to yield AMP plus 2 phosphates (Kaczmarek et al 1996). In 
contrast, the ecto-nucleotide pyrophosphatase/phosphodiesterases (ENPPs), of which 
there are 7 with ENPP-1 being the best characterised and studied (Terkeltaub 2001, 
Mackenzie et al 2012), generate AMP plus inorganic PPi from hydrolysis of ATP.  
Figure 1.2. The Purinergic System and its Regulation of AC in VSMCs. 
P2X receptors are ion channels composed of 3 subunits and P2Y receptors are G-protein 
coupled. The expression of P2X receptors 1, 4 and 7 and P2Y receptors 2, 4, 6 and 12 has 
been demonstrated on VSMCs and the preferred agonists for these receptors are shown. 
Additionally, Up
4
A has recently been implicated to promote arterial calcification via 
signalling through P2Y2 and P2Y6 receptors. VSMCs also express adenosine A2 receptors 
(not shown). 
 
ATP and other ligands for P2X and P2Y receptors gain access to the extracellular space in a 
number of ways (see text). ATP is hydrolysed by either CD39 (ecto-nucleoside triphosphate 
diphosphohydrolases (NTPDases)) into AMP plus 2 phosphates (Pi), or by ecto-nucleotide 
pyrophosphatase/phosphodiesterases (ENPPs) into AMP plus inorganic pyrophosphate 
(PPi). AMP is hydrolysed into adenosine (Ad) and Pi by CD73 (ecto-5’-nucleotidase). PPi 
can also reach the extracellular space from within the cell through the putative membrane 
transporter ANK (ankylosis) protein. PPi is subsequently hydrolysed into Pi by tissue non-
specific alkaline phosphatase (TNAP). 
 
PPi is a potent inhibitor of calcification, however it is also the substrate for generation of Pi 
by TNAP and subsequent hydroxyapatite formation. The balance between ENPP1 and 
TNAP activity is therefore critical in determining whether calcification pursues. Autosomal 
recessive mutations in ENPP1 cause arterial calcifications in infancy and autosomal 
recessive mutations in CD73 cause arterial calcifications in adulthood. 
 
UTP: Uridine-5'-tri-phosphate; UDP: Uridine-5'-di-phosphate. 
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This family of enzymes can alternatively hydrolyse ATP to generate adenosine di-
phosphate (ADP) and subsequent AMP with phosphate side-products, although this 
reaction occurs much less readily than that of PPi generation. PPi is a potent 
inhibitor of hydroxyapatite formation (Fleisch et al 1965), and thus tissue 
calcification, but can be converted to phosphate by the action of the enzyme tissue 
non-specific alkaline phosphatase (TNAP) (Murshed et al 2005), thereby promoting 
mineralisation. Intracellular PPi may also be secreted via the ankylosis protein 
(ANK) (Terkeltaub 2001). AMP is converted to adenosine by the action of ecto-5’-
nucleotidase (CD73), which also generates one phosphate molecule (Arch & 
Newsholme 1978). 
1.7.1 Potential sources of extracellular ATP. 
ATP release from erythrocytes (Bergfeld & Forrester 1992) and perivascular nerves 
(Lew & White 1987) has been described. With respect to the cardiovascular system 
specifically, studies have shown that endothelial cells (Bodin & Burnstock 1996) and 
VSMCs (Katsuragi et al 1991) are able to contribute directly to extracellular ATP 
levels. Proposed mechanisms of release from these cells include vesicular 
exocytosis, ATP-binding cassettes, and connexin and pannexin hemi-channels. In 
addition, direct cell surface synthesis of ATP by F1/F0-ATP synthase has been 
proposed (Lohman et al 2012). 
1.8 Purinergic Receptor-Mediated Calcification 
The expression of P2 receptors in VSMCs has been investigated and the presence of 
P2X1, P2X4 and P2X7 has been demonstrated, along with P2Y2, P2Y4, P2Y6 and 
P2Y12. Of the P1 sub-family, A2 receptors are the main receptors present in the 
arterial media (Wang et al 2002, Wang et al 2003, Erlinge & Burnstock 2008, 
Burnstock 2009, Schuchardt et al 2011) (Figure 1.2). 
1.8.1 P2Y receptors. 
P2Y receptors have been directly implicated in the process of AC. Schuchardt and 
colleagues (2012) were able to show enhanced calcification of both cultured rat 
VSMCs and the medial layer of rodent aortic rings on exposure to calcification 
medium (culture medium supplemented with 10mM β-glycerolphosphate) with the 
addition of uridine adenosine tetraphosphate (Up4A). This molecule, released from 
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endothelial cells under conditions such as hypoxia or exposure to shear stress is able 
to activate a number of P2X and P2Y receptors (Matsumoto et al 2011). The authors 
went on to identify P2Y2 and P2Y6 as potential mediators of AC in experiments 
using VSMCs exposed to specific receptor antagonists and also aortic rings from 
P2Y2 KO mice. Furthermore, this study found that Up4A is elevated in patients with 
CKD. 
Of interest, Erlinge and colleagues (1998) have linked P2Y2 receptors to a switch in 
VSMC phenotype from contractile to synthetic in experiments showing that the 
expression of mRNA for this receptor is upregulated in rodent VSMCs in long-term 
culture (representing cells in the synthetic state) compared with rodent aortic medial 
cells (VSMCs in the contractile state). P2Y2 receptor agonists have also been shown 
to increase TNAP activity in human heart valve interstitial cells (Osman et al 2006), 
which was interpreted by the authors to indicate a pro-mineralising function.  
However, the situation is clearly complex, since in contrast to these findings, 
experiments by Cote and colleagues (2012a)  provoked cultured human aortic valve 
interstitial cells to calcify using medium containing 2-5 mM phosphate and exposed 
them to either suramin (a general purinergic receptor antagonist), iso- 
pyridoxalphosphate-6-azopheny-2’,4’-disulfonate (iso-PPADS) (P2X receptor 
antagonist) or CGS15943 (adenosine receptor antagonist). They found that only 
suramin increased mineralisation, whereas the other agents had no effect. They 
concluded that this was consistent with an inhibitory effect of P2Y on valve 
calcification. They went on to show that treatment of cells with 2-thioUTP, a P2Y2 
agonist, reduced mineralisation, and that P2Y2 knockdown increased mineral 
deposition. With further experiments, the authors implicated inhibition of apoptosis 
by P2Y2 as the underlying mechanism that seemed to protect against calcification.  
1.8.2 Other purinergic receptors. 
Although controversial, adenosine has been linked to AC through in vitro 
experiments attempting to explain the mechanism whereby genetic deficiency of the 
enzyme CD73 leads to calcium deposition in peripheral arteries (St Hilaire et al 
2011) (see section 1.10.2.ii). To date, there are no reports of studies investigating the 
role of P2X receptors in this context. However, as will now be discussed, one 
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member of this sub-family – the P2X7 receptor (P2X7R), has several links to 
processes implicated in the biology of arterial calcium deposition, making it worthy 
of exploration as a potential player in the pathogenesis and as a possible therapeutic 
target. 
1.9 The P2X7 Receptor  
1.9.1 Structural properties. 
The basic structure of P2X7R is the same as the other 6 P2X receptors, i.e. an 
oligomer, composed of 3 subunits, each possessing intracellular N- and C- termini 
and two membrane-spanning domains separated by an extracellular loop (Burnstock 
2006). However, P2X7R has several important unique properties which distinguish it 
from other members of the P2X sub-family. These include a markedly higher ATP 
requirement for activation, a substantially (200 amino acids) longer intracellular C-
terminus and the ability to generate a large ‘pore-like’ structure within the cell 
membrane (Suprenant et al 1996).  
Mathematical modelling has been used to predict the possible ‘cascade of events’ 
involved in the production of this transmembrane pore (Yan et al 2010, Pelegrin 
2011), which is thought to be key in mediating many biological actions of P2X7R 
(Wiley et al 2011). Following binding of one ATP molecule, P2X7R undergoes a 
conformational change and the affinity for ATP is reduced. Attachment of a second 
ATP molecule induces further architectural disruption and the opening of a low-
conductance channel, permitting the transmembrane movement of small cations. 
ATP affinity is further reduced. Addition of a third ATP molecule to this complex 
causes a conformational shift back to a symmetrical shape. This is associated with 
formation of the high-conductance pore which is permeable to molecules up to 
900kDa in size.  
P2X7R in the cell membrane is usually anchored to non-muscle myosin and 
disassociation from this protein is thought to be important in the final step of pore 
formation. The C-terminus may well regulate this process as disruption to the normal 
structure of this region of the protein does not affect the ion-channel function of 
P2X7R but does impact on large molecule transmembrane flux (i.e. pore formation) 
(Adinolfi et al 2010). 
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1.9.2 Tissue distribution. 
Originally P2X7R was thought to be exclusively expressed on haemopoietic cells. 
However, it has now been shown to have a fairly ubiquitous distribution in the 
human body although levels of expression differ widely between tissues (Burnstock 
& Knight 2004). In keeping with the known pro-inflammatory role of P2X7R 
(discussed in section 1.9.4), the receptor is most abundant in macrophages and other 
mononuclear peripheral blood cells. Interestingly neutrophils only show intracellular 
expression (Gu et al 2000, Wiley et al 2011). 
In the vascular system, the expression of P2X7R has not been very well 
characterised. However, presence of the receptor has been demonstrated in human 
umbilical cord artery and vein (Piscopiello et al 2013), as well as on human 
endothelial cells (Wilson et al 2007), smooth muscle in veins (Cario-Toumaninatz et 
al 1998) and arterial adventitia in rats (Lewis & Evans 2001). P2X7R protein 
expression in arterial VSMCs has not previously been reported although the presence 
of mRNA has been detected (Wang et al 2002, Schuchardt et al 2011). With 
relevance to the possible link between AC and bone, the presence of P2X7R has 
been demonstrated in both osteoblasts (Gartland et al 2001) and osteoclasts 
(Jorgensen et al 2002). 
1.9.3 Agonists and antagonists. 
1.9.3.i Receptor agonists. 
Compared with other P2X receptors, P2X7R requires much higher concentrations of 
ATP for activation (EC50 > 80–100µM at P2X7R) (Suprenant et al 1996). The most 
potent receptor agonist is the ATP analogue 2,3-(benzoyl-4-benzoyl)-ATP (BzATP) 
for which EC50 = 7µM (Suprenant et al 1996). It should be noted however that 
BzATP is not a specific P2X7R agonist as it is able to activate many other P2X and 
some P2Y receptors (Bianchi et al 1999, Michel et al 2001). BzATP is followed, in 
order of decreasing affinity, by ATP, 2-methylthio-ATP, adenosine-(γ-thio)-
triphosphate and ADP (North 2002). 
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1.9.3.ii Receptor antagonists. 
A number of molecules capable of inhibiting P2X receptors have been used in 
research for many years. Examples of these general P2X antagonists include 
suramin, oxidised ATP and PPADS (Wiley et al 2011). KN-62 is a relatively 
specific antagonist of P2X7R in humans and mice but does not inhibit the receptor in 
rats (Donnelly-Roberts et al 2007).  
Specific antagonists to P2X7R have only become commercially-available over the 
last few years and have greatly facilitated research into the characteristics and 
functions of the receptor. One of the most commonly used agents is A438079 – a 
tetrazole-based compound originally developed by the Abbott Laboratory (Nelson et 
al 2006). This has an IC50 value of 0.1 and 0.3µM for BzATP-induced Ca
2+
 influx 
through human and rat P2X7Rs respectively (Donnelly-Roberts et al 2007). 
A438079 has been widely used for in vitro studies and has also successfully been 
employed in rodent studies to modulate nociception (McGaraughty et al 2007) and 
ameliorate experimental glomerulonephritis (Taylor et al 2009a). Other 
commercially-available specific P2X7R antagonists include A740003, AZ11645373 
and A839977. Early phase human clinical trials in conditions such as rheumatoid 
arthritis have indicated that pharmacological blockade of P2X7R is well tolerated 
and safe (Keystone et al 2012, Stock et al 2012). 
1.9.4 Receptor functions and potential links to CKD-associated AC. 
The best characterised function of P2X7R is its role in mediating assembly of the 
Nacht Domain-, Leucine-Rich Repeat-, and PYD-Containing Protein-3 (NLRP3) 
inflammasome (Di Virgilio 2007). In macrophages primed by stimulants such as 
bacterial-derived lipopolysaccharide (LPS) or inflammatory cytokines such as 
tumour necrosis factor-alpha (TNF-α), P2X7R orchestrates the release of interleukin 
(IL) 1-beta and IL-18 along with caspase-1 activation by inducing inflammasome 
assembly. These events seem to be dependent upon a fall in intracellular potassium 
brought about by ion transit through the P2X7R-associated pore (Booth et al 2012). 
P2X7R therefore appears to function as a ‘damage sensor’ in these circumstances, 
acting to induce a local inflammatory response (Di Virgilio 2007). 
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As reviewed in Part 1 of this introduction (section 1.3), despite a clear role in 
atherosclerosis, inflammatory cells are consistently reported to be absent in medial 
AC lesions (Shanahan et al 1999, Shroff et al 2008). Some authors have shown that 
inflammatory cytokines such as TNF-α can exacerbate VSMC-associated 
calcification in vitro (Tinut et al 2000) and one recent report has linked the NLRP3 
inflammasome itself to calcium deposition (Wen et al 2013). However, a definitive 
contribution of these and associated inflammatory processes in the pathogenesis of 
AC requires confirmation.  
Whilst the role of inflammatory-related mechanisms in AC awaits verification there 
are a number of other known functions of P2X7R which would seem to have a more 
relevant and direct association with what is currently known about the pathogenesis 
of AC. These potential links are outlined below and form the basis upon which the 
primary hypothesis of this thesis is made. 
1.9.4.i P2X7R and bone. 
Early work examining the bone phenotype of mice with a genetic deficiency of 
P2X7R (P2X7
-/-
 mice) indicated a functional role for the receptor in this tissue but 
yielded contrasting results. Studies by Ke et al (2002) suggested that P2X7
-/-
 animals 
had a marked decrease in bone mineral content and bone formation and increased 
bone resorption compared with controls. However, work by Gartland et al (2003a) 
found no difference in BMD and an increase in cortical bone. Importantly, 2 lines of 
P2X7
-/-
 mice have been developed. The Pfizer KO (Solle et al 2001) was produced 
by the insertion of a neomycin cassette into exon 13 resulting in disruption of the C-
terminus. This animal was used by Ke et al (2002). The Gartland group (2003a), in 
contrast, studied the Glaxo (GSK) KO. This mouse was originally generated by the 
insertion of a lacZ transgene into exon 1 (procedure described by Chessell et al 
2005). Subsequent studies have indicated that a functional splice variant, P2X7-k, 
which is expressed in some tissues in the GSK model, escapes inactivation and 
therefore may explain the differences seen between the 2 lines (Nicke et al 2009). 
An alternative splice variant has been described in the Pfizer model but this is non-
functional (Taylor et al 2009b). The implication from these observations is that 
findings in the GSK mouse should be interpreted with caution. 
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Data obtained from in vitro studies have been equally inconclusive. Experiments 
have been conducted examining the role of P2X7R in both osteoblasts and 
osteoclasts but the functional effect of the receptor in both cell types remains 
uncertain. Panupinthu et al (2008) reported a stimulatory effect of P2X7R on bone 
formation which was suggested to occur through osteoblast receptor-mediated 
production of lysophosphatidic acid, a promoter of osteogenesis (Sims et al 2013). In 
contrast, using an armoury of antagonists and agonists, Orriss et al (2012) found that 
P2X7R exerted an inhibitory influence on osteoblast function resulting in suppressed 
bone formation. These authors highlighted a number of methodological differences 
between these two studies to potentially explain the disparate findings. 
In osteoclasts, P2X7R may have an inhibitory effect (prevention of bone resorption), 
as deficiency of the receptor has been shown to suppress apoptosis of mouse 
osteoclasts (Gartland et al 2003b). However, paradoxically, inhibition of the receptor 
using antagonists and a monoclonal antibody has been shown to limit the generation 
of multi-nucleated osteoclasts from precursor cells which would also theoretically 
lead to a net decrease in bone resorption (Agrawal et al 2010). Interestingly, one 
group have reported that P2X7R is required to actually release ATP, which is in turn 
metabolised to adenosine, which signals through P1 receptors to drive giant 
osteoclast formation (Pellegatti et al 2011). Deficiency of P2X7R prevented this 
process and inhibited resorption of bone. 
The exact role of P2X7R in the skeletal system remains elusive, however, there is 
irrefutable evidence to indicate that in some way, the receptor is involved in bone 
homeostasis. Worthy of particular note are the observations that in man, loss-of-
function P2X7R single nucleotide polymorphisms (SNPs) have been associated with 
an increased risk of developing osteoporosis (Gartland et al 2012) and fracture 
(Ohrlendorff et al 2007).  
1.9.4.ii P2X7R and apoptosis. 
Exposure to ATP can result in cell death by P2X7R-mediated mechanisms 
(Franceschi et al 1996). This may be a function of the P2X7R ion-channel as 
relatively a brief exposure to ATP (insufficient to permit pore formation) triggers 
apoptotic death in mast cells (Bulanova et al 2005). However, the pore-forming 
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capacity of P2X7R also seems to be important in causing cell death as it appears to 
lead to osmotic shifts and consequent cytolysis (Suprenant et al 1996).  
P2X7R-mediated apoptosis has been shown in a number of cell types including skin 
epithelia (Gröschel-Stewart et al 1999), astrocytes (Zheng et al 1991), dendritic cells 
(Coutinho-Silva et al 1999), macrophages (Suprenant et al 1996) and, with respect to 
the vascular system, porcine aortic endothelial cells (von Albertini et al 1998). This 
functional role for the receptor appears to be clinically relevant. In experimental 
glomerulonephritis in mice, P2X7R co-localised with glomerular cells positive for 
the apoptotic marker, caspase-3 (Turner et al 2007) and genetic deficiency of P2X7R 
ameliorated renal injury in this model (Taylor et al 2009a). 
With relevance to the possible pathogenesis of AC, P2X7R is thought to enhance 
apoptosis of human osteoblasts (Gartland et al 2001). As discussed above, P2X7R-
mediated apoptosis of osteoclasts has also been reported (Gartland et al 2003b), 
however other groups have suggested a suppressed apoptotic effect (Grol et al 2009). 
Whether P2X7R is also involved in apoptosis of VSMCs is currently unknown. 
1.9.4.iii P2X7R and ECM degradation. 
Release of ECM-degrading enzymes from mononuclear cells represents a further 
mechanism potentially linking P2X7R and AC. Work studying this cell type in 
culture demonstrated P2X7R-dependent release of MMP-9 following exposure to 
ATP. This effect was lost when cells were also treated with P2X7R antagonists (Gu 
& Wiley 2006). In addition, another group were able to show P2X7R-dependent 
release of cathepsins from macrophages in concentrations sufficient to degrade a 
collagen matrix (Lopez-Castejon et al 2010). 
1.9.4.iv P2X7R and renal disease. 
All causes of kidney injury, if unresolved for a prolonged period of time, have the 
potential to result in fibrosis of the renal interstitium. The extent of this fibrosis is 
known to correlate well with declining renal function (i.e. progression of CKD) 
(Bohle et al 1991, Nangaku 2004). P2X7R has been implicated in the aetiology of a 
number of specific renal pathologies including glomerulonephritis (Taylor et al 
2009a), polycystic kidney disease (Chang et al 2011) and diabetic nephropathy 
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(Vonend et al 2004). However, more relevant to the development of AC is a reported 
link between the receptor and tubulointerstitial fibrosis. 
Using the unilateral ureteric obstruction (UUO) model, Goncalves et al (2006) 
demonstrated after 14 days, that kidneys from P2X7
-/-
 mice showed less collagen 
deposition and macrophage infiltration. In addition, significantly fewer 
myofibroblasts were detected in the medulla. Furthermore, in vitro studies have 
revealed a possible P2X7R-mediated cross-talk between renal epithelial cells and 
fibroblasts (Ponnusamy et al 2011) and receptor inhibition has also been shown to 
ameliorate fibrosis in non-renal models (Riteau et al 2010). 
1.10 The ATP-Metabolising System And Calcification 
1.10.1 ATP metabolism and PPi generation: the roles of ENPP-1 and ANK. 
Data implicating direct signalling by purine receptors in the process of AC is just 
beginning to emerge, however more is known about the roles played by the enzymes 
involved in the hydrolysis of ATP (Figure 1.2) and the associated metabolites, in 
particular PPi. The ability of PPi to inhibit ectopic calcification was demonstrated 
almost half a century ago using subcutaneous injections in rats exposed to high doses 
of vitamin D (Fleisch et al 1965). The mechanism whereby this is achieved seems to 
be the chemisorption of PPi onto the surface of hydroxyapatite, preventing 
attachment of further calcium and phosphate, and thus inhibiting crystal growth 
(Francis 1969). More recent work has provided further experimental evidence of the 
importance of PPi in preventing AC. For example, cultured rodent aortic rings 
exposed to an elevated phosphate concentration will calcify following PPi removal 
using alkaline phosphatase (Lomashvili et al 2004). Treatment with intraperitoneal 
(ip) PPi also reduces AC induced in uraemic rats (O’Neill et al 2011) and also in 
ApoE KO mice (Riser et al 2011). In the setting of CKD in man, PPi levels inversely 
correlate with the degree of AC (O’Neill et al 2010), and reduced levels are seen in 
dialysis patients irrespective of dialysis modality, inflammation or nutritional status, 
when compared with control subjects (Lomashvili et al 2005). 
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1.10.1.i Clinical manifestations of genetic mutations in ENPP-1 - generalised AC of 
infancy and autosomal recessive hypophosphataemic rickets type 2. 
As previously discussed (section 1.7), ENPP-1 generates PPi (and AMP) following 
the hydrolysis of ATP and alterations in this reaction are clinically relevant. One of 
the earliest and most significant discoveries in this respect was that autosomal 
recessive mutations leading to inactivation of ENPP-1 result in the condition of 
generalised AC of infancy (GACI) (Rutsch et al 2003). This disorder is characterised 
by increased hydroxyapatite deposition within the elastic laminae of arteries, with 
associated stenosis and mortality. The ectopic calcification seen in this disease is 
presumably due to reduced PPi production and availability. Indeed treatment with 
bisphosphonates, which are analogues of PPi, have been shown to improve the 
prognosis of the condition (Rutsch et al 2008). Subsequent genetic studies have 
demonstrated that inactivating mutations of the ENPP-1 gene can also cause 
autosomal recessive hypophosphataemic rickets type 2 (ARHR2) (Levy-Litan et al 
2010, Lorenz-Depiereux et al 2010). Moreover, the ENPP-1 inactivating K121Q 
(rs1044498) polymorphism is associated with increased AC scores in dialysis 
patients (Eller et al 2008). 
1.10.1.ii Murine models of ENPP-1 deficiency - correlation with human disease. 
The potential importance of ENPP-1 in disorders of calcification was initially 
discovered from work studying the ‘tiptoe walking’ (ttw/ttw) mouse. This mouse, 
originally developed in Japan in 1978 (Hosoda et al 1981), is characterised by 
ectopic calcification most marked in peripheral and intervertebral joints (Sakamoto 
et al 1994), leading to progressive ankylosis. The phenotype was shown to result 
from a nonsense mutation in the ENPP-1 gene (Okawa et al 1998). Subsequently an 
ENPP-1 KO mouse was developed (Sali et al 1999), the phenotype of which has 
been investigated in detail.  
These animals show spontaneous calcification of the coronary arteries and aorta 
(Mackenzie et al 2012) and markers of bone formation are demonstrable in the aortic 
media (Zhu et al 2011). Decreased serum calcium and phosphate concentrations are 
present compared with wild-type (WT) mice (Mackenzie et al 2012). Of interest, 
these mice also show increased levels of the phosphaturic hormone fibroblast growth 
factor 23 (FGF-23) (Mackenzie et al 2012), as has also been reported in ARHR2 
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(Levy-Litan et al 2010, Lorenz-Depiereux et al 2010): FGF23 has been linked to AC 
in patients with CKD (Desjardin et al 2012) and FGF23 mutations that resist 
degradation are the cause of autosomal dominant hypophosphataemic rickets 
(ADHR) (White et al 2000).  
The bones of ENPP-1 KO mice show abnormal mineralisation and architecture, 
probably due to decreased PPi availability for conversion to inorganic phosphate by 
TNAP (Anderson et al 2005). It is interesting to note that while the ENPP-1 KO 
mouse biochemical and bone phenotype is similar to that of patients with ARHR2, 
these patients do not seem to develop AC. Conversely patients with GACI, while 
exhibiting the same vascular changes as ENPP-1 KO mice, do not tend to show the 
same skeletal and biochemical abnormalities.  
1.10.1.iii ENPP-1 regulation at the cellular level. 
Limited information is available on the regulation of ENPP-1 expression and 
function in VSMCs. Using early passage rat VSMCs, Prosdocimo and colleagues 
(2010) showed a decrease in ENPP-1 mRNA expression under calcification 
conditions in vitro, growing cells in 5mM phosphate and 1µM forskolin (used to 
activate adenylate cyclase and thus elevate cyclic AMP (cAMP)) for 10 days. Of 
note, the authors were not able to demonstrate a significant decrease in mRNA 
expression when cells were grown in 5mM phosphate alone, implicating an 
important role for cAMP in the calcification pathway. These authors also assessed 
ENPP-1 protein expression and functional activity, and suggested that while both 
5mM phosphate and 1µM forskolin could independently reduce protein expression 
after 10 days, functional activity was the same as at baseline, as shown by no change 
in methylene ATP (MeATP) metabolism, a specific substrate.  
In contrast to this study, Huang and colleagues (2008), using later passage murine 
aortic VSMCs, showed an increase in ENPP-1 expression following exposure to 
25µM forskolin and 5mM β-glycerolphosphate for 7 days in culture. In addition, 
Mathieu’s group, using human valve cells, found an increase in ENPP-1 expression 
with increasing concentrations of phosphate in the culture medium (Cote et al 
2012a). Furthermore, this group generated data suggesting that non-specific 
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inhibition of ecto-nucleotidases could attenuate AC in rats treated with warfarin 
(Cote et al 2012b).  
It should be noted that this group used a different strain of rodent than Prosdocimo et 
al (2010) and the subtypes of ecto-nucleotidases detected in aortas were markedly 
different between the two laboratories. The regulation of ENPP-1 expression and 
activity is clearly complex and negative feedback mechanisms involving TNAP-
regulated ENPP-1 expression and activity, described in experiments using bone cells 
(Johnson et al 2000) is an added complication. The regulation of ENPP-1 in the 
setting of CKD is currently unknown but worthy of investigation. 
1.10.1.iv The role of ANK. 
Another important player implicated in the generation of extracellular PPi is ANK, a 
transmembrane protein that may mediate intracellular PPi efflux from cells (Ho et al 
2000, Terkeltaub 2001). Autosomal dominant inherited mutations in the gene 
encoding ANK have been demonstrated to cause two different calcification 
disorders: craniometaphyseal dysplasia (Nurnberg et al 2001) and autosomal 
dominant familial calcium PPi dihydrate deposition (Williams et al 2002). 
Furthermore, aortas taken from Ank KO mice calcify more readily than those from 
WT mice when exposed to an elevated phosphate concentration in vitro (Villa-
Bellosta et al 2011a) and Ank KO mice fed a high phosphate diet develop AC 
(Murshed et al 2005). Intriguingly, Villa-Bellosta et al (2011a) have suggested that 
ANK might be able to transport ATP from the intra- to the extracellular 
compartment.  
1.10.2 Roles played by other ecto-nucleotidases. 
1.10.2.i TNAP. 
The availability of PPi is not only dependent on its generation, but also on its 
metabolism which is controlled by the enzyme TNAP. This protein is present on 
most cell types, including VSMCs, and catalyses the conversion of PPi to inorganic 
phosphate, thereby promoting mineralisation (Murshed et al 2005). The human 
condition, hypophosphatasia, is caused by missense loss-of-function mutations in the 
TNAP gene. This inherited trait is considered to be an autosomal dominant negative, 
although recessive inheritance patterns have also been described (Mornet 2007). 
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TNAP serum levels are reduced in these patients, PPi concentrations increased, and 
bone mineralisation impaired (Russell et al 1971). TNAP KO mice die before 
weaning and exhibit a similar phenotype to the human disease (Fedde et al 1999).  
TNAP has been linked to AC. Elegant experiments from O’Neill’s group 
(Lomashvili et al 2008) used two rodent CKD models to demonstrate that both the 
expression and activity of TNAP are increased in uraemic conditions, suggesting this 
as a potential mechanism for the increased prevalence of AC in patients with CKD. 
While the exact pathway mediating the observed increase in TNAP was not 
elucidated, mRNA expression was not increased, but when aortic rings were isolated 
and incubated with uraemic serum, an increase in TNAP activity was detected, 
indicating that an as yet unidentified circulating factor may be responsible for up-
regulating enzyme activity. The authors suggest that this factor is probably not 
phosphate or PTH, because of the low concentrations likely to have been present in 
vitro.  
1.10.2.ii Mutations in NT5E in patients with calcification of arteries and joints. 
Another significant finding arose recently from genetic studies of 3 families 
exhibiting extensive calcification of lower limb vessels in adulthood (St Hilaire et al 
2011). These patients showed autosomal recessive homozygous or compound 
heterozygous mutations in the 5’-nucleotidase, ecto (NT5E) gene, which encodes the 
CD73 protein, an enzyme responsible for the conversion of AMP to adenosine (Arch 
& Newsholme 1978) (Figure 1.2). 
To investigate the potential mechanism behind these findings the investigators 
examined skin fibroblasts from affected individuals and demonstrated a marked 
increase in TNAP activity and calcification when cells were incubated with β-
glycerolphosphate compared with fibroblasts from healthy controls. These effects in 
vitro could be reversed by administration of either adenosine or rescue by 
transfection with a CD73-encoding vector.  
The authors hypothesise that the calcification seen in individuals with CD73 
mutations is due to decreased inhibition of TNAP secondary to reduced levels of 
adenosine. However, as pointed out by some commentators (Robson et al 2011), the 
expression profile of ecto-nucleotidases on fibroblasts is different to that on VSMCs; 
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moreover, CD73 KO mice do not seem to exhibit ectopic calcification. Therefore the 
exact mechanism underlying these intriguing observations remains a subject for 
further investigation.  
1.10.2.iii The potential involvement of CD39 in AC. 
CD39 or NTPDase-1 has not, at present, been linked to AC directly, despite being 
highly expressed by VSMCs (Robson et al 2006). It is of interest that this enzyme, in 
its nucleotide hydrolyzing capacity, has been linked to other important roles within 
the vasculature, including modulation of thrombosis and inflammation (Robson et al 
2005) and regulation of vascular tone (Kauffenstein et al 2010a). In addition, of all 
the ecto-nucleotidases, CD39 has the most evidence linking it directly to regulation 
of signalling through purine receptors (Kauffenstein et al 2010b). CD39 could 
potentially limit the availability of ATP for conversion to PPi by ENPP-1 and so it 
would be of interest to examine the expression and regulation of this enzyme in the 
context of AC.  
PART 3 - Hypotheses, Rationales, Aims and Objectives 
1.11 Primary Hypothesis 
The work in this thesis tested the primary hypothesis that P2X7R contributes to the 
pathogenesis of CKD-associated AC.  
1.11.1 Rationale. 
As reviewed above (section 1.9.4), a large body of evidence links P2X7R, in non-
vascular contexts, to many biological processes thought to be important in mediating 
CKD-associated AC. The potential mechanisms implicated in AC which could 
possibly involve P2X7R, and might therefore be disrupted by receptor inhibition, are 
summarised in Figure 1.3.  
P2X7R is expressed on osteoblasts and reported by some groups to promote bone 
formation. VSMCs are described to convert to osteoblast-like cells (osteogenic 
transformation) during the process of AC where they contribute to ectopic 
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mineralisation in a fashion resembling bone formation. Blockade of P2X7R might 
therefore inhibit this process. Alternatively, other studies have suggested that P2X7R 
may suppress bone formation. Disruption of normal bone homeostasis is associated 
with AC and therefore, conversely, inhibiting P2X7R might ameliorate arterial 
calcium deposition through maintaining systemic bone health.  
In contexts unrelated to bone, AC is closely linked to VSMC apoptosis. Apoptosis is 
mediated by P2X7R in a number of non-vascular cell types and might potentially 
play a similar role in VSMCs. P2X7R is also known to contribute to release of 
enzymes capable of degrading ECM such as MMPs. ECM degradation is thought to 
be an important step in the development of AC and P2X7R blockade might limit this 
process. Finally, there is some evidence to suggest that P2X7R may contribute to the 
progression of CKD in general by promoting renal fibrosis.  
To date, no previous studies have examined whether P2X7R plays a role in the 
development and/or the progression of AC. In addition, despite the adverse impacts 
on health conferred by AC, no specific treatments are currently available. The main 
goal of this project was therefore to determine if P2X7R is implicated in the 
aetiology of AC and whether the receptor might potentially be a future therapeutic 
target. 
1.11.2 Experimental aims and objectives. 
1. To assess the role of P2X7R in AC in vitro using an optimised model.  
Specific objectives: 
a) Confirm the expression of P2X7R in VSMCs. 
b) Optimise an in vitro model of AC. 
c) Examine the effects of P2X7R-specific antagonists and agonists on AC in 
vitro. 
d) Study the effect of P2X7R deficiency on AC in vitro using genetically 
manipulated cells and/or tissue. 
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2. To examine the impact of P2X7R gene deletion on AC in vivo. 
 Specific objectives: 
a) Develop and optimise a non-surgical mouse model of CKD-associated AC. 
b) Determine the effect of P2X7R gene deletion on AC using this model. 
3. To evaluate the effect of pharmacological P2X7R blockade on AC in vivo. 
Specific objectives: 
a) Optimise a rat model of CKD-associated AC. 
b) Determine the expression of P2X7R in normal and calcified rodent arteries. 
c) Investigate the effect of pharmacological P2X7R antagonism on AC in rats. 
d) Assess the influence of pharmacological P2X7R antagonism on AC-related 
cellular pathways in vivo. 
e) Examine the impact of pharmacological P2X7R antagonism on architectural 
changes in rodent bone caused by CKD. 
1.12 Supplementary Hypothesis 
This project also sought to test the hypothesis that the expression profiles of arterial 
ATP-metabolising enzymes are altered in CKD-associated AC. 
1.12.1 Rationale. 
As reviewed in Part 2 of this introduction, several components of the ATP-
metabolising system have links with calcification. However, with the exception of 
TNAP, these ecto-nucleotidases have not been specifically assessed in the setting of 
CKD-associated AC. Uraemia has been shown to alter the activity of TNAP. Similar 
induced functional changes in companion ATP-related proteins could potentially 
impact on the production of molecules known to influence AC, in particular PPi. 
Knowledge of any such regulation would firstly increase the understanding of the 
pathogenesis of AC and secondly, potentially provide novel targets for therapeutic 
interventions.  
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Therefore whilst not the primary goal of this thesis, and not intended to be an 
exhaustive investigation, the work performed in relation to this supplementary 
hypothesis (Chapter 6) strived to generate preliminary data pertaining to the 
expression profiles of the constituents of the arterial ATP-metabolising system. 
Attention centred on ENPP-1 given its capacity to generate PPi. 
1.12.2 Experimental aims and objectives. 
1. To examine the expression of ENPP-1 and associated enzymes responsible for 
ATP metabolism in normal and calcified arteries. 
Specific objectives: 
a) Compare the expression of ENPP-1, CD39, CD73, TNAP and ANK in 
arteries of CKD rats with those from control animals. 
b) Analyse the functional activity of ENPP-1 in arteries taken from CKD rats 
and control animals. 
c) Assess the expression of ENPP-1 in calcified and un-calcified arteries 
taken from humans with ESRD. 
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CHAPTER 2 - MATERIALS AND METHODS 
2.1 Reagents And Materials 
Unless stated otherwise, all reagents were purchased from Sigma (Poole, UK). 
Tissue culture plasticware was manufactured by Corning (New York, USA). 
Microcentrifuge tubes were manufactured by Eppendorf (Hamburg, Germany). 
Dissection equipment was purchased from Thermo Fisher Scientific (Loughborough, 
UK) with the exception of scalpels which were obtained from Scientific Laboratory 
Supplies (SLS) (Nottingham, UK). All experimental diets were produced by SSNIFF 
(Soest, Germany). Suppliers of specific reagents and equipment are detailed in the 
relevant sections below. All water (H2O) used for making reagents and for wash 
steps was molecular biology grade (resistivity 18.2MΩ). 
2.2 Studies With Human Tissue 
2.2.1 Ethical considerations. 
The collection of, and all subsequent research undertaken with human arteries 
described in this thesis were approved by a Committee from the National Research 
Ethics Service. All patients provided prior written consent permitting the removal, 
(at the time of kidney transplantation), and subsequent use for research of, a short 
segment of one inferior epigastric artery. 
2.2.2 Tissue collection, processing and storage. 
Patients admitted to the Royal Free London NHS Foundation Trust in order to 
receive a kidney TP (from a live or a deceased donor), were eligible for inclusion. 
During the TP operation, following the routine surgical division of the inferior 
epigastric artery, a short segment of this vessel (typically 1-2cm in length) was 
removed and immediately placed into a vial containing Medium-199 supplemented 
with 0.1mg/ml streptomycin and 100U/ml penicillin. The sample was then stored at 
4ºC for a maximum of 24 hours before processing.  
A short segment from the end of the vessel was fixed in 10% Neutral-Buffered 
Formalin (NBF) for 24 hours, washed 3 times in Phosphate-Buffered Saline (PBS) 
and embedded in paraffin. The remaining vessel had as much adventitia removed as 
possible following which a transverse cut was made to divide it into 2 equal 
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segments. One half was snap-frozen in liquid nitrogen and stored at -80ºC. The other 
half was put into RNAlater (Qiagen, Manchester, UK) and stored at -20ºC until 
required. 
2.3 Animal Husbandry 
All in vivo work was approved by the Home Office Science Unit and performed 
under personal license 70/24024 and project license 70/7344 (Dr Jill Norman). 
Animals were housed and experimental work performed in the Comparative Biology 
Unit, UCL Medical School, Royal Free Campus. Rats and mice were maintained on 
a 12 hour light-dark cycle and given free access to food and water at all times. 
Animals were fed a standard maintenance diet (Special Diets Services, Essex, UK) 
until such time as dietary manipulation was commenced (see relevant experiments 
for details). Maximum cage occupancy for experiments was 4 for rats and 5 for mice. 
All rats used were adult, male Wistars, aged approximately 10-12 weeks and 
weighing approximately 400g (Charles River, Margate, UK). Genders, strains and 
ages of mice are described in the relevant sections. All animals fed experimental 
diets were weighed weekly with daily visual monitoring of clinical wellbeing. 
2.4 Experiments To Develop A Murine Model Of Chronic Kidney Disease-
Associated Arterial Calcification 
2.4.1 Administration of folic acid to mice. 
2.4.1.i Reagents and diets. 
Folic acid powder was dissolved in 0.3M NaHCO3 solution (vehicle) to obtain the 
required concentration, filtered through a 0.2µM filter and protected from light. The 
concentration of folic acid solution was such that the administered volume was 
consistently between 240-360µl irrespective of the dose received. Solutions were 
always made up fresh and administered within one hour of being prepared. 
The experimental diet used in this study contained 1% (high) phosphate. All other 
constituents were present at normal levels (diet A, Table 2.1). 
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Constituent 
 
DIET A 
 
DIET B 
 
DIET C DIET D DIET E DIET F DIET G 
Adenine (%) [0] 0 0.25 or 0 0.20 or 0.25 0.75 or 0 0.25 0 0.75 
Phosphate (%) [0.5] 1.0 0.92 0.92 0.92 0.92 0.50 0.50 
Calcium (%) [0.7] 0.6 1.0 1.0 1.0 1.0 0.71 0.71 
Crude Protein (%) [17.8] 17.8 2.5 or 7.5 2.5 2.5 2.5 2.5 2.5 
 Crude Fat (%) [4.6] 4.6 7.6 7.6 4.6 4.6 4.6 4.6 
Chocolate Flavour - - + - - - - 
Vitamin D3 (IU/kg) 1000 1000 2000 1000 1000 1000 1000 
Vitamin K3 (mg/kg) 4 4 4 4 4 4 4 
Crude Fibre (%) 5.0 5.0 5.0 5.0 5.0 5.0 5.0 
Crude Ash (%) 5.3 6.3 6.3 6.2 6.3 3.7 3.7 
Starch (%) 29.8 34.4 or 28.7* 34.4 37.3 38.2 38.5 38.5 
Sugar (%) 12.8 26.7 26.7 26.8 26.7 26.0 26.0 
 
Table 2.1. Animal Diets. Summary of the main ingredients contained in experimental animal diets. Figures in bold depict the manipulated components of each formulation 
(i.e. those which differ substantially from physiological levels). Values in square brackets represent approximate ‘normal’ levels of the adjusted constituents in rodent diets 
(personal communications with SSNIFF scientists). Studies which employed each diet are as follows (in order as they appear in the thesis): Diet A – Mouse experiments 
involving folic acid, also used to ‘pre-condition’ some mice for consuming a synthetic diet (see Chapters 2 and 4). Diet B – Pilot studies involving adenine-feeding to mice 
(both protein levels employed), final mouse experiment examining effect of P2X7R gene deletion on AC (2.5% protein diet only, zero adenine contained in control diet for 
this study). C – Pilot studies to optimise mouse adenine-diet. D – First pilot rat study (control diet contained zero adenine), diet administered to rats in ‘V’ and ‘HD’ groups 
in main experiment assessing the use of a P2X7R antagonist on AC in vivo. E – second pilot study in rats. F – Control diet fed to rats in the ‘N’ group in the P2X7R 
antagonist experiment. G – Fed to rats in the ‘A’ group in the P2X7R antagonist experiment, also fed to 3 mice in pilot studies optimising adenine administration. *28.7% 
starch in diet containing 7.5% protein.  
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2.4.1.ii Study protocol. 
DBA/2 mice were obtained from Harlan (Bicester, UK) and an in-house breeding 
colony was established. Females exclusively were used for this study. Mice of 
approximately 20 weeks of age received an ip injection of either folic acid or vehicle 
whilst under mild reversible isofluorane anaesthesia. The following day the high 
phosphate diet was started and continued for 20 weeks at which time mice were 
sacrificed. Blood was sampled at baseline, (before folic acid administration), and at 
subsequent time-points (detailed in Chapter 4). 
2.4.2 Pilot studies to examine the effect of feeding adenine-containing diets to 
mice. 
2.4.2.i Diets. 
Diets B and C (Table 2.1) were principally used for these experiments. These diets 
contained 0.9% (high) phosphate, 1% (high) calcium and 7.6% fat. The fat content 
was elevated slightly from the standard 4.6% in order to try and make the pellets 
softer and more palatable for the mice. Diet C had chocolate flavouring added and a 
slightly elevated (but still physiological) vitamin D3 level (2000 IU/kg). The adenine 
and protein contents of these diets were adjusted as described in Chapter 4. Diet A 
(high phosphate only, Table 2.1) was fed to some mice for a week before the 
adenine-containing feed was started in order to ‘pre-condition’ the animals for eating 
a synthetic diet (see Chapter 4). The effect of 0.75% adenine was examined in 3 
mice (see Chapter 4). 
2.4.2.ii Study animals. 
Mice used in these experiments were aged 10-12 weeks. A number of pilot studies 
using adenine-containing feed were performed (see Chapter 4). The first pilot study 
involved male and female WT DBA/2 mice taken from the in-house breeding 
colony. Subsequent studies assessed C57Bl/6 males (obtained from Charles River, 
Margate, UK) and backcrossed WT male mice of the 5
th
 generation (described in 
section 2.5). 
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2.4.2.iii Administration of diets. 
Test diets were fed to mice for 6 weeks unless they were poorly tolerated and had to 
be withdrawn early. For the early experiments, diets were administered in the form 
of both pellets and powder, however powder tended to be scuffed out into bedding 
and that remaining in feeding bowels found wet. As such, pellets only were used for 
the later studies. 
2.5 Backcrossing Of P2X7
-/-
 Mice Onto The DBA/2 Background 
2.5.1 Background: original generation of P2X7
-/-
 mice. 
Pfizer P2X7
-/-
 mice were originally generated by inserting a neomycin cassette into 
exon 13 and deletion of nucleotides 1527-1607 (Solle et al 2001) and ultimately 
maintained on the Bl/6 background. All P2X7
-/-
 mice used in this thesis are the Pfizer 
model. 
2.5.2 Backcrossing procedure. 
The aim of backcrossing was to transfer the P2X7
-/- 
(on the C57Bl/6, calcification 
resistant background) onto the DBA/2 (calcification prone) background (Eaton et al 
1978). To obtain at least 97% of the DBA/2 background it was calculated that a 
minimum of 5 backcrossings would be required. Initially 3 adult male P2X7
-/- 
mice 
(Pfizer, New York, New York, USA) were kindly donated by Dr Frederick Tam 
(Imperial College, London, UK) and bred with 3 WT female DBA/2 mice (Harlan, 
Bicester, UK). Male offspring identified by genotyping as heterozygous were 
backcrossed with WT DBA/2 females to produce the subsequent generation. 
Initially, male offspring were bred with the original 3 WT female mice, however, 
after generation 3 it was necessary to obtain new, younger females to continue with 
backcrossing. Backcrossing was stopped when the 5
th
 generation had been reached, 
and 5
th
 generation heterozygous mice were then bred to produce WTs and P2X7
-/-
. 
Mice used in the final experiment to assess the effect P2X7R gene deletion on AC 
(see section 2.6 and Chapter 4) were either offspring from these breeding pairs or 
offspring of subsequent WT and KO pairs that were set up. However, as no further 
backcrossing occurred after the 5
th
 generation, all mice were of the same 
background. All mice were genotyped before entry into an experiment. 
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2.5.3 Genotyping of mice. 
Ear punches were obtained under mild, reversible isofluorane anaesthesia. Tissue 
samples were digested and deoxyribonucleic acid (DNA) liberated using an adapted 
‘HotShot’ protocol (Truett et al 2000). This method works on the principle that 
NaOH will denature double-stranded DNA by causing hydrogen bonds between 
nitrogenous bases to loosen. Tris(hydroxymethyl)aminomethane (Tris)-Cl is 
included to maintain pH. 
2.5.3.i Solutions. 
Stock solutions (50x) were made up:  
Solution 1 contained 1.25M NaOH, 10mM ethylenediaminetetraacetic acid (EDTA), 
pH≈12, made by dissolving 50g NaOH and 2.9g EDTA into ≈900ml H2O which was 
then made up to 1L.  
Solution 2 contained 2M Tris-Cl, pH≈5, made by dissolving 315.2g Tris-Cl in 
≈900ml H2O which was then made up to 1L.  
2.5.3.ii Genotyping procedure. 
Fresh 1x aliquots of solutions 1 and 2 were made by adding 1470µl polymerase 
chain reaction (PCR) -grade water to 30ul of each 50x solution. 75µl of solution 1 
was put into each 0.2ml PCR tube and earclips were then added (one per tube). 
Samples were incubated on a GeneAmp PCR System (Applied Biosystems) at 95°C 
for 30 minutes followed by a 4°C hold. Samples were then removed and 75µl of 
solution 2 was added to each. Samples were mixed and then, if not analysed 
immediately, stored at -20°C. 
To run the genotyping reaction, 2µl DNA was added to 23µl of a ‘mastermix ‘of 
reagents, the contents and relative proportions of which were the following: 
 12.5µl REDTaq ReadyMix. 
 1µl of each primer (4 primers were required – see Table 2.2). 
 PCR grade water to make up to 23µl. 
The PCR steps and conditions for genotyping were as follows: 
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1. 3 min at 94°C 
2. 30 seconds at 94°C 
3. 1min at 60°C  
4. 1min at 72°C.  
Steps 2-4 were repeated for 35 cycles. 
5. 2 min at 72°C 
6. Hold at 10°C 
The PCR run was performed using the same machine as that used for DNA 
extraction. PCR products, along with a 100 base-pair (bp) marker ladder (Thermo 
Fisher Scientific), were then electrophoresed on a 2% agarose gel made with 1x TAE 
(Tris-Acetate-EDTA) containing 0.04ul/ml ethidium bromide at 80V for 40min. 1x 
TAE was made by diluting a 50x TAE solution (containing 2M Tris acetate and 
0.05M EDTA at pH 8.2) in H2O. 
Bands were observed under ultraviolet (UV) light in a UV lightbox (Biorad, Hemel 
Hempstead, UK). A single band at 363bp indicated WT; a single band at 280bp 
indicated P2X7
-/-
; double bands indicated heterzygous mice (Figure 2.1). 
               Wild Type Forward TGG ACT TCT CCG ACC TGT CT 
Wild Type Reverse TGG CAT AGC ACC TGT AAG CA 
Mutant Forward CTT GGG TGG AGA GGC TAT TC 
Mutant Reverse AGG TGA GAT GAC AGG AGA TC 
 
Table 2.2. Primers used for P2X7 Genotyping of Mice. 
 
 
 
 
 
 
 
Figure 2.1. Genotyping of Mice. PCR products were run on a 2% agarose gel and visualised under 
UV light. A single band at 363bp indicated WT; a single band at 280bp indicated P2X7
-/-
; double 
bands indicate heterzygous mice. A 100 bp reference ladder is shown in the left-hand land. 
← 363bp 
← 280bp 
100 bp 
ladder 
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2.6 Experiment To Determine The Effect Of P2X7R Gene Deletion On Arterial 
Calcification 
2.6.1 Study animals. 
Male WT and P2X7
-/- 
mice aged 10-14 weeks were entered into the study. The 
generation and background of these mice is described in section 2.5. Where possible, 
mice were caged in pairs, although by necessity a few triplet and singleton cages 
were set up. These were comparable in number for WTs and KOs. Baseline blood 
was taken in the week prior to dietary manipulation. 
2.6.2 Study protocol. 
Mice were divided into 4 groups: WT and P2X7
-/-
 controls (WTC, n=8, and KOC, 
n=8) and WT-adenine and P2X7
-/-
-adenine groups (WTA, n=11, and KOA, n=10). 
Mice were fed a diet containing 0.9% phosphate, 1% calcium, 7.6% fat and 2.5% 
protein with the addition of adenine (0.25%) as appropriate (Diet B, Table 2.1). 
Animals were fed test diets for 6 weeks before sacrifice.  
2.7 Experiment To Assess The Influence Of A Selective P2X7R Antagonist On 
Arterial Calcification In Rats 
2.7.1 Pilot studies examining the effects of administering adenine-containing 
diets to rats. 
Small pilot studies were first undertaken to optimise the in vivo model for use in the 
final experiment. In the first of these, rats were divided into 2 groups (n=4 per 
group). All were fed a diet containing 0.92% phosphorus, 1% calcium and 2.5% 
protein for 4 weeks. 0.75% adenine was added for 4 animals (Diet D, Table 2.1). 
A second pilot study was performed whereby a further 4 rats were fed a similar diet 
but with an adenine content of 0.25% (Diet E, Table 2.1) for 6 weeks. This regime 
was not as successful for inducing AC as Diet D hence 0.75% adenine was employed 
in the final experiment (see below and Chapter 5 for details). 
2.7.2 Group and dietary assignments for final experiment. 
Rats were divided into 5 groups and fed test diets for 4 weeks. The ‘control’ group 
(N, n=10), received a diet containing a normal amount of phosphate (0.5%) and 
calcium (0.7%) and a low (2.5%) protein content  (Diet F, Table 2.1). The ‘adenine 
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alone’ group (A, n=6), received a similar diet but with the addition of 0.75% adenine 
(Diet G, Table 2.1). The ‘vehicle-treated’ (V, n=9), ‘low-dose P2X7R antagonist-
treated’ (LD, n=7) and ‘high-dose P2X7R antagonist-treated’ (HD, n=8) groups were 
fed a similar diet to the A group, but with elevated levels of phosphate and calcium 
(0.92% and 1% respectively), i.e. the diet from the pilot experiments which resulted 
in the most consistent AC (Diet D, Table 2.1). 
2.7.3 Preparation and administration of the selective P2X7R antagonist. 
For the duration of the 4 weeks, animals in the V, LD and HD groups received twice 
daily oral gavage of either the P2X7R antagonist AZ11657312 (AstraZeneca, 
Cheshire, UK) (LD and HD groups) or vehicle alone (0.5% hydroxypropyl 
methylcellulose/0.1% Tween80) (HPMC) (AstraZeneca) (V group). LD rats received 
20mg/kg per dose, the HD group received 60mg/kg. These doses were selected based 
upon previous data (held by AstraZeneca), showing biological effects of the higher 
dose in other, (non-vascular related), in vivo experimental rat models. Owing to 
practical and logistical restrictions, the N and A groups were not gavaged and were 
run either side, (A group before, and N group after), of the period during which 
gavaging of the other 3 groups took place.  
AZ11657312 was provided as a powder and the manufacturer advised that the 
compound would be soluble in HPMC for up to 2 weeks at ambient temperature, in 
the dark at pH 6.5. In general, fresh batches were made up on a weekly basis. The 
required mass of powder was weighed out and placed into a sterile receptacle 
marked with accurate volume indicators. Approximately 75% of the required vehicle 
volume was then added before briefly vortexing to wet the compound. The pH was 
then brought up to 6.5 with the drop-wise addition of 0.1M NaOH and vehicle added 
to make up to the final required volume. Aliquots of 10ml were made and stored at 
room temperature in the dark (wrapped in aluminium foil). All stocks of the vehicle 
were also brought up to pH 6.5 by the drop-wise addition of 0.1M NaOH and stored 
similarly.  
2.7.3.i Compound administration by oral gavage. 
Oral gavaging was performed at 8am and 4pm daily throughout the study period. 
Animals were scruffed, and a metal gavage cannula, connected to a 5ml syringe 
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containing the appropriate volume of study agent, was passed down the oesophagus 
into the stomach prior to administration. Animals were immediately returned to their 
cage and observed for signs of distress. On occasion, usually due to severe resistance 
in passing the gavage cannula, dosing was not attempted (detailed in Chapter 5). 
2.7.4 Determination of serum levels of AZ11657312. 
To assess whether adequate serum concentrations of antagonist were maintained for 
a sufficient length of time, blood samples were taken from rats in the HD group. 4 
rats had blood withdrawn from the tail vein on the first day of study at 2 hours post 
first dose (peak), and immediately before the second dose (trough). Further blood 
samples were taken on day 14 (trough level) and at sacrifice (trough). In addition, 
day 14 peak samples were taken from the other 4 HD rats. Serum drug 
concentrations were measured post hoc by liquid chromatography-tandem mass 
spectrometry (Xenogesis, Nottingham, UK). 
2.7.5 Collection of biological samples. 
On day 14 of study, rats had 500µl blood withdrawn from a tail vein for assessment 
of renal and liver function. On the penultimate day of study, immediately following 
the morning gavage, rats were put into individual metabolic cages for 24 hours 
where they were provided with free access to study diet and water. The following 
morning they were weighed and returned to their home cage. The urine volume was 
measured before snap freezing 5 x 1ml aliquots, and the water intake determined. 
Rats were then sacrificed and tissue collected. 
2.8 Blood Sampling From Rodents 
Blood samples from live mice were obtained from either the tail or saphenous veins. 
Blood from deceased mice was obtained via cardiac puncture using a 25G needle. 
Mouse blood was collected in 250µl lithium-heparin containing microvettes 
(Sarstedt, Leicester, UK). Following collection, blood was centrifuged at 400xg for 
20 minutes at room temperature. Serum was then removed, aliquotted out, and stored 
at -80ºC. 
Blood samples from live rats were taken from the tail vein using a ‘butterfly’ needle, 
collected into the same type of receptacle, and processed in the same way, as mouse 
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samples. The exception to this was for samples taken for measurement of drug levels 
which were collected into EDTA-containing vials (Sarstedt). Blood samples from 
deceased rats were taken via cardiac puncture using a 23G needle, and collected into 
6ml, lithium-heparin containing vials (Sarstedt). Following collection, blood was 
centrifuged at 400xg for 20 minutes. Serum was then collected, aliquotted, and 
stored at -80ºC. 
2.9 Harvesting And Storage Of Rodent Tissue 
Mice and rats were individually sacrificed by exposure to an elevated CO2 
concentration. Death was confirmed by cervical dislocation. The ventral surface was 
then sprayed with 70% ethanol and a midline incision made, starting over the lower 
abdomen and working up until the diaphragm was punctured. This was then divided, 
the rib cage reflected, and blood drawn from the right ventricle. 
Liver, spleen, bowel and lungs were removed, following which both kidneys were 
dissected out and weighed. For rats, a transverse incision was made to divide the left 
kidney into upper and lower halves. A transverse slice was taken from the cut 
surface of the upper half and fixed in 4% paraformaldehyde (PFA) (TAAB, 
Aldermaston, UK) for 24 hours before washing 3 times in PBS. Specimens were 
kept at 4ºC in PBS until processing for histological assessment. The remaining left 
upper pole was cut in half longitudinally. One half was snap-frozen in liquid nitrogen 
and stored at -80ºC, the other half was stored at -20 ºC in RNAlater (Qiagen, 
Manchester, UK). For mice, the top half of the left kidney was fixed in 4% PFA 
(TAAB) and subsequently processed as described above. The lower half was snap-
frozen. 
Following harvesting of kidney tissue, a cut was made through the right iliac artery 
and the aorta flushed through with ice-cold PBS. Aortas were then dissected out and 
cleaned of excess connective tissue. Rat aortas were divided into 3 sections – arch, 
thoracic and abdominal. The first 2cm of thoracic and abdominal aorta, and the 
aortic arch from the root to the brachiocephalic branch, were all placed into PBS for 
subsequent quantitative analysis of calcium content. The next 2mm from each 
segment was fixed in 4% PFA (TAAB) for histological assessment (subsequent 
handling was as described for kidney tissue above). The remaining arch and thoracic 
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aorta were snap-frozen in liquid nitrogen and stored at -80ºC. A small segment of 
abdominal aorta was snap-frozen and stored in a similar way, however the majority 
of remaining abdominal aorta was stored in RNA later (Qiagen) at -20ºC. For mouse 
aortas, a thin slice was taken from the proximal arch and fixed for histological 
processing and the rest of the arch (until just distal to the third branch) was put into 
PBS for subsequent assessment of calcium content. The remaining aorta was all 
placed into RNAlater (Qiagen) except for a thin slice taken at the level of the 
diaphragm for histological processing as above. 
Finally, the right femur (rats) was dissected out, quickly cleaned and fixed in 10% 
NBF for 48 hours, before being moved into 70% ethanol at room temperature for 
medium-term storage. 
2.10 Biochemical Analysis Of Serum And Urine 
2.10.1 Routine biochemistry. 
All routine serum and urine biochemical analysis was performed at MRC Harwell, 
Oxfordshire, UK. The majority of analytical techniques involved colourimetric 
quantification of analytes following a reaction with specific reagents (all detailed in 
Hough et al 2002). Creatinine was analysed using the enzymatic method and urea 
using the urease/glutamate dehydrogenase method. Calcium and phosphate were 
analysed using arsenazo III and molybdate respectively. Alkaline phosphatase (ALP) 
was measured using 4-nitrophenylphosphate and albumin using bromocresol green. 
Cholesterol analysis employed cholesterol oxidase and peroxidase and alanine 
transaminase (ALT) measurement utilised a modified technique without pyridoxyl 
phosphate. Urinary protein was determined photometrically. 
2.10.1.i Calculation of corrected calcium. 
Corrected calcium was determined by the following formula: 
Corrected calcium = measured total calcium - ((measured albumin - 30) x 0.017) 
This is based on the assumption that there is 0.017 mmol/l calcium per g/l albumin 
and that average albumin = 30g/l (Stechman et al 2010). 
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2.10.2 PTH Enzyme-Linked Immunosorbent Assay (ELISA). 
2.10.2.i General principle. 
The PTH concentration in rat serum was measured using the Rat Intact PTH ELISA 
Kit (Immutopics Inc, San Clemente, California, USA). This kit utilises the 
‘sandwich’ ELISA principle whereby samples are incubated in a streptavidin-coated 
well together with 2 PTH antibodies (a biotinylated capture antibody and a 
horseradish peroxidase (HRP) -conjugated antibody respectively) to form a complex. 
Following the incubation period and a series of wash steps, a substrate solution is 
applied to the residual complex bound to the well and incubated. The colour intensity 
produced by the resultant reaction is directly proportional to the amount of PTH 
present and this can be measured spectrophotometrically. 
2.10.2.ii Method. 
Serum samples were slowly thawed on ice and then centrifuged at 400xg at 4ºC for 1 
minute in order to pellet off any fibrin strands or cellular debris. Samples, positive 
controls and standards (all 25µl) were pipetted out in duplicate into test wells 
(positive controls and standards were provided in the kit). A solution (100µl) 
containing both antibodies was then applied to all wells which were incubated at 
room temperature for 3 hours in the dark with gentle rocking. An additional volume 
of one sample was run without antibody added as a negative control. 
Following this incubation step wells were washed 5 times with 350µl wash solution 
before applying 150µl ELISA HRP substrate for 30 minutes (incubation carried out 
at room temperature in the dark with gentle rocking). Absorbance was then read at 
620nm. ELISA Stop Solution (100µl) was then immediately added to each well and 
mixed for 1 minute. The absorbance was then read at 450nm on a microplate reader 
(EZ Read 400; Biochrom Ltd, Cambridge, UK). Final PTH concentrations were 
calculated using the standard curve. The standards provided in the kit were such that 
the working range for the assay was 0 – 3160 pg/ml.  
2.10.3 PPi assay. 
To assess relative differences in PPi content between serum samples, the 
‘Pyrophosphate Assay Kit II’ was used (Abcam, Cambridge, UK). This kit uses a 
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proprietary fluorogenic PPi sensor which has a fluorescence intensity proportional to 
the concentration of PPi present. 
Initially, 20µl of each serum sample was added to 80µl PBS and the absorbance 
profile read in order to assess for scatter and any potential absorbance within the 
range of emission wavelengths relevant for the measurement of PPi fluorescence. No 
major absorbance peaks were detected around 470nm for any sample, and in general 
the degree of scatter was similar for all. 
For PPi measurement, 50µl serum was incubated with 50µl PPi sensor at room 
temperature in the dark for 10 minutes before reading the fluorescence at Ex/Em = 
370/470nm using a FLUOstar Omega plate reader (BMG Labtech, Ortenberg, 
Germany). Test samples were run in duplicate, and in addition, a further 50µl 
volume of each was analysed without the presence of PPi sensor in order to control 
for background autofluorescence. The final results were calculated as the mean of 
duplicate samples and expressed in arbitrary fluorescence units. 
2.11 Assessment Of ENPP-1 Activity In Arterial Tissue 
ENPP-1 activity was assessed by colourimetrically measuring the hydrolysis of the 
synthetic substrate thymidine 5’-monophosphate p-nitrophenyl ester sodium salt 
(pNP-TMP) (Nam et al 2011, Lomashvili et al 2011). This reaction liberates p-
nitrophenylate which causes the reaction solution to turn yellow, the optical density 
of which can be measured at 405nm. It should be noted that this assay is not specific 
for ENPP-1 as pNP-TMP is also a substrate for other ENPPs. However, as ENPP-1 
has been shown to be the dominant ENPP in both cultured VSMCs and in-tact 
arterial tissue (Villa-Bellosta et al 2011a) this system represents a reasonable method 
for evaluating its activity.  
Arterial tissue was taken from storage at -80ºC and slowly thawed on ice in isotonic 
buffer (PBS containing 1mM CaCl2). Volumes of reaction solution (200µl), 
consisting of 180µl buffer and 20µl pNP-TMP (5mM final concentration), were 
pipetted into a 96 well-plate and baseline optical density readings were taken. 
Arterial segments had any residual blot clot removed and were divided in 2 in order 
to run samples in duplicate. These were then placed into the reaction solution-
containing wells and incubated at room temperature in the dark for 1 hour. Wells 
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containing only reaction solution and/or isotonic buffer (without tissue) were run as 
negative controls. Rings were removed from their wells, dried overnight and 
weighed. The final optical density of each individual reaction was recorded and the 
mean taken of replicate samples. Results were expressed as change in optical density 
(arbitrary units) per mg tissue. 
2.12 Micro-Computerised Tomography (CT) Analysis Of Bone 
All work involving micro-CT technology was performed in collaboration with 
Professor Tim Arnett (UCL, London). 
2.12.1 General principles. 
Examination of an object by micro-CT enables information to be obtained about its 
3-dimensional (3D) structure in a convenient and relatively quick manner. Test 
objects are held in place on a high-precision stage and rotated. Two-dimensional X-
ray shadows are obtained from a number of angular viewpoints and these are used to 
reconstruct cross-sectional images of the object using a well-defined cone-beam 
algorithm originally described by Feldkamp et al (1984). Ultimately this information 
generates a 3D representation of the internal micro-structure of the object under 
examination. 
2.12.2 Micro-CT scanning. 
Femurs were taken from storage (in 70% ethanol), wrapped in cling-film (to prevent 
drying out and movement artefact during scanning), and mounted on the stage of the 
scanner (SKYSCAN 1172, Brucker, Kontich, Belgium). Scanning conditions 
consisted of a 0.5mm aluminium filter, an X-ray voltage of 40kV, an X-ray current 
of 250µA and a camera resolution of 2000x1048. The rotation step was set a 0.4º. 
Scans typically lasted an hour in length. Upon completion of the scan, cross-
sectional images were reconstructed as outlined above. 
2.12.3 Data analysis. 
In order to analyze trabecular and cortical bone parameters it was first necessary to 
define a ‘reference point’ on each femur to ensure measurements were standardised 
across samples. This point was determined using the reconstructed images and 
moving up slice by slice, starting at the growth plate, until the first ‘broken bridge’ 
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of primary spongiosa was seen (Figure 2.2A). For each femur, the trabecular bone 
was examined in a 1mm long segment starting 3mm above the reference point, and 
cortical bone was examined in a 1mm long segment starting 6.5mm above the 
reference point. 
The areas containing trabecular and cortical bone to be analyzed were defined in the 
respective 1mm segments on each femur by digitally drawing round the ‘region of 
interest’ every 10 slices (Figures 2.2B and C). Slices in between were automatically 
interpolated by the computer programme. Regions of interest were then converted 
into binary images and processed by SKYSCAN software to generate measurements 
of bone parameters. 
2.13 Tissue Culture 
2.13.1 Specific reagents. 
The P2X7R antagonists A438079 and A839977 were both purchased from Tocris 
(Bristol, UK). BzATP and A438079 were made up in sterile H2O. A839977 was 
made up in dimethyl sulfoxide (DMSO). Corresponding volumes of these vehicular 
agents were added to control medium for experiments. 
For experiments using elastase, porcine pancreatic elastase was bought as lyophilised 
powder and reconstituted with sterile H2O. This was then aliquotted and stored at -
20ºC. For experiments, the required volume of thawed elastase solution was added 
directly to culture medium. 
For experiments using alkaline phosphatase, calf intestinal alkaline phosphatase 
(Invitrogen, Paisley, UK) was purchased as a solution and stored at -20ºC until  
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B C 
Figure 2.2. Micro-CT Analysis of Bone. A: Identification of Reference Point. The 
‘reference point’ on each femur was determined by moving up slice by slice, starting at 
the growth plate, until the first ‘broken bridge’ of primary spongiosa was seen (arrow). 
For each femur, the trabecular bone was examined in a 1mm long segment starting 3mm 
above the reference point, and cortical bone was examined in a 1mm long segment 
starting 6.5mm above the reference point. B: Cortical Bone Region of Interest. A line 
was digitally drawn around the whole cross-sectional image followed by a second line 
within the central portion of the image in order to exclude any trabecular bone. The area 
selected for analysis was then highlighted red. C: Trabecular Bone Region of Interest. A 
single line was digitally drawn in the centre of the image in order to separate the cortical 
and trabecular bone. The area selected for analysis was then highlighted red. 
A 
 53 
     
required. It was then added directly to culture medium to obtain the required 
concentration. 
To increase the pH of tissue culture medium, drops of sterile 10M NaOH were added 
to basal medium. Following mixing, the pH of a 3ml aliquot was taken immediately 
using a pH probe. 
2.13.2 In vitro culture of human VSMCs. 
Primary human VSMCs (hVSMCs) (TCS Cell Works, Buckingham, UK) were 
grown at 37°C and 5% CO2 in cell culture flasks containing medium M199 (Lonza, 
Slough, UK) supplemented with growth factors (smooth muscle cell growth 
supplement, (TCS Cell Works)), 5% fetal calf serum (as part of the growth 
supplement), 4mM L-glutamine (Invitrogen), 25ug/ml gentamicin and 50ng/ml 
amphotericin. At approximately 80% confluence cells were trypsinised and passaged 
at no greater than 1:3 split using warmed 1X 0.05% trypsin-EDTA (Invitrogen). For 
experiments, cells were used at passage 6-10 and plated at an approximate density of 
1x10
4
 cells per ml. Cells were counted using a haemocytometer and non-viable cells 
were stained with trypan blue.  
At 50-60% confluency cells were serum-starved overnight and then exposed to 
experimental medium. ‘Calcification-promoting medium’ was made by 
supplementing basal medium with small volumes of either 3M CaCl and/or 3M 
NaH2PO4 to obtain the required concentration of calcium and phosphate 
respectively. In all experimental medium (control or calcification-promoting) serum 
was supplemented to 4% unless otherwise indicated and contained gentamcin, 
amphotericin and L-glutamine at the same concentrations as detailed above. 
Experiments ran for the time courses indicated (see Chapter 3). Medium was 
changed every 2-3 days. 
2.13.3 Generation of rodent VSMCs. 
To reduce the number of animals used, aortas of Sprague-Dawley rats taken from 
control arms of experiments were kindly donated from others in our group. Aortas 
were cleaned of blood, fat and connective tissue under a dissecting microscope and 
cut into rings approximately 1mm in depth. Rings were then cultured in identical 
conditions as those described for hVSMCs. It was usual to observe outgrowths of 
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cells after 2 weeks. When significant outgrowths were visible, rings were then taken 
out and placed in fresh culture dishes. Cells were trypsinised and placed in fresh 
culture dishes as described above. Cells were characterised as VSMCs by positive 
immunofluorescent staining for α-SMA and smooth muscle myosin heavy chain 
(SMMHC), and also by light microscopic evaluation of their growth pattern, with 
‘hill-and-valley’ morphology considered typical of VSMCs (Proudfoot & Shanahan 
2012) (shown in Chapter 3). 
2.13.4 Culture of rodent aortic rings. 
Unless otherwise stated, all aortic ring culture experiments were performed using 
medium M199 containing Earle's buffered salt solution, 4mM L-glutamine, 6 g/L 4-
(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) and 2.2 g/L NaHCO3 
(Lonza), supplemented with 25ug/ml gentamicin and 50ng/ml amphotericin. 
Wistar rats (of similar characteristics as those described for in vivo work above) were 
sacrificed by exposure to an elevated carbon dioxide concentration. Aortas were 
immediately dissected out using standard sterile procedures and placed into culture 
medium on ice. Fine dissection of the aorta was then performed using a dissecting 
microscope in a Class II lamina flow cabinet. Blood, fat and connective tissue was 
removed but a small covering of adventitia was left in situ to minimise injury to the 
medial layer. Injury to the arterial media at time of harvest has been shown to 
contribute to calcification (Lomashvili et al 2004). Aortas were then divided into 
segments of approximately 3-4mm in length, taken from the thoracic to the distal 
abdominal section, measured using a ruler under the microscopic. Segments were 
placed into individual wells of a 24-well plate containing culture medium which had 
been left to equilibrate in an incubator at 37°C and 5% CO2 for a number of hours 
beforehand. A typical aorta yielded around 20 segments of this size.  
The following day rings were exposed to experimental medium. Rings from adjacent 
segments of aorta would be exposed to different study conditions. To make 
experimental medium, individual volumes (one per condition) of basal medium were 
placed in an incubator for at least 1 hour to equilibrate to 37°C and 5% CO2. 
Individual volumes were then quickly taken out of the incubator, an appropriate 
volume of NaH2PO4 added to bring the phosphate concentration up to the required 
 55 
     
level, and then placed back in the incubator for at least another hour. This was 
necessary to avoid major increases in medium pH (due to loss of CO2 buffering) 
which might result in precipitation of the supplemented ions (Lomashvili et al 2004). 
Following this, the necessary volume of reagent (e.g. P2X7R antagonist) was added 
to generate the final experimental medium. Rings were then cultured in their 
respective medium for 10 days. Medium was changed every 2-3 days following this 
protocol. 
2.14 Viability Testing Of Cultured Aortas 
Viability of cultured aortas was assessed as a function of the ATP-metabolising 
capacity of the vessel. Rings were cultured as described above except that the 
medium did not contain phenol-red (Invitrogen). At desired time-points medium was 
removed from rings and immediately snap-frozen in liquid nitrogen and stored at -
20ºC until required. Rings were immediately placed into fresh medium. 
The ATP content of culture medium was determined using the Adenosine 5’-
triphosphate (ATP) Bioluminescent Assay Kit (FLAA). A master mix of reaction 
reagents was made up in the following proportions: 300µl ATP Assay Mix 
(containing luciferase, luciferin, MgSO4, dithiothreitol (DTT), EDTA, bovine serum 
albumin (BSA) and tricine buffer salts) made up initially in H2O, 600µl Dilution 
Buffer (containing MgSO4, DTT, EDTA, BSA and tricine buffer salts) made up 
initially in H2O and 600µl H2O. 
Culture medium (50µl) was added to 100µl master mix. A standard curve was also 
prepared. Samples were then analysed using an Anthos Lucy 1 Luminometer 
(Anthos Labtech Instruments, Salzburg, Austria). 
2.15 O-Cresolphthalein Complexone Method To Quantify The Calcium Content 
Of A Solution 
2.15.1 General principle. 
This method utilises the principle that in an alkaline medium, calcium ions form a 
violet-coloured complex with o-cresolphthalein. 8-hydroxyquinoline is included in 
the reaction to minimise any interference from magnesium ions (Sarkar & Chauhan 
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1967). The absorbance of the resultant complex can be measured 
spectophotometrically and compared to a standard curve. 
2.15.2 Sample preparation. 
Medium was removed and cells and aortic rings were washed twice in PBS (free of 
calcium and magnesium), and in the case of rings, as much as possible of the 
adventitia was removed under a dissecting microscope (usually all although this was 
not possible in the case of rings from mice). Rings were then placed in 150ul 0.6M 
HCl overnight to liberate the deposited calcium. For cells, 0.6M HCl was applied 
directly into the wells and plates were then left overnight. For in vivo samples, aortic 
segments were cleaned of adherent blood clot and fat, washed twice in PBS, and 
placed overnight in 0.6M HCl (500µl for rat aortas and 150µl for mouse tissue). 
Calcium content of the HCl was subsequently quantified using the o-cresolphthalein 
complexone method. 
2.15.3 Reagents. 
Colour reagent: 25mg o-cresolphthalein complexone powder was dissolved in a 
solution containing 15ml 11.6M HCl and 25ml H2O. Following this 250mg 8 
hydroxy-quinoline was added and the volume made up to 250ml with H2O before 
dissolving completely.  
Alkaline buffer: 37.8 ml of 2-amino-2-methyl-1-propanol with 150ml H2O. The pH 
was adjusted to 10.7 with 11.6M HCl and the volume made up to 250ml with H2O.  
Both the colour reagent and alkaline buffer were shielded from light prior to use.  
For each analysis appropriate calcium standards were prepared from a 50mg/dl stock 
standard which was made by dissolving 625 mg of dried and desiccated calcium 
carbonate with 3.5ml 11.6M HCl in a total volume of 500ml H2O. 
2.15.4 Quantification of calcium. 
Test samples and appropriately diluted standards (all 100µl) were pipetted into 
sterile 5ml tubes. Colour reagent (2ml) was added to each, followed by 2ml of 
alkaline-buffer. Samples were then incubated at room temperature in the dark for 15 
minutes in order for the colour to stabilize. Duplicate 100µl volumes were then 
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pipetted into a flat bottomed, transparent 96-well plate and read at 562nm on a 
microplate reader (EZ Read 400; Biochrom Ltd). A standard curve was constructed 
against which test sample readings were compared (Figure 2.3). 
The calcium concentration was then ‘corrected’ for tissue dry weight, (for aortic 
samples), or protein content for cells. Aortic rings/segments were dried at 50ºC 
overnight and weighed on a semi-micro balance capable of measuring down to 10µg 
(ME235S, Sartorius, Epsom, UK). For cells, 2 washes in PBS were performed before 
lysis in 0.1% sodium docecyl sulphate (SDS) and 0.1M NaOH. The lysate protein 
concentrations were then measured using the bicinchoninic acid (BCA) assay 
(Pierce) (method described under ‘Western blotting’). 
 
 
Figure 2.3. Representative Standard Curve for Quantifying Calcium 
Concentration. Optical density is plotted linearly against calcium concentration 
with an R
2 
value of 0.996 in this example. 
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2.16 Quantitative Polymerase Chain Reaction (qPCR) 
2.16.1 General principles. 
The purpose of PCR is to amplify, (by making several million copies of), a gene 
sequence from a small starting quantity of DNA in order to permit its detection. A 
DNA template is entered into a reaction alongside oligonucleotide primers specific 
for the gene of interest, deoxynucleotides (dNTPs) and a DNA-polymerase enzyme. 
Following an initial exposure to 95ºC to activate the polymerase, reactants pass 
through 3 steps, each at optimised temperatures, to permit DNA denaturing, primer 
annealing and product extension respectively. These steps are repeated for a number 
of cycles. After each cycle the amount of product doubles, meaning that an 
exponential increase occurs as the reaction proceeds, and this continues until one or 
more of the reagents has been exhausted. 
Quantitative PCR is an adaptation of this basic technique, and has been designed in 
order to measure the magnitude of gene expression in the starting material. Analysis 
is made during the exponential phase of the reaction so that reagents are not limited, 
and before the products are so abundant that they may hybridize and interfere with 
primer binding. All qPCR formats rely on the detection of a fluorescent signal which 
increases with rising product. The fluorescent dye SYBR green was used for all 
qPCR assays in this thesis.  
SYBR green binds strongly to double-stranded DNA, and in the bound state the level 
of fluorescence increases 100-fold. It can therefore be included in a qPCR assay, 
where the increase in fluorescence will be directly proportional to the accumulating 
product (Schneeberger et al 1995). Fluorescence intensity at a defined threshold can 
be compared to that of known standards in order to determine the starting quantity of 
mRNA, following normalisation to a number of ‘housekeeping’ genes. 
Due to the extreme sensitivity of qPCR, and the almost ubiquitous presence of 
RNAse enzymes in the environment, it is of paramount importance to adhere to strict 
handling and operating procedures when carrying out work with RNA. Ideally, 
specific work surfaces should be reserved for PCR work, and gloves and laboratory 
coats should be worn at all times. All reagents should be ‘PCR-grade’ and all 
equipment verified as being ‘RNAse free’. It is also vital to apply a high level of 
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quality control to the RNA samples used for downstream applications, and this 
should include an assessment of purity and integrity. 
2.16.2 RNA extraction from aortas. 
RNA extraction was performed using the RNeasy Fibrous Tissue Mini Kit (Qiagen) 
according to the provided protocol. This is a column-based system whereby tissue is 
exposed to a number of agents, proprietary buffers and centrifugation wash steps, 
ultimately resulting in RNA binding to a silica membrane from which it can be 
eluted. 
Arterial tissue was placed in RNAlater (Qiagen) following harvest, and stored at -
20ºC prior to RNA extraction. Segments were taken from storage, cleaned of 
residual blood clot and as much adventitia as possible, then placed in individual, 
round bottomed, 2ml tubes, each containing 2 x 5mm stainless steel beads (all 
Qiagen). ‘Buffer RLT’ (300µl), supplemented with 10µl/ml of β-mercaptoethanol, 
was then added to each sample and these were then immediately shaken for 5-10 
minutes at 50Hz using a TissueLyzer LT (Qiagen) to achieve full lysis and 
homogenisation. ‘Buffer RLT’ contains guanidine thiocyanate, a chaotropic agent, 
which aids both lysis of tissue and binding of RNA to the silica membrane. The 
addition of β-mercaptoethanol serves to inactivate RNAses. 
Lysates were transferred to fresh tubes, and 590µl of RNAse-free H2O followed by 
10µl of proteinase K added, before heating at 55ºC for 10 minutes. Proteinase K 
serves to remove contractile proteins and connective tissue, usually high in 
abundance within fibrous tissue such as aorta, in order to aid RNA purification. 
Tubes were then centrifuged for 3 minutes at 10000xg, the supernatant transferred 
into a fresh tube and 450µl 100% ethanol mixed with the lysate to provide 
favourable binding conditions to the membrane. Each sample was added to a spin 
column and centrifuged at 8000xg for 15 seconds, following which the membrane 
was washed by centrifuging through 350µl ‘buffer RW1’. 
To remove any potential contamination from DNA, an on-column DNAse digestion 
step was performed. Prior to use, 1500 Kunitz units of lyophilised DNase were 
reconstituted in 550µl of RNase-free water and aliquotted. Following reconstitution, 
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10µl was added to 70µl of ‘buffer RDD’, gently mixed, and applied directly to the 
membrane for 15 minutes. 
The membrane was then washed as before with ‘buffer RW1’, following which 
500µl ‘buffer RPE’ containing 4 volumes of 100% ethanol was added to remove 
trace salts. The column was then centrifuged for 15 seconds at 8000xg. In order to 
dry the membrane and avoid carryover of ethanol, this step was repeated but with 
centrifugation for 2 minutes. 
Finally, to elute the RNA, 30µl was added to the membrane and the column 
centrifuged at 8000xg for 1 minute. To maximise the RNA yield, the elutant was 
then re-applied onto the membrane and the column was again centrifuged. RNA was 
aliquotted for analysis of concentration, purity and integrity, and for use in 
downstream applications. Samples were stored at -80ºC until required. 
2.16.3 Measurement of RNA concentration and purity. 
The concentration and purity of all RNA samples used for qPCR were measured, 
using a Nanodrop 2000 (Thermo Fisher Scientific). This instrument is a scanning 
spectrophotometer which uses fibre-optic technology. Nucleic acid has a peak 
absorption wavelength of 260nm and this property can be used to determine the 
concentration of RNA or DNA within a sample. Potential contaminants have 
different absorbance wavelengths, for example protein absorbs at 280nm, and the 
ratio of 260/280 can be measured. 260/280 ratios of over 1.7 are generally 
considered to indicate an acceptable level of RNA purity (Fleige & Pfaffl 2006). 
RNA (1µl) was loaded onto the instrument pedestal for readings to be taken (Figure 
2.4). 
2.16.4 Assessment of RNA integrity. 
RNA integrity was assessed using a Bioanalyzer 2100 (Agilent, Wokingham, UK). 
This technology involves a ‘chip’ containing micro-channels, into which a sieving 
polymer and a fluorescent dye (combined beforehand in the form of a ‘gel-matrix’) 
are loaded. Samples are electrophoresed through the gel-matrix, and due to the 
presence of a constant mass-to-charge ratio RNAs are separated according to size. 
Each RNA molecule takes up the dye, and RNA-dye complexes are detected using a 
laser. The information obtained is converted into an electropherogram (Figure 2.5) 
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and used to generate an RNA integrity number (RIN). Values exceeding 5 are 
suggested to be imply sufficient integrity for qPCR assays with values above 8 said 
to represent highly preserved RNA integrity (Fleige & Pfaffl 2006). In some 
instances, usually due to a low yield of RNA following extraction from tissue, 
integrity was not measured. This was mainly an issue for tissue culture work and 
samples from human vessels. All aortas from in vivo animal experiments had an 
assessment of RNA integrity performed. 
2.16.5 Synthesis of complementary DNA (cDNA). 
For PCR to proceed, a starting DNA template is required. It was therefore first 
necessary to generate cDNA templates by subjecting each RNA sample to a reverse 
transcription (RT) reaction. The SuperScript VILO cDNA Synthesis kit (Invitrogen) 
was used for this purpose and reactions were performed using a G-Storm Thermal 
Cycler (G-Storm, Somerton, UK). 
A mastermix containing 10X SuperScript Enzyme Mix (2µl per sample), and 5X 
Reaction Mix (4µl per sample,) was made first. The Enzyme Mix contains an 
engineered Moloney-Murine Leukemia Virus (M-MLV) reverse transcriptase, 
RNase H activity, recombinant ribonuclease inhibitor and a proprietary helper 
protein. The Reaction Mix contains random primers, MgCl2 and dNTPs in an 
optimised buffer. Mastermix (6µl) was then added to the appropriate volume of RNA 
and the reaction volume made up to 20µl. ‘Non-RT’ control reactions were also set 
up for samples in an identical fashion, except RNAse-free water replaced the 10X 
Enzyme Mix. For samples taken from rat in vivo experiments, 1µg of aortic RNA 
was reverse transcribed. Due to less available tissue and lower RNA yields, 200ng of 
RNA was reverse transcribed from cultured rings, and 100ng from human arteries. 
Samples were incubated at 25ºC for 10 minutes to permit primer annealing, followed 
by 42ºC for an hour in order for cDNA synthesis to occur. The reaction was then 
terminated by heating to 85ºC for 5 minutes. After cooling, products were diluted 
down 1.10 (in vivo samples) in yeast transfer RNA (tRNA) (10µg/ml) (which acts as 
a carrier molecule). Aliquots were made and stored at -80ºC. Tissue culture samples 
were diluted 1.5 and human samples were used undiluted.  
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Figure 2.4. Assessment of RNA Purity. Representative spectral pattern of RNA 
extracted from rat aorta analysed on a Nanodrop. The trace has a peak at 260nm 
due to absorbance by nucleic acid (closed arrow). There is a trough at 230nm 
consistent with uncontaminated RNA (broken arrow). The 260/280 ratio of this 
sample was 1.98. 
Figure 2.5. Assessment of RNA Integrity. Representative appearance of an 
electropherogram generated by analysing a sample of RNA extracted from a rat 
aorta on the Bioanalyser. The key elements suggestive of high quality RNA are a 
single marker peak (arrow) and 2 major ribosomal peaks corresponding to 18S and 
28S (starred). The RIN of this sample was 9.4 indicating highly preserved integrity 
of RNA. 
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2.16.6 Primer design and optimisation. 
Primers were designed using Primer-Blast software, freely available online from the 
National Centre for Biotechnology Information. Intron-spanning primers pairs were 
designed and selected for use if the amplicon product was less than 200 base pairs 
(bps) in length. Secondary structure formation was minimised by assessing primer 
pairs using the ‘two-state melting’ application, freely available through the mfold 
web server (hosted by the RNA Institute, College of Arts and Sciences, State 
University of New York at Albany). Primers which generate a positive ‘delta G’ 
value with this tool are less likely to form secondary structures. 
If optimisation of assay conditions was required for primer pairs, a series of reactions 
were run on a G-Storm Thermal Cycler (G-Storm) set up to include a temperature 
gradient step (56ºC-66ºC) during the annealing phase of each cycle. A range of 
primer concentrations was trialled under these conditions. Products were then 
electrophoresed in a similar fashion to that described below, and the reaction 
conditions yielding the strongest, single band, selected for use in the final assay 
(Figure 2.6). Details of specific primers pairs for each gene studied along with the 
PCR conditions used for each assay are given in Table 2.3 (human) and Table 2.4 
(rat). 
 
Figure 2.6. Optimisation of qPCR Assay for Runx-2. A series of reactions were run on a G-
Storm Thermal Cycler set up to include a temperature gradient step (56º-66º) during the annealing 
phase of each cycle. A range of primer concentrations was trialled under these conditions. Products 
were then electrophoresed on a 2% agarose gel and the reaction conditions yielding the strongest, 
single band, selected for use in the final assay. In this example, 5 annealing temperatures were 
trialled (57º, 58º, 60º, 62º and 64º as indicated) at 2 different primer concentrations as shown. The 
strongest single product (at the correct size of 129bp for runx-2) was detected at a concentration of 
0.25µM primer at 58º (white arrow) so these reaction conditions were used for the final assay. A 
100bp reference ladder was also run as indicated. 
0.5µM primer 0.25µM primer 
100 bp 
ladder 
← 129bp 
↑ 
57ºC 
↑ 
58ºC 
↑ 
60ºC 
↑ 
62ºC 
↑ 
64ºC 
↑ 
64ºC 
↑ 
62ºC 
↑ 
60ºC 
↑ 
58ºC 
↑ 
57ºC 
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Gene Forward Primer Reverse Primer Primer Concentration 
(µM) 
No. of 
cycles 
Annealing Temp. 
(deg. C) 
 
RPL13a CCTGGAGGAGAAGAGGAAAGAGA TTGAGGACCTCTGTGTATTTGTCAA 0.50 40 58 
SDHA AGAAGCCCTTTGAGGAGCA CGATCACGGGTCTATATTCCAGA 0.50 40 58 
HPRT TGACACTGGCAAAACAATGCA GGTCCTTTTCACCAGCAAGCT 0.50 40 58 
ENPP-1 AAAGTACTCTCGCTGGTATTGTC TCACAGCGACAGTTCCCAAA 0.50 40 60 
ANK GCAGCCCACATCAAGAAGTT TCCAAAACATCACGAAACAGA 0.50 40 60 
 
Table 2.3. qPCR of Human RNA. Primers used for qPCR analysis of RNA extracted from human arterial tissue and details of cycle number and annealing temperature for 
each assay. RPL13a: ribosomal protein L13a; SDHA: succinate dehydrogenase complex, subunit A; HPRT: hypoxanthine-guanine phosphoribosyltransferase.
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Gene Forward Primer Reverse Primer Primer Concentration 
(µM) 
No. of 
cycles 
Annealing Temp. 
(deg. C) 
 
β-actin CCCGCGAGTACAACCTTCT CGTCATCCATGGCGAACT 0.25 30 58 
YWHAZ CTACCGCTACTTGGCTGAGG TGTGACTGGTCCACAATTCC 0.50 40 57 
28S TGCAGATCATGCTGTTTAAGAAC GGACCTGCTCCCCAGATT 0.50 40 57 
SDHA CCCTGAGCATTGCAGAATC CATTTGCCTTAATCGGAGGA 0.50 40 60 
HPRT GACCGGTTCTGTCATGTCG ACCTGGTTCATCATCACTAATCAC 0.50 40 57 
P2X7R AAGAAGTGTGAGCCCATCGT GCTCGTCCACAAAGGACAC 0.50 40 60 
α-SMA GTGTGAAGAGGAAGACAGCACA ATTCCAACCATCACTCCCTGGTG 0.25 30 58 
SM22 CCAAGCCTTTTCTGCCTCAA GCCATTCTTCAGCCACACCT 0.50 40 60 
Smoothelin GGCTCGTCCACTCCAATGAC GTTTGGTCCTCTCGGTCGAA 0.50 40 60 
Runx-2 AACCACAGAACCACAAGTGC TTGCAGCCTTAAATGACTCGGT 0.25 45 58 
Osterix GCCACCCATTGCCAGTAATCT AGCTTCTTCCTGGGGAGGCTA 0.50 40 60 
BMP-2 GACTGCGGTCTCCTAAAGGTC GGGGAAGCAGCAACACTAGA 0.50 40 60 
Caspase-3 CCGACTTCCTGTATGCTTACTA CATGACCCGTCCCTTGAA 0.50 40 60 
NLRP3 CTGCAGAGCCTACAGTTGGG GTCCTGCTTCCACACCTACC 0.50 40 60 
ENPP-1 TTCCTGTCCCAGTGTCCAAT TGATCGGCACAATCGAAG 0.50 40 60 
CD73 CTTCTGAACAGCACCATTCG CCTCCACTGGTTAATGTCTGC 0.50 40 60 
CD39 GGGCCTATGGGTGGATTACT AAGTTTAGCCAACTCTGTTCCTG 0.50 40 60 
TNAP GCACAACATCAAGGACATCG TCAGTTCTGTTCTTGGGGTAT 0.50 40 62 
ANKH TCCACACCCTGATAGCCTAC ATTGAGGCACATCCCACCAG 0.50 40 60 
 
Table 2.4. qPCR of Rat RNA. Primers used for qPCR analysis of RNA extracted from rat aorta and details of cycle number and annealing temperature for each assay. 
YWHAZ: Tyrosine 3-Monooxygenase/Tryptophan 5-Monooxygenase Activation Protein Zeta; 28S: 28S Ribosomal RNA.
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2.16.7 Preparation of cDNA standards. 
To generate standards for each gene, a qPCR assay was performed using cDNA from 
a single control sample (non-calcified vessel for human tissue). Five replicates were 
run in the case of rodent samples whereas only a single assay was possible with 
human tissue due to the limited starting material available. Melt curves (see section 
2.16.8) were inspected to ascertain whether single peaks were present.  
The PCR products were then pooled and added in a ratio of 4:1 to 10X ‘Bluejuice’ 
PCR loading buffer (Invitrogen) which was pre-diluted 1 in 20 (so as not to obscure 
visualisation of bands under UV light). Samples were then electrophoresed at 80V 
for 40 minutes on a 2% agarose gel made with 1x TAE containing 0.04ul/ml 
ethidium bromide. A 100bp reference ladder (Thermo Fisher Scientific) was run in 
one lane in order to ascertain the size of DNA bands. Gels were viewed under UV 
light with the presence of a single band of the expected size taken as confirmation of 
primer specificity (Figure 2.7). 
 
Figure 2.7. Assessing Specificity of Primers. Upon completion of a qPCR assay 
the products from the replicate samples were pooled, electrophoresed on a 2% 
agarose gel and then visualised under UV light. Primer pairs were accepted if a 
single band of the expected size was evident (starred). If multiple bands were 
detected (arrowed lanes) primers were rejected. A reference 100bp ladder is shown 
in the left-hand lane. 
* * * * * ↑ ↑ ↑ 
100 bp 
ladder 
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The Geneclean Spin Kit (MPBiomedicals, Solon, USA) was then used to extract and 
purify cDNA from gels. This kit employs the principle that DNA will bind to silica 
in an environment high in chaotropic salt, and will elute when the salt concentration 
is lowered. DNA bands were excised from agarose gels under UV light, placed into a 
spin column containing 400µl ‘Geneclean Spin Glassmilk’ and melted at 55ºC. The 
Glassmilk contains a suspension of proprietary silica matrix and chaotropic binding 
salt thereby providing the necessary conditions for DNA binding.  
Following a centrifugation step with ‘Geneclean Spin New Wash’, a solution 
containing NaCl, Tris, EDTA and ethanol (added prior to use) which acts to remove 
any remaining salt and agarose whilst ensuring DNA remains bound, the column was 
centrifuged for 2 minutes at 14000xg to dry the pellet. ‘Geneclean Spin Elution 
Solution’ (15µl), (PCR-grade water provided with the kit), was added to the column 
and the pellet suspended within it. DNA was eluted and collected by centrifugation 
at 14000xg for 30 seconds. 
The concentration of extracted cDNA was measured using a Nanodrop (Thermo 
Fisher Scientific) thereby enabling subsequent calculation of the number of DNA 
copies present in 1µl by applying the following equations: 
1. MMW of amplicon = amplicon length (in bp) x 660   
[MMW: mean molecular weight; 660 = MMW of 1bp] 
2. Amplicon copy number in 1ng = (6.02 x 1023 / MW amplicon) x 10-9 
[6.02x10
23
 = Avogadro’s constant] 
3. Number of copies in 1µl = cDNA/µl x copies of amplicon/ng 
By diluting the concentrated cDNA it was possible to prepare standards from 10
7 
- 
10
2
 per 2µl (the volume used in qPCR assays). These were made up in tRNA and 
stored at -80ºC. 
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2.16.8 Quantitative PCR. 
For every gene, each test sample was run in duplicate, and 6 standards (10
2
 – 107), 
were run in triplicate. RT-negative and tRNA (diluent alone) samples were also run 
as negative controls on each occasion. 
Reactions volumes of 10µl were prepared using a CAS-1200 robotic pipetting device 
(Qiagen). cDNA (2µl) was added to a mastermix containing 5µl SensiMix 
SYBR Hi-ROX (Bioline, London, UK) and an equal volume and concentration of 
forward and reverse primers (see Tables 2.3 and 2.4 for details), made up to 8µl with 
RNase-free water. The SensiMix reagent contains SYBR Green I dye, dNTPs, 
stabilisers and enhancers. 
Reactions were run on a RotorGene 6000 (Qiagen). Reactions commenced with a 10 
minute hold at 95ºC for polymerase activation, followed by repeated cycles of 
denaturation, annealing and extension steps, all 10 seconds in length. The number of 
cycles and annealing temperature varied according to the primer pairs, details of 
which are given in Tables 2.3 (human) and 2.4 (rat). After the final cycle, a melt 
curve was constructed by increasing the temperature from 72ºC to 95ºC by 1ºC every 
5 seconds.  
Upon completion of the run, an assessment was made of the standard curve linearity 
(r
2
 value) and reaction efficiency (Figure 2.8A). Accepted values were >0.99 and 
0.85-1.10 respectively. Melt curves were also inspected to verify that single peaks 
had been obtained (Figure 2.8B). Gene copy numbers from each sample were then 
determined by comparing the cycle number (Ct value) at which the fluorescence 
threshold (automatically determined by the RotorGene system) was reached, to the 
standard curve (Figure 2.8C). Final copy numbers were calculated from the 
geometric means of duplicate samples. 
2.16.9 Calculation of gene copy number. 
In order to compare copy numbers of a gene of interest between samples from 
different treatment groups, it is necessary to normalise the results to one or more 
stable ‘housekeeping’ genes, the expression of which should not change regardless 
of experimental conditions. By using a panel of stable housekeeping genes in 
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combination for this normalisation process, a greater level of accuracy can be 
achieved.  
GeNorm software was used to facilitate the choosing of the most stable 
housekeeping genes to use for normalisation. The mathematical principles 
underlying this programme were originally described by Vandesompele et al (2002). 
GeNorm calculates the average pairwise variation for a gene with all other tested 
reference genes, to derive a stability factor ‘M’. It is then possible to choose the most 
stable combination of housekeeping genes. From this selection, the geometric mean 
is calculated in order to derive a ‘normalisation factor’ for each test sample, by 
which all raw copy numbers are divided in order to obtain the final corrected copy 
number for each gene of interest. 
Figure 2.8. An Optimised qPCR Assay. Representative results obtained from an optimised qPCR 
assay analysing rat aortic RNA. A: Standard curve generated from the results in Figure C. In this 
example R
2 
was 0.999 and the efficiency was 0.95. B: Typical melt-curve showing a single peak for 
all samples and standards suggestive of a single reaction product. C: Typical results of a qPCR 
assay. Fluorescence is plotted against cycle number with the red horizontal line representing the 
automatically derived threshold at which Ct readings are taken. Standards (each in triplicate) are 
seen as the pink, orange, green, yellow, blue and red lines (10
7 
- 10
2
 respectively) (arrows). Samples 
are indicated by purple lines. Turquoise and brown lines represent reverse transcription-negative 
and tRNA samples respectively and all fall below the threshold line indicating absence of RNA 
content. 
A 
C 
B 
       
70 
      
2.17 Western Blotting 
2.17.1 General principles. 
The purpose of a Western blot is to detect the presence of a protein within a 
biological sample. The starting material (cells or tissue) is homogenised in a lysis 
buffer, containing protease and phosphatase inhibitors to minimise degradation, in 
order to liberate proteins. The denatured lysate is then electrophoresed through a 
SDS polyacrylamide gel, resulting in the separation of proteins according to their 
molecular weight. The protein bands are then transferred onto a membrane, usually 
nitrocellulose, by applying a voltage across the gel. Once transferred onto the 
membrane, an antibody specific to the protein of interest (primary antibody) can be 
applied, followed by a secondary antibody, commonly an HRP-conjugated. 
Numerous secondary antibodies can bind to one primary antibody, and by cleaving 
the chemiluminescent agent that is subsequently applied to the membrane, the signal 
generated is amplified. The final signal is detected by exposing the membrane to a 
photosensitive film which is then developed. 
2.17.2 Solutions. 
Radioimmunoprecipitation assay (RIPA) buffer: 1% Triton X100; 0.1% SDS; 
150mM NaCl; 10mM Tris pH 7.2; 0.5% NP40; Protease and phosphatase inhibitor 
cocktail, 1 tablet in 10ml (Thermo Fisher Scientific). 
Stacking gel: 3.4ml water; 630ul 1M Tris pH 6.8; 750ul 30% Protogel acrylamide 
(National Diagnostics, Hessle, UK); 50ul 10% SDS; 75ul 10% ammonium persulfate 
(APS); 10ul tetramethylethylenediamine (TEMED) (BioRad). 
10% resolving gel: 4ml water; 2.5ml 1.5M Tris pH 8.8; 3.34ml 30% Protogel 
acrylamide (National Diagnostics); 100ul 10% SDS; 80ul 10% APS; 10ul TEMED 
(BioRad). 
10x SDS Polyacrylamide Gel Electrophoresis (PAGE) Running buffer: 30.3g Tris 
base; 144.1g glycine; 10ml 10% SDS; made up to 1L with distilled water. 
Transfer buffer (Bjerrum and Schafer-Nielson): 5.82g Tris; 2.93g glycine; 3.75ml 
10% SDS; 200ml methanol; made up to 1L with distilled water. 
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10x Tris-Buffered Saline (TBS): 900 ml distilled ater; 24g Tris base; 88g NaCl; pH 
then adjusted to 7.6 with 12M HCl and solution made up to 1L with distilled water. 
Blocking solution: Required % protein (non-fat milk powder or BSA as indicated) 
added to 1L 1xTBS/T (TBS/Tween) (made by adding 1ml Tween to 999ml of 1x 
TBS i.e. 0.1% Tween). 
2.17.3 Protein extraction from aortic tissue. 
Aortic rings were snap-frozen in liquid nitrogen immediately following harvest and 
subsequently stored at -80ºC. For protein extraction, the frozen tissue was transferred 
into a 2ml round-bottomed collection tube containing 2x5mm steel balls (all Qiagen) 
which had all been kept on dry ice for 30 minutes beforehand. RIPA buffer (150µl) 
was then added and the tube immediately rapidly shaken at 50Hz for approximately 
4x5 minute bursts using a TissueLyzer LT (Qiagen) in order to homogenise the 
tissue. The resultant lysate was then transferred into a fresh tube on ice and 
centrifuged at 8000xg for 5 minutes. The supernatant was removed and aliquots 
made for long-term storage at -20ºC. A 5µl aliquot was used to determine the protein 
concentration as described below.  
2.17.4 Measurement of sample protein content. 
The protein concentration of tissue lysates was determined using the BCA protein 
assay (Pierce). This technique utilises the fact that in the presence of an alkaline 
medium, protein will reduce Cu
2+
 to Cu
1+
. The resulting Cu
1+ 
will chelate with BCA 
to form a purple, water soluble compound, the absorbance of which increases 
linearly with increasing protein concentration over a wide range of values, and can 
be measured spectophotometrically at 562nm. Using this method, a standard curve 
can be constructed using known concentrations of BSA, against which experimental 
samples can be compared in order to measure total protein content. 
To generate protein standards, appropriate dilutions of BSA stock solution (2mg/ml) 
were made using H2O to form volumes of 20µl. To each 20µl standard, 5µl of RIPA 
buffer was added. For test samples, 5µl of lysate was added to 20µl H2O. A mixture 
was then made, in a 50:1 ratio, of ‘reagent A’ (containing sodium carbonate, sodium 
bicarbonate, BCA and sodium tartrate in 0.1M sodium hydroxide), and ‘reagent B’ 
(containing 4% cupric sulphate). The working reagent (200µl) was then added to 
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each standard and test sample before incubating at 37ºC for 30 minutes. After 
cooling to room temperature, the absorbance of duplicate 100µl aliquots, placed in a 
96 well, transparent, flat-bottomed plate was read on a microplate reader (EZ Read 
400; Biochrom Ltd). A standard curve was generated and test sample protein 
concentrations calculated. 
2.17.5 Electrophoresis. 
Electrophoresis was performed using a BioRad Mini-Protean II System (BioRad). To 
prepare samples for electrophoresis, appropriate volumes of lysis (RIPA) buffer were 
added to each to equalise volumes, following which a 1X loading buffer (Biorad) 
was added in a ratio of 1:1. Samples were heated at 95°C for 10 minutes to denature 
and then centrifuged at 10000xg for 30 seconds. Samples were loaded onto the gel 
immersed in 1x running buffer. A Spectra Multi-colour Broad Range Protein Ladder 
(Thermo Fisher Scientific) (10µl) was loaded into one of the lanes in order to 
ascertain the molecular weight of subsequently detected protein bands. Gels were 
initially run at 10mA. When samples had stacked at the stacking gel/resolving gel 
interface, the current was increased to 20mA and the gel run until the loading dye 
reached the bottom of the gel. 
2.17.6 Transfer. 
For semi-dry transfer, gels were removed from the cassette and gently rocked in 
transfer buffer for 30 minutes. Following this the gel was placed on top of 0.2µm 
nitrocellulose membrane (GE Healthcare Life Science, Amersham, UK) which was 
placed onto 4-5 layers of filter paper on the transfer plate (Semi-dry Transblot, 
BioRad). Air bubbles were removed and the gel covered in further filter paper. All 
filter paper and nitrocellulose had also been pre-soaked in transfer buffer. Transfer 
was performed at 12V for 45 minutes. Successful transfer was assessed by staining 
the nitrocellulose membrane with Ponceau S. This stain was removed by washing 
several times in water. The membrane was then blocked by gently agitating in 
blocking solution for at least 2 hours at room temperature. 
2.17.7 Protein labelling and visualisation. 
Primary antibodies were made up in blocking solution and applied at the appropriate 
concentration for the indicated time period (Table 2.5). Membranes were washed for 
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5 minutes 4 times in TBS/T following which the secondary antibody, made up in 
blocking solution was applied for the required time (Table 2.5). Membranes were 
washed for 5 minutes 3 times in TBS/T, followed by a final 5 minute wash in PBS. 
The chemiluminescent substrate Lumiglo (New England Biolabs, Hitchin, UK) was 
then applied for 1 minute. Excess substrate was dabbed off, the membrane wrapped 
in parafilm and placed in a developing cassette (Kodak, Rochester, New York, 
USA). In a darkroom, photo-sensitive film was applied to the wrapped membrane 
and held within the cassette for the required length of time (typically a number of 
seconds). Blots were then developed using a Compact X4 automatic processor 
(Xograph, Stonehouse, UK). Image J software was used to compare bands by 
densitometry.  
2.18 Immunofluorescence 
Cells were grown in 8 well chamber slides (BD Falcon, Oxford, UK) until 80% 
confluent. Culture medium was then gently tipped off, cells were washed once in 
PBS supplemented with 0.9mM calcium and 0.49mM magnesium and 200ul 4% 
PFA was then applied for 5 minutes followed by 3 washes in PBS. If 
permeabilisation was required, 200ul ice-cold methanol was applied to wells for 5 
minutes followed by 3 PBS washes. Cells were then blocked for 30 minutes with 
200µl serum from the species in which the secondary antibody was derived. The 
primary antibody (Table 2.6), made up in PBS, was then applied for the indicated 
length of time. IgG from the primary species was applied at equivalent 
concentrations as a control for non-specific binding. Slides were washed 3 times in 
PBS and the appropriate secondary antibody (Table 2.6), made up in PBS, was 
applied for 1 hour. Cells were then washed 3 times in PBS and finally in H2O before 
being mounted with hard-set mounting medium (Vector Labs, Peterborough, UK) 
which included 4',6-diamidino-2-phenylindole (DAPI) for nuclear visualisation. 
Once set, slides were examined using an epifluorescence microscope (Zeiss, 
Cambridge, UK). 
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Target Protein Primary  
Antibody 
Primary Dilution 
(Time and 
incubation 
temperature) 
 
Secondary 
Antibody 
Secondary 
Dilution 
(Time and 
incubation 
temperature) 
 
Human P2X7R ab109246 
 (Abcam) 
Rabbit 
monoclonal 
1:1000 
(overnight at 4ºC) 
HRP-conjugated  
Goat anti-Rabbit 
polyclonal 
(Thermo Fisher) 
1:3000 
(1 hour at room 
temperature) 
Rat P2X7R ab109246 
 (Abcam) 
Rabbit 
monoclonal 
1:1000 
(overnight at 4ºC) 
HRP-conjugated 
Goat anti-rabbit 
polyclonal  
(Thermo Fisher) 
1:3000 
(1 hour at room 
temperature) 
Rat α-actin A2228 
(Sigma) 
Mouse 
monoclonal 
1:10,000 
(1 hour at room 
temperature) 
HRP-conjugated 
Rabbit anti-mouse 
polyclonal  
(Abcam) 
1:3000 
(1 hour at room 
temperature) 
 
Human 
GAPDH 
ab8245 
(Abcam) 
Mouse 
monoclonal 
1:10,000 
(1 hour at room 
temperature) 
HRP-conjugated 
Rabbit anti-mouse 
polyclonal  
(Abcam) 
1:3000 
(1 hour at room 
temperature) 
 
Rat GAPDH ab8245 
(Abcam) 
Mouse 
monoclonal 
1:10,000 
(1 hour at room 
temperature) 
HRP-conjugated 
Rabbit anti-mouse 
polyclonal  
(Abcam) 
1:3000 
(1 hour at room 
temperature) 
 
 
Table 2.5. Antibodies used for Western Blots. GAPDH: Glyceraldehyde 3-Phosphate Dehydrogenase. 
 
Target Protein Primary 
Antibody 
Primary Dilution 
(Time and 
incubation 
temperature) 
 
Secondary 
Antibody 
Secondary 
Dilution 
(Time and 
incubation 
temperature) 
 
Human P2X7R ab109246 
 (Abcam) 
Rabbit 
monoclonal 
1:250 
(overnight at 4ºC) 
Dylight 488-
conjugated goat 
anti-rabbit 
(Vector Labs) 
1:100 
(1hour at room 
temperature) 
Rat α-SMA M0851 
(DAKO) 
1:50 
(overnight at 4ºC) 
Dylight 488-
conjugated horse 
anti-mouse 
(Vector Labs) 
1:100 
(1hour at room 
temperature) 
Rat SMMHC sc6956 
(Santa Cruz) 
1:500 
(overnight at 4ºC) 
Dylight 488-
conjugated horse 
anti-mouse 
(Vector Labs) 
1:100 
(1hour at room 
temperature) 
  
Table 2.6. Antibodies used for Immunofluorescence. 
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2.19 Histological Analysis 
2.19.1 Sample preparation and deparaffinisation of sections. 
Tissue samples were fixed in either 4% PFA or 10% NBF as indicated. Initial 
processing, embedding into paraffin and cutting of sections, along with staining for 
haematoxylin and eosin (H & E) and Picrosirius red was performed by Ms Mahrokh 
Nohadani. 
Slides were deparaffinised and rehydrated by performing the following washes: 
1. Xylene: 2 x 3 minutes 
2. 100% ethanol: 2 x 3 minutes 
3. 95% ethanol: 3 minutes 
4. 70 % ethanol: 3 minutes 
5. 50 % ethanol: 3 minutes 
6. H2O 
2.19.2 Silver nitrate stain according to von Kossa. 
The von Kossa technique for staining tissue mineralisation was first described in 
1901 (von Kossa 1901). Under a strong light source, calcium ions within salt 
compounds, (usually calcium-phosphate), become reduced and replaced with silver. 
This is visualised as a deep metallic silver colour on microscopy. 
All reagents were purchased from Merck Millipore (Watford, UK). Following 
deparaffinisation and hydration to water, slides were rinsed in several changes of 
distilled water and incubated with 1% silver nitrate solution under ultraviolet light 
for 25 minutes. Slides were rinsed in H2O. 5% sodium thiosulfate was applied for 5 
minutes to remove unreacted silver before rinsing again in H2O. Nuclear fast red 
counterstain was applied for 5 minutes. Slides were rinsed in H2O, dehydrated 
through graded alcohol and cleared in xylene. Coverslips were applied using 
permanent mounting medium (Vector Labs). 
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2.19.3.i Semi-quantitative scoring of calcium deposition. 
Sections of von Kossa-stained human vessels were examined using light-
microscopy. The positively-stained vessel circumference was scored on a semi-
quantitative scale of 0, < 25, 25-50 or < 50% calcified. 
2.19.3 Alizarin red staining. 
Alizarin red will complex with di-cationic ions in a chelation process. As such this 
stain is not strictly specific for calcium, however, because other di-cations are rarely 
present in as high abundance as calcium in tissues of interest, it can be used as a 
complementary stain to the von Kossa method (Puchtler et al 1969). 
Following deparaffinisation and hydration to water, slides were stained with 2% 
Alizarin red stain (pH adjusted to 4.2 using 10% ammonium hydroxide) for 2 
minutes. Slides were dehydrated by dipping 20 times in acetone and then 20 times in 
a 1:1 solution of acetone-xylene. Slides were cleared in xylene and mounted with 
permanent mounting medium. 
2.19.4 Quantification of renal fibrosis on Picrosirius red stained kidney sections. 
Picrosirius red is a strong anionic dye which binds to basic groups present within 
collagen resulting in a distinct red stain (Junqueira et al 1979). When applied to 
kidney tissue it can therefore be used to assess the extent of interstitial fibrosis. 
Starting from the top of each histological section and moving clockwise around the 
cortex, 4 random digital images were taken of the interstitial compartment, ensuring 
that glomeruli and large vessels were excluded.  
Image J software was then used to quantify the amount of fibrosis within each 
section. This was achieved by first opening the image and defining the ‘area at risk’ 
by adjusting the brightness and saturation sliders in such a way so as to leave the 
tubulointerstitium selected whilst excluding tubular lumen (Figure 2.9A). The 
number of pixels within this defined area was then quantified. By adjusting the 
sliders again it was possible to highlight just the positively-stained red areas (Figure 
2.9B) in which the total number of pixels was measured. The percentage of the area 
at risk that was stained red was then calculated. This protocol was followed in a 
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blinded fashion for all samples from all rodents and the mean percentage was 
determined for each animal. 
 
 
 
 
 
 
 
 
 
 
2.20 Statistical Analysis 
Unless stated otherwise all data in this thesis have been presented as mean ± standard 
deviation (SD). Statistical analysis was performed using either Prism (GraphPad, 
San Diego, USA) or SPSS (IBM, Armonk, USA). Differences between two groups 
were compared using a 2-tailed t-test or Mann-Whitney U (MWU) test for normally- 
or non-normally-distributed data respectively. For comparisons between more than 2 
groups, Analysis of Variance (ANOVA) was used for normally-distributed data and 
the Kruskal Wallis (KW) test if non-normally-distributed. In the case of multiple 
comparisons, a post hoc Bonferroni correction was made (Dunn’s post-test following 
KW tests). Groups compared by post hoc testing are clearly indicated in the relevant 
figures. Correlation analyses were performed by determining Spearman’s rho. P 
values of < 0.05 were considered statistically significant.  
 
Figure 2.9. Quantification of Picrosirius Red Staining of Kidney Sections. 
Analysis was performed using Image J Software. A: Defining the ‘area at risk’ of 
fibrosis (tubulointerstitium). Colour threshold sliders were adjusted to define the 
‘area at risk’ i.e. tubulointerstitial compartment. The number of pixels was 
determined in the total area excluding the sections outlined in yellow i.e. tubular 
lumens including those containing 2,8-dihydroxyadenine crystals (seen as black 
intra-tubular structures). B: Defining the fibrotic tubulointerstitium. Colour slider 
threshold sliders were adjusted to define only the tissue stained red (fibrotic areas) 
and the number pixels was determined. This figure was then divided by the ‘area at 
risk’ value to determine the % fibrosis. 
A B 
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CHAPTER 3 – OPTIMISATION OF A TISSUE CULTURE MODEL TO 
ASSESS THE ROLE OF P2X7R IN ARTERIAL CALCIFICATION 
3.1 Introduction 
Much of the current understanding about the pathogenic pathways involved in AC 
has come from the results of in vitro studies (Shanahan et al 2011, Shanahan 2013). 
Experiments whereby primary VSMCs (Proudfoot et al 1998), and more recently 
intact arterial rings (Lomashvili et al 2004, Shroff et al 2010), have been cultured in 
a medium containing an elevated concentration of phosphate and/or calcium have 
permitted investigators to assess the cellular responses and changes occurring under 
these conditions. With relevance to the potential role of P2X7R, a number of groups 
using these experimental systems have been able to advance the concepts of 
osteogenic transformation and apoptosis of VSMCs as being of fundamental 
importance in the pathogenesis of AC in patients with CKD (see Shroff et al 2013). 
The work in this chapter sought to optimise a tissue culture model of, and 
subsequently investigate the role of P2X7R in, AC. A number of P2X7R antagonists 
are commercially available, and BzATP, whilst not entirely specific, is a receptor 
agonist (Wiley et al 2011). These agents have been widely used in tissue culture 
models to investigate P2X7R in other biological contexts, and thus they were 
employed here to examine the role of this receptor in AC. The generation of P2X7
-/-
 
mice in this thesis (described in Chapters 2 and 4) permitted another way of 
examining the effect of P2X7R ligation under these experimental conditions.  
3.2 Results 
3.2.1 P2X7R is expressed in primary hVSMCs in vitro. 
An initial aim of the in vitro work was to determine whether hVSMCs express 
P2X7R. To address this question, cells were cultured and examined by 
immunofluorescence, and cellular protein was extracted for Western blotting. By 
immunofluorescence, expression of P2X7R was clearly evident in hVSMCs (Figure 
3.1). In many cells there appeared to be sparing in the peri-nuclear region. By 
Western blotting a distinct, single band was detected at 69kDa consistent with the 
molecular weight of P2X7R (Figure 3.2). 
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Figure 3.1. Immunofluorescent Staining of P2X7R in hVSMCs. Cells were 
cultured for 3 days before fixing. A: P2X7R staining (green). Nuclei are 
counterstained blue with DAPI. B: Corresponding rabbit IgG control. 
Magnification x10. 
A B 
Figure 3.2. Western Blot of P2X7R Protein from Cultured hVSMCs A single 
band of approximately 69kDa was detected consistent with P2X7R (upper band). 
The lower bands represents GAPDH at a molecular weight of 36kDa. The 2 lanes 
shown are duplicates from the same batch of (uncalcified) hVSMCs cultured in 
normal Medium-199.  
P2X7R (69kDa) 
GAPDH (36kDa) 
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3.2.2 Experiments culturing VSMCs in high calcium and phosphate-containing 
medium yield inconsistent results. 
With P2X7R expression confirmed in VSMCs, its role in VSMC-associated 
calcification in vitro was assessed. A commonly used model of AC is the in vitro 
culture of VSMCs in a medium containing an elevated concentration of phosphate 
and/or calcium (see Chapter 1, section 1.4.1). This in vitro system was therefore 
initially employed to assess the influence of the selective P2X7R antagonist, 
A438079, on hVSMC-associated calcium deposition. Several experiments were 
performed, using commercially-available hVSMCs from two different donors. 
In hVSMCs from donor 1, the addition of 10µM A438079 to the calcification 
medium resulted in a trend towards decreased calcium deposition after 6 days (6.4 ± 
3.4 vs 2.8 ± 1.6µg/µg without and with A438079, respectively; p = 0.200) (Figure 
3.3). However, a second, repeat experiment using cells from this donor yielded 
minimal calcification in all groups, including the control cells cultured in 
calcification medium alone (data not shown).  
The supply of cells from this first donor was limited, so a second donor’s cells were 
obtained for use. In contrast to the results for donor 1, in hVSMCs from donor 2 a 
trend was seen towards enhanced calcium deposition in the presence of increasing 
concentrations of A438079 at day 6 (0.61 ± 0.11 vs 0.78 ± 0.06 vs 0.86 ± 0.16µg/µg 
for control, 5µM and 10µM A438079, respectively; p = 0.067). A similar but less 
marked trend was seen at day 4 (p = 0.177) (Figure 3.4). However, a repeat 
experiment with these cells yielded equivocal calcium deposition at days 4 and 6 
across all groups (p = 0.112 and 0.733 respectively) (Figure 3.4), and two subsequent 
experiments with cells from this donor failed to result in calcification in any culture 
well (data not shown). 
A striking feature of this model which became apparent after a number of 
experiments had been performed was the inconsistency of calcification. It was not 
uncommon to observe calcium deposition in association with cells in one 
experiment, only for it to be absent when culturing cells from the same donor under 
identical conditions a second or third time. In addition to the ‘inter-experiment’ 
calcification variability, in experiments where calcium deposition was observed, the 
cell donor appeared to be exerting a major influence on the outcome i.e. the effect of 
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A438079 on mineralisation. Given this latter observation, it was decided to try and 
standardise the genetic background of cells in an attempt to gain more reproducible 
results by eliminating the potential effects of human variation. 
Figure 3.3. The Effect of the Specific P2X7R Antagonist A438079 on hVSMC-
Associated Calcification (Donor 1). Cells from the first donor were cultured for 6 
days in either normal control Medium-199 (N Med) or in ‘calcification’ Medium-199 
(Cal Med) containing calcium and phosphate concentrations of 2.7mM and 2mM 
respectively. The specific P2X7R antagonist A438079 was added where indicated to 
a final concentration of 10µM. N=3 per group. Error bars represent mean ± SD. 
Figure 3.4. The Effect of the Specific P2X7R Antagonist A438079 on hVSMC-
Associated Calcification (Donor 2). Cells from the second donor were cultured for 
either 4 or 6 days in normal control Medium-199 (N Med) or ‘calcification’ Medium-
199 (Cal Med) containing calcium and phosphate concentrations of 2.7mM and 2mM 
respectively. The specific P2X7R antagonist A438079 was added where indicated to 
a final concentration of either 5 (+5) or 10 (+10) µM. N=3 per group. Error bars 
represent mean ± SD. 
1
st
 experiment  2
nd
 experiment 
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3.2.2.i Generation of, and calcification experiments using, rat VSMCs. 
Rat VSMCs (rVSMCs) were obtained by isolating VSMCs from outgrowths from 
Sprague-Dawley rat aortas as described in Chapter 2 (section 2.13.3). Cells were 
characterised by demonstrating positive immunofluorescence for the VSMC-specific 
markers α-SMA and SMMHC, in addition to the typical ‘hill-and-valley’ VSMC 
growth pattern (Proudfoot & Shanahan 2012) (Figure 3.5).  
 
 
 
 
 
 
 
 
 
 
 
Several experiments were performed using rVSMCs at early passage number (P < 3) 
to assess the effect of A438079 on calcification and also to ascertain the optimal 
culture conditions for this cell type in this model. Despite numerous attempts, as 
with hVSMCs, experimental results were inconsistent. Specifically, in a number of 
experiments no calcification occurred at all in several culture wells, including some 
containing cells just cultured in calcification medium alone, whereas in other wells it 
did (data not shown). 
At this point a review of the model was undertaken. Given both the gross 
inconsistency in calcium deposition and the documented concerns regarding its 
A B C 
D 
Figure 3.5. Characterisation and Culture of rVSMCs. A-C: Immunofluorescent 
staining of fixed, permeablised cells for VSMC specific markers. A: α-SMA 
(green). B: SMMHC (green). C: Corresponding anti-mouse IgG control. Nuclei are 
stained blue with DAPI. D: Phase-contrast appearance of cell growth pattern 
displaying a ‘hill-and-valley’ morphology typical of VSMCs (arrows represent 
‘hills’). A-C: magnification x40. D: magnification x4. 
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biological relevance, both of which are discussed below, this in vitro system was 
abandoned as an experimental tool for work in this thesis in favour of the aortic ring 
ex vivo culture model. 
3.2.3 Characterisation and optimisation of an ex vivo aortic ring calcification 
model. 
3.2.3.i Calcification of rat aortic rings can be induced by culturing in a medium 
containing phosphate concentrations above 2.5mM. 
Previous reports had suggested that normal vessels, from both humans (Shroff et al 
2010) and rats (Lomashvili et al 2004), would maintain viability but not calcify if 
cultured in a high phosphate-containing medium alone. To test these observations, 
rings of rat aorta were cultured in media containing a range of increasing phosphate 
concentrations (1 - 3.8mM) for 10 days. 
Calcification was evident in rings cultured in phosphate concentrations of ≥ 2.5mM 
as assessed by von Kossa staining (Figure 3.6). Mineralisation was seen as linear 
deposits, tracking along the elastic laminae between VSMCs (Figure 3.7). VSMCs in 
these vessels appeared morphologically normal on H & E staining (Figure 3.8). In 
rings containing heavier calcium deposition, more notable in those cultured in 
phosphate concentrations > 3mM, marked, circumferential mineralisation was 
evident, completely disrupting the normal vessel architecture, presumably as a 
consequence of the more brittle sections ‘fracturing’ during sectioning (Figure 3.6). 
Calcification was also frequently observed in the adventitia (Figure 3.7), highlighting 
the importance of removing this layer prior to calcification quantification in order to 
accurately ascertain the degree of medial calcium deposition. 
Rings cultured in 3mM phosphate had marked calcium deposition without overt 
disruption of the vessel wall on histological assessment. It was therefore decided to 
set 3mM as the phosphate concentration for subsequent work with this model. 
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A B 
C D 
F E 
Figure 3.6. Calcification of Rat Aortic Rings in vitro with Increasing 
Phosphate Concentrations. Rat aortic rings were cultured in Medium-199 
containing increasing concentrations of phosphate (A-F: 0.9 (basal), 2.0, 2.5, 3.0, 
3.3 and 3.8mM, respectively). Silver nitrate stained (von Kossa stain) calcium 
deposits appear black (arrow in C) and cell nuclei are counterstained with 
aluminium red stain. Calcium deposition was evident at phosphate concentrations 
≥ 2.5mM. Tissue cultured in phosphate concentrations above 3mM (E and F) was 
profoundly calcified which led to sections ‘fracturing’ upon processing limiting 
histochemical assessment of VSMCs. Magnification x10. 
Figure 3.7. Digitally Magnified Images of Calcified Rat Aorta. A: Von Kossa 
stain with aluminium-red counterstain. B: Alizarin Red stain.  With both stains, 
mineral deposits are seen ‘tracking’ along elastin fibres between VSMCs. Areas of 
positive staining are also seen within the adventitia (arrows). Original 
magnification x10, image cropped using Microsoft Office 2010. 
A B 
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3.2.3.ii Viability of rings is maintained following culture in 3mM phosphate for 10 
days. 
Whilst it was noted that VSMCs appeared normal on H & E staining in rings 
cultured under these conditions, a more robust assessment of tissue viability was 
desirable. One indicator of viability was the change in colour of culture medium. 
Consistent with the generation of acidic products from metabolic activity, in wells 
containing arterial rings the phenol red pH indicator in the culture medium changed 
colour from red to orange-yellow in the 2-3 days between media changes. 
Quantitative measurement of tissue metabolic activity (and hence viability) was 
undertaken by determining the ATP content of culture medium from wells 
containing rings as compared with ‘ring-free’ medium at day 10. Culture medium 
containing phosphate concentrations of 1, 2 and 3mM was studied. The ATP content 
of ‘tissue-naïve’ culture medium (all phosphate concentrations combined) at day 10 
was 445 ± 59nM. In contrast, ATP was barely detectable (0.03 ± 0.03nM) in culture 
medium in which rings had been present, consistent with active consumption and 
tissue viability. No differences were detected between media of different phosphate 
concentrations (Figure 3.9). 
 
 
Figure 3.8. H & E Stain of Normal and Calcified Aortic Rings. Rat aortic rings 
were cultured in A: basal or B: 3mM phosphate-containing Medium-199 for 10 
days. H & E stained calcified regions appear purple (arrow). VSMCs in areas 
adjacent to calcification appear similar compared with normal tissue. 
Magnification x63. 
A B 
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3.2.3.iii Time-course of cultured aortic ring calcification. 
To ascertain the temporal relationship between time in culture and calcium 
deposition, rings were cultured in 3mM phosphate medium and examined by von 
Kossa staining at baseline and 3, 7 and 10 days. No calcification was observed in 
rings at baseline. At day 3 rings were essentially free of mineralisation, however 
occasionally a tiny speck of calcium was detected on an elastin fibre suggesting that 
calcium deposition is initiated at approximately this time-point in this model. 
Calcification was established although not florid on day 7 and widespread by day 10 
(Figure 3.10). 
 
 
 
 
 
 
 
Figure 3.9. Measurement of ATP in Culture Medium to Assess Tissue Viability. 
Rat aortic rings were cultured for 10 days in Medium-199 containing 1, 2 or 3mM 
phosphate (P) as indicated. Wells containing Medium-199 at the same phosphate 
concentrations were maintained under identical conditions but without aortic rings. 
The ATP concentration in the medium from each well was measured. Each symbol 
represents a single culture well. Horizontal bars represent group means. 
A 
C 
B 
Figure 3.10. Calcification of Rat Aortic Rings Over 
Time. Rat aortic rings were cultured in Medium-199 
containing 3mM phosphate. Rings were removed from 
culture after A: 3, B: 7 and C: 10 days and stained 
with von Kossa reagent. Calcification was barely 
detectable at day 3 (arrow shows one tiny speck of 
staining). By day 7 calcification was more established 
and widespread by day 10. Magnification x10. 
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3.2.3.iv Attempts to improve the consistency of aortic ring calcification. 
In contrast to the VSMC culture model, it was extremely rare for aortic rings not to 
calcify. However, the degree of calcification between rings within experiments did 
vary widely, and it was observed that rings which originated from the abdominal 
section of the aorta tended to calcify more than those from the thoracic region. There 
are a number of reports describing modifications to this model which are suggested 
to improve its consistency and so further optimisation was attempted. 
One group suggested that pre-incubating rings in porcine pancreatic elastase (0.01 
units/ml) for 24 hours leads to more reliable calcification, presumably as a result of 
initiating elastin breakdown and facilitating adherence of mineral deposits (Scialla et 
al 2013). However, in the current model, after 10 days of culture in 3mM phosphate 
medium, less calcium was detected in rings that had been pre-incubated with elastase 
compared with those which had not (39.4 ± 20.2 vs 3.8 ± 6.6µg/mg without and with 
elastase treatment respectively; n = 3 for each group; p = 0.100) (Figure 3.11A, B 
and C). Rings that had been exposed to elastase weighed significantly less than 
controls (0.61 ± 0.28 vs 0.27 ± 0.07mg for controls vs elastase treated; p = 0.016) 
(Figure 3.11D) and on H & E staining the structure appeared much less organised 
(Figure 3.11E and F), both factors presumably reflecting elastin degradation and 
integral tissue ‘scaffolding’ loss. 
In the original description of the aortic ring model, alkaline phosphatase was added 
to the culture medium to induce calcification (Lomashvili et al 2004). This effect 
was assumed to occur as a result of the enzyme hydrolysing the calcification 
inhibitor, PPi, generated by the cultured tissue. It was therefore assessed, in a single 
experiment, whether following this method would produce more uniform 
calcification in the present model. Unexpectedly, not only was a similar, wide range 
of mineralisation observed between rings, there was a reduction in calcification, 
albeit non-significant, in rings treated with alkaline phosphatase (data not shown).  
It is well documented that calcium deposition is favoured by a more alkaline 
environment (Lomashvili et al 2006, Villa-Bellosta et al 2011b). Therefore in a final 
attempt to obtain a more consistent level of calcification within experiments, the 
culture medium pH was adjusted to 7.4 with the addition of NaOH. This resulted in 
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crystals, (presumably calcium-phosphate in composition), precipitating in the culture 
medium, usually within 48 hours. This limited the available soluble mineral and 
resulted in decreased in calcification.  
 
Figure 3.11. The Effect of Elastase on Cultured Aortic Rings. Rat aortic rings 
were cultured in either basal (N Med) or 3mM phosphate-containing (3mM P) 
Medium-199 for 10 days (n=6 per group). Prior to high phosphate exposure, 3 rings 
from each group were incubated in 0.01 units/ml porcine pancreatic elastase for 24 
hours. A and B: Representative von Kossa stain of rings cultured in 3mM P without 
or with elastase treatment respectively. C: Quantification of calcium deposition in all 
groups. D: Weights of rings treated with elastase compared with controls. E and F: H 
& E staining of rings with and without elastase treatment respectively. Those 
exposed to elastase exhibited deranged architecture (E) compared with controls (F). 
Error bars represent mean ± SD. A & B: original magnification x10 (digitally 
cropped with Microsoft Office 2010). E & F: magnification x63. 
A B 
E 
C 
F 
D 
p = 0.016 
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As none of these steps lead to any improvement in the consistency of calcification it 
was accepted that this would be a feature of the model. Therefore, to aid 
interpretation and increase the precision of results, it was decided to aim for an 
arbitrary minimum of 5 replicates per group for each subsequent experiment.  
3.2.4 The role of P2X7R in AC using an ex vivo model. 
3.2.4.i The effect of pharmacological manipulation of P2X7R on rat aortic ring 
calcification. 
To investigate the role of P2X7R in AC, rat aortic rings were first cultured in 3mM 
phosphate for 10 days with or without the presence of either the selective receptor 
antagonist A438079 (20µM), or agonist BzATP (100µM). Three consecutive 
experiments were initially performed, each using an aorta from a different rat. 
Experiment 1:  6 rings were used per group with half taken for quantification of 
calcium and half for histological analysis. Calcification was similar in all three 
groups (3.6 ± 3.4 vs 4.8 ± 7.1 vs 4.6 ± 4.1µg/mg for control vs antagonist vs BzATP-
treated rings, respectively; p = 0.733) (Figure 3.12A). The pattern of calcium 
deposition was identical for all groups as assessed by von Kossa staining. In 
addition, H & E staining demonstrated that VSMCs in vessels treated with both 
A438079 and BzATP appeared identical to those from control tissue (not shown). 
Experiment 2: A non-statistically significant reduction in calcification was detected 
in rings treated with both A438079 and BzATP. The mean calcium deposition in 
rings cultured in 3mM phosphate alone was 79.2 ± 48.8 compared with 52.9 ± 51.1 
and 54.4 ± 28.6µg/mg for the A438079 and BzATP treated rings, respectively (n = 8 
per group; p = 0.357) (Figure 3.12B).  
Experiment 3: A similar reduction in calcification was apparent in rings cultured in 
the presence of both pharmacological agents (45.6 ± 35.9, 15.8 ± 13.5 and 24.7 ± 
15.1µg/mg for control, A438079 and BzATP-treated rings, respectively) (n = 6 per 
group; p = 0.113) (Figure 3.12C). 
As wide standard deviations were seen within groups, a fourth study was conducted 
comparing just A438079 treatment to control, but increasing the number of rings per 
group to 10. In this experiment calcium deposition was more equivalent between 
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groups, in keeping with the results from the first experiment. Control ring 
calcification was 5.5 ± 5.9 vs 4.2 ± 7.1µg/mg for those treated with the antagonist (p 
= 0.248) (Figure 3.12D). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
With no significant impact observed after 4 experiments using A438079, a single 
experiment was performed with a second P2X7R antagonist, A839977, tested over a 
range of concentrations (50nM, 500nM and 5µM). Again the wide standard 
deviations limited interpretation of the data, however, no significant differences in 
calcification were detected across the 4 groups (p = 0.411) (Figure 3.13). 
 
Figure 3.12. The Effect of the Specific P2X7R Antagonist A438079 and Agonist 
BzATP on Aortic Ring Calcification. Rings were cultured for 10 days in Medium-
199 containing a phosphate concentration of 3mM (3mM P) with or without the 
presence of either the specific P2X7R antagonist A438079 (20µM) or agonist BzATP 
(100µM) (only A438079 in D). A-D represent consecutive experiments. Each symbol 
represents an individual ring and horizontal bars represent group means. 
A B 
C D 
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3.2.4.ii Cultured aortic rings from WT and P2X7
-/-
 mice exhibit a similar degree of 
calcification. 
To complement the studies using pharmacological agents active at P2X7R, 2 
experiments were performed using a similar ex vivo model, but culturing aortic rings 
from WT and P2X7
-/-
 female mice. These mice had been backcrossed through 5 
generations onto the calcification-prone DBA/2 background (Eaton et al 1978) (see 
Chapter 2, section 2.5). Due to the extremely small size of the murine aortic 
segments, when rings were harvested after 10 days in culture it was essentially 
impossible to remove the adventitial layer without damaging the rings and losing 
some calcified deposits. Therefore it was decided to quantify the calcium deposition 
for each ring with the adventitia intact. To ensure that medial calcification had 
occurred, von Kossa staining of a selection of rings was undertaken. This 
demonstrated mineral deposits along medial elastin fibres. Staining was, as expected, 
also present in the adventitia (Figure 3.14A). 
In the first of these experiments, there was a non-significant increase in calcification 
in the KO rings (27.7 ± 40.3 vs 105.8 ± 87.6µg/mg for WT vs KO; n = 6 per group; 
p = 0.093) (Figure 3.14B). In the second, calcium deposition was similar for both 
genotypes (356.8 ± 182.0 vs 409.8 ± 209.2µg/mg for WT vs KO; n = 5 per group; p 
= 0.548) (Figure 3.14C). The magnitude of calcification was several-fold higher in 
Figure 3.13. The Effect of the Specific P2X7R Antagonist A839977 on Aortic 
Ring Calcification. Rings were cultured for 10 days in Medium-199 containing 3mM 
phosphate (3mM P) alone or the specific P2X7R antagonist A839977 at the 
concentrations indicated. Each symbol represents an individual ring and horizontal 
bars represent group means. 
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the second experiment, possibly owing to a greater amount of residual adventitia 
being left on these rings following the initial dissection. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.2.5 Expression of mRNA for P2X7R, markers of VSMC phenotype and 
caspase-3. 
The expression of P2X7R mRNA was assessed in cultured rodent aortic rings at 
baseline and at 3 time-points (days 3, 7 and 10) under control and calcification-
promoting (3mM phosphate) conditions (i.e. 7 groups). Aortas from 3 rats were cut 
into rings and distributed between the 7 groups, (n ≥ 5 per group). In addition, to 
ascertain whether osteogenic transformation and apoptosis occur in this model, 
mRNA expression of the VSMC-specific marker SM-22, the osteogenic 
Ad 
A 
C B 
Figure 3.14. The Influence of P2X7R Gene Deletion on Aortic Ring Calcification. 
Aortic rings from WT and P2X7
-/- 
(KO) female mice were cultured for 10 days in 
Medium-199 containing 3mM phosphate. A: Von Kossa staining of a calcified ring 
from a WT mouse after 10 days in culture. Arrows indicate calcium deposition along 
elastin fibres. ‘Ad’ indicates the adventitia. This could not be removed during these 
experiments due to technical difficulty (described in the text) and did stain for 
mineral deposits. B and C: Calcium quantification results from 2 consecutive 
experiments. Each symbol represents one ring and horizontal bars represent group 
means. A: magnification x63. 
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transcription factors runx-2 and osterix and caspase-3 (as an indicator of apoptosis) 
was examined (Table 3.1, Figures 3.15 and 3.16).  
It was notable that time in culture alone seemed to exert an effect on mRNA 
expression i.e. results from the baseline samples differed from those rings cultured in 
normal medium, and that at the later time-points – especially by day 10, the standard 
deviation became extremely wide (Table 3.1). The A260/280 ratios of samples 
varied although all groups contained a spread of values and the expression of mRNA 
for the housekeeping genes examined (HPRT, 28S and SDHA) did not significantly 
differ between groups (not shown). The mean absolute copy numbers of mRNA for 
these three housekeeping genes were 9,088 ± 3,745, 35,371 ± 15,521 and 50,702 ± 
20,404 respectively.  
Overall there was no significant difference in the expression of P2X7R mRNA 
between groups (Figure 3.15A, Table 3.1). Notably, the absolute copy numbers of 
mRNA were extremely low being in the order of just a few hundred. Protein 
extraction from these small samples was difficult however a Western blot was 
performed to confirm that P2X7R protein was expressed in cultured aortic rings 
(Figure 3.15B). The regulation of arterial protein expression by calcification was 
assessed in vivo and is described in Chapter 5. 
Expression of mRNA for the VSMC-specific marker SM-22 was examined. A 
striking contrast was seen between the expression in baseline tissue and control 
samples at later time-points with a statistically significant decrease observed on days 
3 and 7. No significant difference was detected for samples cultured in high 
phosphate medium compared with the time-point controls (Figure 3.16A, Table 3.1). 
An attempt was made to quantify the expression of mRNA for the osteogenic 
transcription factors runx-2 and osterix, however, these were barely detectable (< 
100 copies) in all groups (control and calcified) (not shown). Expression of mRNA 
for the apoptosis marker caspase-3 increased from baseline in control samples at 
subsequent time-points. This reached statistical significance by day 7 and remained 
significant at day 10. Again, culture in high phosphate medium did not significantly 
influence mRNA expression (Figure 3.16B, Table 3.1). 
        
 
      
9
4
 
Gene  
 
 
Baseline 
n=7 
Day 3 – Control 
n=5 
Day 3 -  HP 
n=5 
Day 7 – Control 
n=5 
Day 7 - HP 
n=5 
Day 10 – Control 
n=5 
Day 10 – HP 
n=6 
p value 
(KW test) 
P2X7R 
 
238 ± 32 126 ± 54 111 ± 45 162 ± 54 151 ± 106 280 ± 111 126 ± 62   0.007 
SM-22 
 
2,833,000 ± 
454,601 
 
77,586 ± 
87,614** 
39,795 ±  
35,792 
90,013 ±  
56,516* 
128,843 ± 
177,288 
689,904 ± 
749,773 
156,555 ± 
205,496 
  0.001 
Caspase-3 
 
5,121 ±  
1,373 
 
13,532 ±  
2,466 
10,804 ±  
2,195 
18,216 ± 
4,283*** 
15,962 ±  
5,282 
20,394 ± 
2,801*** 
12,608 ±  
3,579 
<0.001 
 
Table 3.1. mRNA Copy Numbers for P2X7R, SM-22 and Caspase-3 in Cultured Rat Aortic Rings Over Time. Quantification of mRNA copy numbers for indicated 
genes in rat aortic rings cultured in either control or 3mM (high) phosphate-containing (HP) Medium-199 over time. As initial KW test indicated p<0.05 for all genes, post 
hoc tests compared all control groups with baseline and control with HP at each time-point.  *p<0.05; **p<0.01;***p<0.001 (all compared to baseline). Data are presented as 
mean ± SD. 
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Figure 3.15. Expression of P2X7R in Control and Calcified Rat Aortic Rings. A: 
Quantification of P2X7R mRNA copy numbers in rat aortic rings cultured in either 
control or 3mM (high) phosphate-containing (HP) Medium-199 over time. Post hoc 
tests compared all control groups with baseline and control with HP at each time-
point. ‘D’ designates number of days in culture. Error bars represent mean ± SD. 
Number of rings per group from left to right = 7,5,5,5,5,5,6. B: Western blot of 
protein extracted from a single control and a single calcified aortic ring after 10 days 
in culture demonstrating the presence of P2X7R protein. 
Control Calcified 
P2X7R  
(69kDa) 
GAPDH  
(36kDa) 
A B 
SM-22 Caspase-3 
* 
*** *** 
** 
Figure 3.16. mRNA Copy Numbers for SM-22 and Caspase-3 in Cultured Rat 
Aortic Rings Over Time. Quantification of A: SM-22 and B: Caspase-3 mRNA 
copy numbers in rat aortic rings cultured in either control or 3mM (high) phosphate-
containing (HP) Medium-199 over time. Initial KW test indicated p<0.05 for both 
genes. Post hoc tests compared all control groups with baseline and control with HP 
at each time-point. *p<0.05; **p<0.1; ***p<0.001 all compared to baseline. ‘D’ 
designates number of days in culture. Error bars represent mean ± SD. Number of 
rings per group from left to right = 7,5,5,5,5,5,6.  
A B 
D3 D7 D10 
    D3     D7   D10   D3    D7   D10 
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3.3 Discussion 
Previous reports investigating the expression profiles of P2 receptors in the 
vasculature (Wang et al 2002, Schuchardt et al 2011) have indicated that P2X7R is 
expressed at the mRNA level in VSMCs although its presence at the protein level 
has not been described. In the current work, P2X7R mRNA appeared to be expressed 
at a very low level in normal rat aorta and in vitro was not modified by a ‘pro-
calcification’ environment. Despite the low level of mRNA, P2X7R protein is 
expressed in hVSMCs and in rat aorta. 
The primary objective of the work described in this chapter was to ascertain whether 
P2X7R influences calcium deposition in an in vitro model of AC. A number of 
experiments, using a variety of culture systems, give the overriding impression that it 
does not, at least not to any major extent. Some experiments showed trends towards 
an attenuating effect of P2X7R, whilst others suggested that it might enhance 
calcification. There were also a number of experiments which suggested no effect 
and overall there was no convincing evidence to indicate a significant role either way 
for P2X7R in this setting. However, this conclusion does need to be taken within the 
context of the experimental systems used and with consideration of their limitations. 
The lack of effect of P2X7R is unlikely to be explained by suboptimal dosing of the 
pharmacological agents employed. A438079 is a P2X7R antagonist with an IC50 
value of 0.1 and 0.3µM for BzATP induced Ca
2+
 influx through human and rat 
P2X7Rs respectively (Donnelly-Robert et al 2007). The compound has been shown 
to not be active at other purine receptors (P2X3, P2X4 and P2Y2) at concentrations 
up to approximately 10µM (Nelson et al 2006) and this limit of specificity is 
probably higher (McGaraughty et al 2007). Subtle effects at other purine receptors 
cannot be excluded but would be expected to be minor at most, given the lack of 
effect at the selected P2 receptors examined in the study by Nelson et al (2006). 
A438079 has also been shown to have little activity at a wide array of other cell 
surface receptors (Donnelly-Robert et al 2007). Thus whilst only a single dose of 
20µM was used for experiments with rat aortic rings, this concentration should have 
achieved essentially total blockade of P2X7R. The second antagonist employed, 
A839977, has not been so widely used, 3 concentrations (50nM, 500nM and 5µM) 
were trialled in the single experiment examining its effect. Nonetheless, the IC50 of 
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this agent at rat P2X7R is 42nM (Honore et al 2009) and hence adequate antagonism 
should have been achieved. BzATP, whilst frequently cited as such, is not a specific 
agonist at P2X7R having partial activity a number of other P2 receptors (Bianchi et 
al 1999, Michel et al 2001). However, 100µM (the concentration used in this 
chapter), is generally considered to be appropriate to obtain relatively specific 
activation of P2X7R (Orriss et al 2012), and in practical terms provides the best 
means of achieving this.  Taken together these data suggest that the pharmacological 
manipulation of P2X7R in this chapter should have been successful. 
Of the number of theoretical ways in which P2X7R might influence AC (outlined in 
Chapter 1, summarised in Figure 1.3), only some are relevant and potentially able to 
be evaluated in these in vitro models. In essence, the systems described in this 
chapter are modelling ‘phosphate-induced calcification’. This is clearly very 
different from calcification induced by a uraemic milieu where phosphate is only one 
of several factors likely to be involved. It therefore follows that only the influence of 
P2X7R on phosphate-driven VSMC osteogenic transformation and/or apoptosis can 
be assessed in these models, whereas its effect on a pathway such as uraemia-
induced disruption of normal bone physiology and related vascular effects cannot be. 
That osteogenic transformation is necessary to induce calcification is a frequently 
stated conclusion from experiments using cultured VSMCs (Shanahan et al 2011, 
Shanahan 2013, Shroff et al 2013). However, this has been refuted by some groups. 
For example, a study which exposed both formalin-fixed and viable control VSMCs 
to high phosphate medium in vitro found greater calcium deposition associated with 
the fixed cells (Villa-Bellosta et al 2011b). The authors therefore concluded that 
VSMC-associated calcification was actively inhibited by viable cells rather than 
induced following an active switch in phenotype. Another report, from a different 
group, demonstrated that a change in phenotype of VSMCs towards an osteoblast-
like cell only occurred after mineralisation was present, thereby suggesting that it 
was the calcium-phosphate crystals themselves causing the switch, not vice-versa 
(Sage et al 2011). Reports of osteogenic transformation occurring in the ring culture 
model are also variable. Some authors have shown positive immunohistochemical 
staining for osteogenic markers in calcified cultured arteries (Shroff et al 2010). 
However, other groups that have published widely using this system have suggested 
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that the switch in cell phenotype does not occur (Lomshvili et al 2008, Lomshvili et 
al 2011). The same can be said for apoptosis (Lomashvili et al 2004).  
The aim of the work in this chapter was not specifically to confirm or refute these 
previous findings, however the analysis of mRNA expression for the genes of 
interest described here raises some points of note. No significant differences were 
found at any time-point for control versus calcified aortas in any marker of VSMC 
phenotype or the apoptosis marker caspase-3. No markers of osteogenic 
transformation were detected. These findings would seem to support the view that 
VSMC osteogenic transformation and apoptosis are not involved in the calcification 
process in this experimental system and therefore raise questions about their 
involvement in the process of AC in general. If in fact these 2 mechanisms do not 
occur in this context, then it is unsurprising that P2X7R did not exert any significant 
impact on calcium deposition in the experiments described in this chapter.  
The results from experiments using cultured VSMCs are difficult to interpret due to 
the profound experimental variability. In a number of experiments, some cells, and 
on occasion all cells, cultured in ‘calcification’ medium alone, i.e. those intended to 
serve as control calcified cells, failed to exhibit any calcium deposition. This was not 
an infrequent finding, essentially meaning that any differences in calcium deposition 
occurring in groups treated with A438079 could not, with any confidence, be 
assigned to the effect of treatment. 
The reliability and consistency of this model have been challenged previously, with a 
number of authors commenting that the range of phosphate added to the culture 
medium in order to observe calcification varies tremendously between laboratories 
(Villa-Bellosta et al 2011b). Indeed, some groups have reported calcification with as 
little as 2mM P in the culture medium (Villa-Bellosta et al 2011b), whereas others 
have not been able to induce any calcium deposition with concentrations below 5mM 
(Ciceri et al 2012a). Furthermore, groups have reported that in some circumstances 
they were unable to induce any calcification in certain batches of cells which were 
therefore not used for experiments (Shalhoub et al 2010). There are also instances of 
groups having to alter the length of time cells were left in culture to yield 
calcification when experiments were performed on different occasions (Ciceri et al 
2012a, Ciceri et al 2012b). Personal communications to a number of researchers in 
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the field have also added weight to the conclusion that this model suffers from 
marked variability and inconsistency. 
Whilst these inconsistencies make results difficult to interpret, potentially a more 
fundamental limitation of this model might be its lack of biological relevance. This 
was ultimately the reason for abandoning it as an experimental tool for work in this 
thesis. VSMCs in culture lack their normal ECM.  In particular, the elastic lamina is 
absent, which is the initial site of calcification within the arterial wall as shown by 
work in this thesis (Figure 3.6 and also see Chapters 5 & 6) and other investigators 
(Lanzer et al 2014). In addition, the use of serum and associated growth factors, 
along with variations in cell passage number, can grossly influence VSMC 
phenotype and may promote proliferation (Zeidan et al 2000, Lomashvili et al 2004, 
Nakano-Kurimoto et al 2009). Therefore this system simulates a very different 
environment from that seen in vivo. Furthermore, exactly what is ‘calcifying’ in this 
setting is not altogether clear. Cultured VSMCs are reported to secrete matrix-
vesicles upon which calcium is deposited (Reynolds et al 2004). However, there are 
reports demonstrating that much of the ‘calcification’ that is seen results from 
passive deposition of calcium-phosphate crystals onto the culture plate (Sage et al 
2011). Additionally, calcium deposition has been shown to occur in this context with 
other, non-vascular cells, such as those from the renal proximal tubule (Villa-
Bellosta et al 2011b, Sage et al 2011). 
Some, but by no means all, of these issues are overcome with the aortic ring ex vivo 
model. Here, tissue is essentially ‘intact’ and, as demonstrated, calcification occurs 
along elastin fibres thereby bearing a closer resemblance to findings in patients with 
CKD (see Chapter 6). Aortic rings cultured in 3mM phosphate consistently calcified 
without the need for any additional supplements to the medium or pre-treatment. 
This is in contrast to previous reports using this model. Rat rings cultured in 3.8mM 
phosphate were shown to be free of calcification after 10 days in culture unless 
alkaline phosphatase was added to the culture medium (Lomashvili et al 2004), and 
human vessels from healthy control patients did not calcify in a medium containing 
2mM phosphate plus 2.7mM calcium whereas those from patients on dialysis did 
(Shroff et al 2010). The latter of these reports can conceivably be explained by the 
differences in species and/or the concentrations of phosphate and calcium used 
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(although the calcium x phosphate product is identical to that used in the current 
work, the individual ion concentrations differ). It is more difficult to reconcile the 
lack of calcification described in the former study with the observations made in this 
chapter, especially as a lower phosphate concentration was used here. Indeed, when 
rings were cultured in 3.8mM phosphate in the present work, calcification of almost 
the entire vessel was seen. In addition, when rings were cultured with alkaline 
phosphatase, less calcification was observed. Apart from the basic culture medium 
and strain of rat (Dulbecco’s Modified Eagle Medium (DMEM) and Sprague-
Dawley, respectively, in the original report by Lomashvili et al (2004)), an identical 
protocol to that described was used so it is unclear why the opposite effect occurred. 
It is possible that there were subtle differences in the composition of reagents and/or 
culture environment not specified in the initial paper. As the primary goal of using 
alkaline phosphatase in the current work was to improve the consistency of 
calcification, and after one attempt a reduction in calcium deposition was seen, this 
approach was not pursued further. It is therefore possible that the findings in this 
single experiment were spurious, however, the use of 3mM phosphate to induce 
calcification without additional reagents was consistent throughout the work 
described in this chapter and is clearly in contrast to this original report. 
Another advantage of the ring culture system is that serum and growth factor 
supplementation are unnecessary to maintain cell viability, thereby minimising the 
effect these additives can have on cell activity and phenotype. However, the analysis 
of mRNA for SM-22 suggests that expression of this VSMC marker, and therefore 
possibly VSMC phenotype, are modified by simply maintaining rings in normal 
culture medium. In addition, the results for caspase-3 indicate that even these 
‘control’ conditions may induce some degree of apoptosis. That changes in gene 
expression profiles can be induced by culture conditions alone was shown in a 
previous report which described a change from baseline in runx-2 mRNA expression 
in control rings cultured for 3 days without the addition of any ‘extra’ reagent 
(Lomashvili et al 2011). Although the ring culture model has a number of 
advantages over primary cell culture, maintenance of cell phenotype and absence of 
apoptosis, previously cited to be additional benefits (Lomashvili et al 2004, Shroff et 
al 2010) were not observed in the studies presented herein. 
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The magnitude of calcification differed between experiments performed in this 
chapter and wide standard deviations in calcification were frequently seen within 
groups of cultured rings. Attempts to improve the consistency of calcification were 
unsuccessful. Unexpectedly, the ‘pre-treatment’ of rings with elastase for 24 hours 
led to a reduction in calcification. The report originally detailing this method 
suggested that in vitro, elastase initiates elastin breakdown, mimicking the in vivo 
histological findings from calcified mouse aortas described by the same group, 
leading to more consistent calcification (Scialla et al 2013). As this group cultured 
mouse aortic rings, (in contrast to the rat vessels used in the present work), it is 
possible that species differences account for the disparate findings. The fact that in 
the current study elastase-treated rings weighed much less than the corresponding 
controls suggests that the enzyme was in effect causing overt elastin dissolution 
rather than just initiating its breakdown. This might also explain the reduced 
calcification.  
A number of potential reasons exist to account for the variability in calcification 
between rings within individual experiments. The importance of removing the 
adventitia from vessels prior to quantifying medial calcium deposition was 
demonstrated histologically, with deposits frequently seen within the adventitial 
layer. However, in removing the adventitia there is the potential to damage the vessel 
and dislodge adherent calcium. This may occur to different, random extents between 
rings. Removing the adventitia prior to commencing the experiment is not a solution 
to this problem as this can damage the medial layer resulting in more calcification 
and thus cause greater variability overall (Lomashvili et al  2004). It is also possible 
that rings from different sections of the aorta calcify differently. A notable feature of 
the rat in vivo work in this thesis (Chapter 5) is that the abdominal aorta seems to 
calcify before the thoracic segment and the aortic arch, as has been described 
previously in animal experiments (Shobeiri et al 2013). Whatever the explanation(s), 
none of these factors should have biased the outcome in either direction since all 
rings were handled in the same way. Additionally, adjacent rings were exposed to 
different treatments thereby eliminating the potential effects conferred by where on 
the aorta the ring originated from. 
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3.4 Summary 
The results from this chapter suggest that P2X7R does not influence AC in the tissue 
culture models employed. How relevant these experimental systems are to ‘real life’ 
biology remains unclear. In particular, it is uncertain whether some mechanisms 
widely reported to be important in the pathogenesis of AC occur in these settings. 
The role(s) of P2X7R in AC pathways which are dependent upon a uraemic milieu 
cannot easily be tested under these conditions. In vivo studies are necessary to 
investigate these processes and were the focus of the work described in Chapters 4 
and 5. 
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CHAPTER 4 – DEVELOPMENT OF A NOVEL MOUSE MODEL TO 
STUDY THE EFFECT OF P2X7R DEFICIENCY ON CHRONIC KIDNEY 
DISEASE-ASSOCIATED ARTERIAL CALCIFICATION  
4.1 Introduction 
VSMC or ring culture models can be used to study calcium deposition and cellular 
changes that occur in response to agents thought to be important in the process of 
CKD-associated AC. However, as alluded to in Chapter 3 it is extremely difficult to 
simulate a ‘uraemic milieu’ per se in vitro, and these models have a number of other 
limitations. In vivo systems provide a complementary approach to in vitro studies 
and permit investigation under more biologically and physiologically relevant 
conditions. 
A number of pathways thought to contribute to the pathogenesis CKD-associated AC 
have been described which are dependent upon systemic changes induced by renal 
impairment, and therefore can only really be assessed in vivo. Two examples of these 
are disturbances in bone homeostasis (Persy & D’Haese 2009) and arterial ECM 
degradation (Pai & Giachelli 2010). P2X7R is potentially relevant to both, having 
been linked to these processes in other contexts (Grol et al 2009, Gu & Wiley 2006). 
In addition, P2X7R has been shown to attenuate progression of CKD itself in some 
animal models (Goncalves et al 2006) and therefore in so doing might concurrently 
retard progression of AC. Finally, the work in Chapter 3 cast some doubt as to 
whether osteogenic transformation and apoptosis of VSMCs, pathways that 
hypothetically might be influenced by P2X7R, are involved in the development of 
AC. Assessing these pathways in vivo and specifically in the setting of CKD along 
with any impact of P2X7R is therefore relevant and desirable. 
The aim of the work described in this chapter was to assess whether P2X7R 
deficiency influences the development and progression of CKD-associated AC in 
vivo by comparing P2X7
-/-
 mice with WT controls in an appropriate disease model. 
As reviewed in Chapter 1 (section 1.4.3), just one murine model of CKD-associated 
AC is described in the literature (El Abadi et al 2009). The original report detailing 
the development of this model indicated that CKD alone was not sufficient for AC to 
develop and that it had to be combined with a high phosphate diet. The model itself 
involves extensive surgical manipulation (5/6
th
 nephrectomy) thereby limiting its 
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availability to those with specialist expertise and is inevitably associated with a high 
rate of animal loss. Furthermore, it appears the effect is limited to female mice and 
requires a number of months for established arterial disease to develop. An initial 
objective of the current work was therefore to develop a non-surgical and more 
convenient mouse model of CKD-associated AC to use as an experimental tool.  
Importantly, DBA/2 mice, a strain prone to arterial calcification, were used in this 
original study as the C57Bl/6 genetic background is thought to confer resistance to 
this disease (Eaton et al 1978). P2X7
-/-
 mice were created in the C57Bl/6 strain 
(Solle et al 2001). It was therefore necessary to backcross these mice through 5 
generations onto the DBA/2 background prior to performing the experiments 
examining the role of genetic deletion on AC (as described in Chapter 2). While the 
backcrossing was in progress, attempts to develop the experimental model were 
carried out with WT DBA/2 mice. 
The propensity of 2 agents, folic acid and adenine, to induce CKD was investigated 
in this chapter. Folic acid has been widely used to induce renal fibrosis in mice (Fink 
et al 1987, Long et al 2008, Bechtel et al 2010), although no reports are available 
detailing its use in female DBA/2 animals. This work therefore first sought to 
determine whether this agent, in combination with high phosphate feeding, would 
lead to AC. Dietary adenine is widely used to induce CKD and AC in rats (Shobeiri 
et al 2010, Neven & D’Haese 2011) and was the basic model employed for the work 
detailed in Chapter 5. However, adenine has only recently been administered to mice 
and AC has not previously been described (Tamura et al 2009, Tanaka et al 2009, 
Oyama et al 2010, Schiavi et al 2012, Jia et al 2013, Santana et al 2013). Of 
relevance, these studies all administered adenine to mice on calcification-resistant 
backgrounds. In addition, studies in rats have highlighted the importance of using a 
low dietary protein content in order to reliably induce AC (Price et al 2006). This 
work therefore also investigated whether an adenine-containing diet with 
adjustments in protein content could induce CKD and AC in calcification-prone 
mice. 
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4.2 Results 
4.2.1 Administration of folic acid to WT DBA/2 mice. 
Folic acid has successfully been used to induce CKD in other (non-DBA/2) strains of 
mice, with an ip dose of generally 240µg/g or less reported to result in renal fibrosis 
(Long et al 2008). This concentration was therefore initially administered to 6 WT 
female DBA/2 mice with a further 4 receiving vehicle control. High phosphate 
feeding (Diet A, Table 2.1) commenced the day after the ip injection for all animals 
and continued for 20 weeks. 
The appearance, movement and social interaction of all 6 mice injected with 240µg/g 
folic acid was indistinguishable from the 4 controls at all times following treatment. 
Mean weight change after 7 days in controls was +2.5 ± 7.6% compared with -1.0 ± 
5.7% in folic acid-treated animals (p = 0.430). The corresponding values at 20 weeks 
were +0.1 ± 3.4 vs +2.4 ± 5.8% (p = 0.493) (Figure 4.1).  
 
 
 
 
 
 
 
 
Serum concentrations of urea, creatinine, phosphate, calcium (uncorrected due to 
insufficient serum for additional measurement of albumin) and alkaline phosphatase 
were measured at baseline, 2, 5, 9, 15 and 20 weeks. In addition, serum was 
collected from 2 mice after 3 days in order to assess for acute kidney injury. With the 
exception of phosphate, which showed an approximate 2-fold increase at 20 weeks 
compared to baseline in both groups, all biochemical parameters remained relatively 
Figure 4.1. Weight Loss in Mice Treated with Folic Acid. Percent weight loss at 
selected time-points compared with baseline in control mice (n=4, filled squares) and 
those treated with 240 (n=6, unfilled squares) and 300µg/g folic acid (n=3, unfilled 
triangles). Data are presented as mean ± SD. 
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stable throughout the study period. There were no significant differences between 
groups in the absolute change of any analyte at week 20 compared to baseline 
(Figure 4.2).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Histologically, kidneys taken from animals in both groups were indistinguishable, 
exhibiting essentially a normal appearance (Figure 4.3). No calcification was 
  Creatinine 
  ALP 
  Calcium   Phosphate 
  Urea 
Figure 4.2. Serum Biochemistry in Mice Treated with Folic Acid. Concentrations 
of indicated serum parameters over time in control mice (n=4, filled squares) and 
those treated with 240 (n=6, unfilled squares) and 300µg/g folic acid (n=3, unfilled 
triangles). Data are presented as mean ± SD. 
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detected in any aorta from these mice either biochemically or histologically (Figure 
4.3). 
 
 
 
 
 
 
 
 
 
 
 
 
As no disease was induced by this protocol, a further 4 mice were given an ip dose of 
300µg/g (an increase of 25%). One of these mice died in the first week following 
injection, however this was deemed to have occurred due to peritonitis, as cloudy 
peritoneal fluid was observed during post-mortem examination, rather than any folic 
acid-induced acute kidney injury. The other 3 mice remained well for the 20 week 
study period. Serum urea taken at day 3 from these mice showed a mean fold 
increase of 2.0 ± 0.7 possibly suggesting some degree of kidney injury but there 
were no clinical manifestations of this and in particular all 3 animals gained a small 
amount of weight during the first 14 days of study. After this point all serum 
parameters remained relatively stable compared to baseline and of similar 
magnitudes to the results obtained for the control and 240µg/g groups described 
A 
D C 
B 
Figure 4.3. Absence of Kidney and Aortic Disease in Mice Treated with 240µg/g 
Folic Acid. Representative H & E staining of kidney sections with corresponding 
von Kossa staining of aortas taken from female mice. A & B: Control mice. C & D: 
240µg/g folic acid-treated. A & C magnification x10. B & D magnification x63. 
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above (Figure 4.2). There was no aortic calcification and no histological abnormality 
in aortas or kidneys after 20 weeks. 
Given that the concentrations of folic acid administered to this point had no effect, it 
seemed likely that much higher doses would be required to induce renal injury. It 
was therefore decided to double the original starting dose to 480µg/g and examine 
the effect in a further 6 female DBA/2 mice. All but one of these animals died in the 
first week. Histological examination of kidneys from deceased mice revealed dilated 
tubules with flattened epithelium, a number containing casts and other debris - all 
findings consistent with a folic acid-induced acute kidney injury (Figure 4.4).  
 
 
 
 
 
 
 
 
Of particular note, the one mouse that did not die in the first week initially lost 
weight without appearing overtly unwell and had a serum urea rise from 4.4mmol/l 
at baseline to 71.0mmol/l at day 3. However, it gained weight over subsequent days 
to survive the 20 week study period. Following sacrifice, the histological appearance 
of the kidney from this mouse was not noticeably different from the control kidneys 
previously examined (Figure 4.5A). However, von Kossa staining demonstrated 
calcium deposits within the aorta which were clearly seen to be associated with 
elastin fibres in the medial layer of the vessel (Figure 4.5B and C). 
 
 
C 
C 
Figure 4.4. Acute Tubular Injury in Mice Treated with 480µg/g Folic Acid.  
H & E stained kidney sections from a mouse which died within 3 days following 
treatment with 480µg/g folic acid. Features of acute tubular injury are present 
including epithelial flattening and intra-luminal debris (arrows) and tubular casts 
(‘C’). Magnification x20. 
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Although AC was evident in this one animal, the mortality rate of 83% associated 
with this higher dose of folic acid was clearly unacceptably high. A further dose 
adjustment was therefore made and 360µg/g was administered to 2 mice. Both 
animals died during the first week following injection of folic acid with similar 
histological renal findings to those described for 480µg/g (not shown). Following 
these attempts it became clear that the use of folic acid was unlikely to prove 
successful for inducing the required clinical characteristics. An alternative chemical 
agent for induction of renal disease with AC was therefore sought. 
 
 
 
A 
C 
B 
Figure 4.5. Kidney and Aortic Disease in One Mouse Treated with 480µg/g Folic 
Acid. A: H & E stain of kidney tissue demonstrating essentially normal features. B: 
von Kossa stain of aorta. Calcium deposits are stained black (arrows and inside box). 
Counterstained with aluminium red. C: Close up of boxed section in ‘B’ 
demonstrating calcium deposition along elastic fibres. A & B magnification x10; C 
magnification x63. 
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4.2.2 Optimisation of an adenine-based regime. 
4.2.2.i A diet containing high phosphate, low protein and adenine induces CKD and 
AC in male DBA/2 mice. 
Initially 16 WT DBA/2 mice, (8 male and 8 female), were assigned to receive a high 
phosphate diet containing 0.25% adenine and either 7.5% or 2.5% protein (split 
evenly between genders) for 6 weeks (Diet B, Table 2.1). Of the 4 male mice on the 
7.5% protein diet, 2 had to be caged individually as they did not have any littermates. 
One of these mice was noted to display atypical behaviour from the outset of the 
experiment and died during the first week. Post-mortem examination revealed a 
massively distended bladder probably caused by 2,8-dihydroxyadenine crystals 
causing obstructive nephropathy (Santana et al 2013). The other mouse died at day 
13 and of note, von Kossa staining of the abdominal aorta revealed calcium 
deposition within the arterial media. It became clear that mice fed this diet could not 
be caged individually. Therefore to assess whether aortic calcification would occur 
consistently with the 7.5% protein diet it was decided to administer it to a further 8 
males and 4 females (not needing to be caged individually). One further male 
receiving this diet died but all other mice (including those in other arms of this pilot 
study) survived through to 6 weeks. 
Changes in weight varied significantly between groups (Figure 4.6). The male mice 
on 2.5% protein had the greatest weight loss, exceeding that of the females on 2.5% 
protein although not reaching statistical significance. Male mice on 7.5% protein 
also lost weight but significantly less than males on 2.5% protein. Females on 7.5% 
protein gained a little weight overall. Although the weight loss was quite extensive 
in some cases, no surviving mice displayed any manifestations of distress and 
exhibited normal behaviour throughout the experiment. 
Calcium was detected in the aortic arch and abdominal aorta from 3 of the 4 male 
mice fed 2.5% protein and 2 of the 9 surviving males fed 7.5% protein. Aortic 
calcification was only detectable in one female mouse fed 2.5% protein and was 
absent in all 8 females fed 7.5% protein (Figure 4.7). Histologically, kidneys from 
animals with demonstrable aortic calcification exhibited increased tubulointerstitial 
changes (tubular dilatation and epithelial flattening) and fibrosis when compared 
with those from animals without arterial mineral deposition. Green-brown crystals 
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were frequently observed in tubular lumen consistent with precipitation of 2,8-
dihydroxyadnine (Figure 4.7). 
A summary of the serum biochemical changes from baseline for all surviving mice is 
given in Table 4.1 and Figure 4.8. Creatinine and phosphate both increased 
significantly more in males fed 2.5% protein compared with females fed 2.5% and 
males fed 7.5%. Males on the 2.5% protein diet also had a significantly greater 
increase in corrected calcium compared with males on 7.5% and a significantly 
smaller drop in albumin compared with females fed 2.5%. Females fed 7.5% protein 
had a significantly greater increase in corrected calcium and albumin compared with 
males fed 7.5% and females fed 2.5% respectively. No statistically significant 
differences were detected between any group for either urea or ALP. It was notable 
that serum urea concentrations were usually not elevated compared with baseline and 
actually decreased in 3 groups. 
 
 
 
 
 
 
 
 
 
 
 
 
A B 
Figure 4.6. Weight Loss in Adenine-Fed Mice. Graphs depicting the weight loss 
during the pilot study of feeding male and female mice a 0.25% adenine-containing 
diet with varying protein contents as indicated. A: Percent weight loss compared with 
baseline at various time-points. Data is presented as mean ± SD. B: Final percent 
weight loss compared with baseline. Post hoc tests were performed when ANOVA 
indicated p<0.05 and compared groups matched for gender and protein. 
a 
p<0.001 
compared with male 2.5% protein.
 b 
p<0.001 compared with female 2.5% protein. 
c 
p<0.001 compared with male 7.5% protein. Each points represents an individual 
animal. Horizontal bars represent group means. 
  a
 
   b,c
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A B 
D C 
G H 
F E 
I 
Figure 4.7. Kidney and Aortic Disease 
in Adenine-Fed Mice. Representative H 
& E stained kidney sections with 
corresponding von Kossa-stained aortic 
sections from mice  fed 0.25% adenine 
diets of varying protein content. Calcium 
deposits stain black. A & B: Male mouse 
fed 2.5% protein. C & D: Female mouse 
fed 2.5% protein. E & F: Male mouse fed 
7.5% protein. G & H: Female mouse fed 
7.5% protein. I: High-magnification view 
showing an intra-luminal 2,8-dihydroxyadenine crystal (arrow). A, C, E and G 
magnification x10. B, D, F, H and I magnification x40. 
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Corrected 
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ALP Albumin 
Figure 4.8. Changes in Serum Biochemistry in Adenine-Fed Mice. Changes in serum 
biochemistry from baseline in male (M) and female (F) mice fed a 0.25% adenine-
containing diet with varying protein (Pr) contents as indicated for 6 weeks. Post hoc tests 
were performed if ANOVA indicated p<0.05 and compared groups matched for gender 
and protein. These conditions were met for all parameters except urea and ALP.  
a 
p<0.05; 
b 
p<0.01;
 c 
p<0.001 compared with male 2.5% protein. 
d 
p<0.001 compared with male 
7.5% protein. 
e 
p<0.001 compared with female 2.5% protein. Each point represents an 
individual animal. Horizontal bars represent group means. 
  a
 
     b
 
  a
 
  c
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Parameter  
(Change From Baseline) 
 
Male 2.5% Protein Female 2.5% Protein Male 7.5% Protein Female 7.5% Protein P value 
 (ANOVA) 
Creatinine (µmol/l) 28.6 ± 8.1 12.8 ± 1.9
a
 12.1 ± 9.5
b
 7.9 ± 2.4 <0.001 
Urea (mmol/l) -0.9 ± 2.3 -3.5 ± 1.4 2.3 ± 4.2 -1.1 ± 3.5 >0.5 
Phosphate (mmol/l) 5.1 ± 1.8 1.6 ± 0.6
c
 3.1 ± 1.0
a
 3.1 ± 0.9 0.002 
Corrected Calcium (mmol/l) 0.58 ± 0.18 0.42 ± 0.14 0.13 ± 0.12
c
 0.35 ± 0.09
d
 <0.001 
Albumin (g/l) -7.2 ± 3.1 -11.8 ± 0.5
c
 -0.2 ± 2.9 1.5 ± 1.9
e
 <0.001 
ALP (U/l) -24.3 ± 16.4 -133.0 ± 32.7 -113.9 ± 58.1 -99.8 ± 81.5 >0.05 
 
Table 4.1. Changes in Serum Biochemistry in Adenine-Fed Mice. Changes in serum biochemistry from baseline in male and female mice fed a 0.25% adenine-containing 
diet with varying protein contents as indicated for 6 weeks. Post hoc tests were performed if ANOVA indicated p<0.05 and compared groups matched for gender and protein. 
These conditions were met for all parameters except urea and ALP.  
a 
p<0.05; 
b 
p<0.01;
 c 
p<0.001 compared with male 2.5% protein. 
d 
p<0.001 compared with male 7.5% 
protein. 
e 
p<0.001 compared with female 2.5% protein. Data are presented as mean ± SD. 
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4.2.2.ii A modified adenine-containing diet is poorly tolerated by C57Bl/6 mice. 
Previous reports had suggested that mice on the C57Bl/6 background are resistant to 
AC (Eaton et al 1978, El Abbadi et al 2009). To confirm whether this was also the 
case using an adenine-containing diet to induce disease, the most efficacious regime 
from the previous experiment (Diet B with 2.5% protein, Table 2.1) was fed to 5 
male C57Bl/6 mice. This proved to be tolerated extremely poorly. One mouse had to 
be sacrificed after 3 weeks and the other 4 by the end of the 4
th
 week. By this time-
point all mice had lost 40-50% body weight and exhibited a range of signs indicating 
poor health. A post-mortem examination was performed on all 5 animals and of note 
the mouse removed in the 3
rd
 week did have evidence of aortic calcification, 
however no arterial disease was observed in the other 4 mice. Baseline biochemistry 
was not measured in these animals, however the final serum creatinine and 
phosphate concentrations were 93.8 ± 14.1µmol/l and 6.7 ± 0.8mmol/l respectively, 
indicating advanced renal impairment. 
4.2.2.iii Male offspring of 5
th
 generation backcrossed mice exhibit AC on a modified 
adenine-diet. 
The unsuccessful use of the adenine-containing diet in C57Bl/6 mice confirmed the 
necessity of moving the P2X7R gene deletion onto the DBA/2 background. 
Therefore when offspring were produced from mice backcrossed through 5 
generations, 4 WT males were fed Diet B (2.5% protein) (Table 2.1) to assess 
whether disease could be induced. These 4 mice were first fed a high phosphate diet 
(Diet A, Table 2.1) for one week in an attempt to aid acclimatisation to the adenine-
diet (being of similar consistency and texture). Diet A (Table 2.1) had previously 
been shown (having been used as the control diet in the experiments using folic acid 
described above) to have minimal effects on biochemistry or weight change and was 
again well tolerated here by these 4 mice. The trajectory of weight loss over the next 
6 weeks was similar to that seen with the original 4 WT DBA/2 males fed this diet 
(not shown). One mouse died one day before the 6 week time-point and post-mortem 
examination revealed calcification within the aortic arch. At the end of 6 weeks the 
other 3 mice were switched back to the high phosphate ‘acclimatisation’ diet (Diet 
A, Table 2.1) in order to see whether they would gain weight whilst potentially 
permitting any AC to continually develop in the context of established CKD. 
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Unexpectedly this intervention was not tolerated and all 3 animals died during the 
subsequent 7 days. However, post-mortem examination and subsequent analysis 
demonstrated calcium deposition in the aortic arches of all 3 animals confirming the 
propensity of this new strain (5
th
 generation back-crossed mice) to develop AC when 
fed Diet B (containing 2.5% protein, Table 2.1). 
4.2.2.iv Diets containing a higher adenine content or flavour enhancers are poorly 
tolerated. 
A number of further dietary modifications were evaluated in an attempt to produce a 
regime that was more palatable, in the hope of inducing CKD and AC that was not 
associated with such a degree of weight loss. To assess whether a 0.75% adenine-
containing diet could be given for a brief (3 day) period with subsequent high 
phosphate feeding alone, 3 male 5
th
 generation mice were fed this regime. All 
animals became extremely sick within 3 days, 2 died and the other was returned to a 
high phosphate diet alone. After 6 weeks this mouse showed no evidence of disease. 
Chocolate-flavoured diets are commercially available which mice are reported to 
find very palatable (personal communications with scientists at SSNIFF). To 
investigate whether this would improve the intake of adenine-containing diets, 2 
chocolate-flavoured formulations were trialled, one containing 0.25% and the other 
0.20% adenine. Both contained 2.5% protein (Diet C, Table 2.1). Each diet was fed 
to 4 male 5
th
 generation mice and overall they were tolerated extremely poorly. All 
mice had to be sacrificed by 4 weeks. No AC was detected in these animals. 
4.2.3 The effect of P2X7R gene deletion on CKD-associated AC. 
4.2.3.i Selection of dietary regime. 
Given the results from all of the pilot studies detailed above it was clear that the 
optimal experimental conditions were met when male mice (5
th
 generation 
backcross) were fed a high phosphate, 0.25% adenine, 2.5% protein-containing diet 
(Diet B, Table 2.1) for 6 weeks without any initial ‘acclimatisation’ feeding. This 
regime was therefore administered to 11 WT (WTA) and 10 P2X7
-/-
 (KOA) mice. A 
control (C) diet (Diet B without adenine, Table 2.1) was fed to 8 mice of each 
genotype (WTC and KOC respectively). 
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4.2.3.ii Survival and qualitative outcomes. 
Generally animals tolerated their respective diets very well and remained well 
throughout the study period. Only one animal (a KOA mouse) died. All mice lost 
weight with both genotypes losing more weight on the adenine-diet compared with 
their respective controls. Genotype did not significantly influence the degree of 
weight loss with either diet (Figure 4.9). 
 
 
 
 
 
 
 
 
 
4.2.3.iv Analysis of aortic calcification 
The number of animals exhibiting aortic calcification at the end of 6 weeks was very 
low. No animals on the control diet had disease. A single WTA mouse and 2 KOA 
mice had detectable aortic calcium deposition. The magnitude of calcification was 
higher in the WTA mouse than in the 2 KO animals (255 vs 62 and 31µg/mg tissue, 
respectively). 
4.2.3.v Analysis of biochemistry. 
There were no significant differences in the change of any serum parameter between 
KO mice and their corresponding WT controls on either diet (Table 4.2 and Figure 
4.10). Serum creatinine remained largely unchanged in control mice with a 
significant increase occurring in both genotypes fed the adenine diet. Urea 
A B  a
 
 b
 
Figure 4.9. Weight Loss in WT and KO Mice. Graphs depicting the weight loss 
seen during the final experiment feeding a 0.25% adenine-containing diet with a 
2.5% protein content to WT and KO mice. A: Percent weight loss compared with 
baseline over time. Data is presented as mean ± SD. B: Final percent weight loss 
compared with baseline. Post hoc tests were performed when ANOVA indicated 
p<0.05 and compared groups matched for diet and genotype. 
a 
p<0.001 compared 
with WTC.
 b 
p<0.001 compared with KOC. Each points represents an individual 
animal. Horizontal bars represent group means. 
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concentrations dropped in all groups. The degree of this drop was less in adenine-fed 
mice but only reached significance in the KO cohort. In contrast, phosphate 
concentrations increased in all groups with a greater elevation seen in adenine-fed 
animals but only reaching significance in WT mice. Due to limited serum, baseline 
phosphate could not be measured in one KOA mouse and it is possible that the 
change in phosphate would have reached significance in KO mice had this 
measurement been available. No significant differences were detected for either 
corrected calcium or albumin which increased and decreased, respectively, in all 4 
groups. The change in ALP did not reach statistical significance, although it only 
increased in the KOA group (having decreased in the other 3). 
4.2.3.vi Relationship of aortic calcification to biological parameters. 
The 2 KOA mice with detectable aortic calcification were also the 2 with the greatest 
weight loss in that group. In contrast, in the WTA group 6 mice (55%) lost more 
weight than the animal exhibiting arterial disease.  
Taking all mice into account, the 3 with aortic calcification had the 3 highest end-
point creatinine values. Due to limited serum a baseline reading could not be 
measured for one of these mice, however the other 2 also had the greatest creatinine 
increase.  Similar findings were apparent for serum urea concentrations, with these 3 
mice having the first, second and fourth highest final readings.  
The final serum phosphate in the calcified WTA mouse exceeded the upper limit of 
the assay and one of the KOA mice with AC had the second highest phosphate 
overall. However, there were 3 mice with final phosphates exceeding that of the 
other KOA mouse with AC (however a baseline value was again absent for this 
mouse and the change in phosphate may well have exceeded that of these other 3 
mice). 
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Parameter  
(Change From Baseline) 
 
WTC KOC WTA KOA P value  
(ANOVA) 
Creatinine (µmol/l) -3.2 ± 3.0 0.6 ± 6.7 22.0 ± 12.3
b 
18.7 ± 13.5
d 
<0.001 
Urea (mmol/l) -4.2 ± 1.3 -6.3 ± 2.8 -0.8 ± 4.4 -1.2 ± 3.0
c
 0.005 
Phosphate (mmol/l) 2.4 ± 0.5 2.8 ± 0.5 3.8 ± 1.3
a
 3.9 ± 1.3 0.016 
Corrected Calcium (mmol/l) 0.41 ± 0.05 0.29 ± 0.24 0.42 ± 0.17 0.40 ± 0.18 0.449 
Albumin (g/l) -2.9 ± 1.7 -2.2 ± 5.4 -3.7 ± 2.3 -3.3 ± 3.2 0.847 
ALP (U/l) -14.5 ± 26.1 -24.0 ± 44.6 -35.4 ± 53.3 16.4 ± 22.3 0.066 
 
Table 4.2. Serum Biochemistry Changes in WT and KO Mice. Absolute changes from baseline in serum biochemistry for each group. Post hoc tests were performed if the 
initial ANOVA indicated p<0.05 and compared groups matched for diet and genotype. These conditions were not met for  corrected calcium, albumin and ALP. 
a 
p<0.05; 
b 
p<0.001 (both compared with WTC). 
 c 
p<0.05; 
 d 
p<0.01 (both compared with KOC). Data are presented as mean ± SD. 
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4.3 Discussion 
The number of mice with detectable aortic calcification in the final experiment was 
unexpectedly and disappointingly low, making it difficult to draw any conclusions 
about the effect of P2X7R-deficiency on CKD-associated AC. The fact that 2/10 
KOA mice developed AC and a further one died, compared with just 1/11 in the 
WTA group manifesting arterial disease coupled with zero mortality might suggest 
that P2X7R-deficiency is detrimental in this context. Realistically the ‘event rate’ 
was too low to definitively make any judgement, however the results perhaps hint 
that lack of P2X7R is not beneficial.  
P2X7
-/- 
mice are described to be viable, fertile and undistinguishable from WTs by 
simple observation (Solle et al 2001). This was found to be the case here even after 
moving onto the new genetic background. Furthermore there were no differences in 
serum biochemistry between WT and KO mice at baseline or after 6 weeks feeding 
on either diet (adenine-containing or control). Previous reports that have implicated a 
protective effect of P2X7R deletion on renal fibrosis have used histological 
parameters as primary outcomes (Goncalves et al 2006). An in-depth 
histopathological analysis of kidney tissue was beyond the scope of the work in this 
chapter and so it is therefore possible, despite the lack of difference in biochemistry 
between genotypes, that there were changes in inflammatory infiltrates (which have 
been described by other groups that have fed adenine to mice) (Oyama et al 2010, Jia 
et al 2013). 
The immediate and most fundamental question arising from the work described in 
this chapter is why there was so much disparity between the pilot and final studies in 
the success of inducing AC. There appears to be no obvious answer to this. In terms 
of other measureable parameters, disease progression seems to have been similar 
between male mice fed 2.5% protein in the adenine pilot studies and those in the 
final experiment. Weight loss in WT mice during the final experiment was 
essentially identical to that seen in the pilot study. The change in serum creatinine 
was a little higher in pilot mice overall, however there were a number of WTA and 
KOA animals that did not display AC but had creatinine changes in excess of all 
pilot study mice. It therefore seems that other factors must have been present to 
explain the contrasting findings. 
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One possibility is that there were subtle genetic differences between the 5
th
 
generation mice used in the pilot study, all of which developed AC, and those in the 
main experiment. However, the 3 mice with aortic disease in the final study were all 
of different parentage and housed with littermates which did not display AC thus 
arguing against a genetic-related factor.  
Another potential explanation is the one week ‘acclimatisation’ period employed in 
the pilot study during which mice were fed a high phosphate diet (Diet A, Table 2.1). 
This was not done in the main experiment as in the pilot study it had not obviously 
influenced subsequent dietary intake of the adenine-containing feed, or weight loss, 
and one animal had died before 6 weeks on the adenine diet. Diet A (Table 2.1) did 
not influence any biochemical parameter during the first 2 weeks of feeding as 
shown by the studies with folic acid during which it was fed to all mice. Therefore 
whilst not impossible, it is difficult to see how an initial one week period on this diet 
would greatly enhance rates of aortic calcification. Mice in the pilot study were 
converted back to Diet A (Table 2.1) after 6 weeks of adenine feeding but all died 
within a few days of the switch. This brief period of time after the dietary change 
seems too short for extensive disease to develop and AC was almost certainly 
present before this point. A further possible reason for the contrasting findings could 
relate to subtle differences in the make-up of the diets however this also seems 
unlikely given that although different batches, they were made by the same 
manufacturer to the same formulation and specification and stored in identical 
fashion.  
All in vivo models of AC are reported to result in variable rates of calcification 
which may ultimately have been the reason for the present findings. Only one murine 
model of CKD-associated AC has previously been described (El-Abbadi et al 2009) 
and in this original report all mice (n=7) exhibited some degree of aortic calcification 
but a wide range of values was seen. Of note however, all control animals were 
found to have mild degrees of aortic calcification and some CKD mice only had AC 
to a similar degree as this ’healthy’ cohort. A number of subsequent studies (all by 
the Giachelli laboratory) have employed this model (Pai et al 2011, Lau et al 2012a, 
Lau et al 2012b, Scialla et al 2013) and confirm variability in calcification. The 
study by Scialla et al (2013) reported only a 50% success of AC induction. No 
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definitive explanation for this variability has been put forward by any group - it is 
almost certainly multi-factorial and likely that many of these unidentified 
determinants were at play in the current work. 
When considering the potential utility of the model developed in this chapter as a 
future experimental tool, it is worth making comparisons (in respect of factors other 
than calcification consistency) with that established by Giachelli’s group (El-Abbadi 
et al 2009). Advantages of adenine feeding include the no requirement for surgery, 
and hence no peri-operative mortality, a relatively short length of time necessary for 
AC to develop (mice are usually followed for at least 3 months with the surgical 
model) and the no gender dependence (male mice are not used in the surgical model 
due to an increased resistance to AC). In terms of biochemistry, only selected 
parameters have been reported in the surgical model. Urea rather than creatinine has 
been used as a marker of renal impairment and shows an approximate 3-fold 
elevation compared with controls. This is in contrast to the present work in which 
serum urea was, if anything, slightly decreased - almost certainly a reflection of both 
decreased body weight and protein intake. This is definitely a limitation of the 
adenine-based model. Weight loss also occurs in the surgical model but has not been 
reported in terms of ‘percentage loss’ so it is difficult to make an accurate 
comparison with the results here. Creatinine appears to be a better marker of renal 
function in the adenine-model as it consistently increased. Elevations in serum 
phosphate are comparable between the two models, however an increase in ALP is 
seen in the Giachelli model (in contrast to a general decrease with adenine) along 
with an elevated PTH (which was not measured in the present work due to the 
limited volume of serum). In keeping with these serum results, high-turnover bone 
disease has been demonstrated with the surgical model (Lau et al 2012a). Analysis of 
bone was not performed in the current work so it is unclear whether the two systems 
are equivalent in this respect. 
The work by Giachelli’s group and the results from the adenine experiments here do 
indicate that for AC to occur, an advanced state of renal impairment needs to be 
reached.  Folic acid was essentially unsuccessful for inducing renal disease in the 
present work. In retrospect, successful studies that have employed folic acid to 
induce CKD report obtaining less than 30% fibrosis after 20 weeks associated with 
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serum creatinine values of around half those detected in adenine-fed mice with AC 
in this work (Bechtel et al 2010). Folic acid is therefore unlikely to achieve the 
necessary degree of renal impairment required for AC to develop.  
When considering the conditions necessary for AC to develop in vivo, the fates of 3 
mice involved in the pilot studies, all of which displayed calcified aortas, are 
particularly intriguing. The animals in question are the one female DBA/2 
administered 480µg/g folic acid, the one male C57Bl/6 (which died in week 3) and 
the male DBA/2 (which died at day 13). These mice are biologically diverse 
differing in gender, strain and method used to induce disease. Furthermore, disease 
in the latter 2 animals developed relatively rapidly (in less than 3 weeks). The 
uniting factor seems to be that all 3 had pronounced weight loss over a few days and 
whilst one remained fairly well and recovered, the other 2 quickly declined. A 
number of systemic changes are likely to be present in this clinical setting. Renal 
impairment is inevitable with a consequential elevation in serum phosphate. 
Additionally, these animals were almost certainly profoundly volume-contracted. 
The fact that AC appears to be able to develop very quickly (within days) under 
these circumstances raises the possibility that in this context ectopic calcification 
occurs due to mechanisms other than those requiring ‘active’ and ‘cell-mediated’ 
changes. C57Bl/6 mice are resistant to AC and this is thought to be due in part to a 
greater expression of the Abcc6 gene (Meng et al 2007). The fact that one of these 
mice developed AC demonstrates that this resistance can be overcome in certain 
situations. One possibility is that under these conditions of advanced dehydration 
and mineral imbalance the systemic environment simply favours passive 
precipitation of mineral. 
Male mice were more prone to disease with adenine feeding whereas only females 
are reported to develop AC with the surgical model (El-Abbadi et al 2009). In many 
mouse models of renal disease males appear to be affected to a greater degree than 
females (Si et al 2009). This disparity has often been attributed to hormonal 
influences and may well be the explanation here. Clearly with surgical induction 
disease will be induced irrespective of hormonal effects, although why males should 
be resistant to AC in this context is unknown. The greater success of AC induction 
with lower dietary protein is consistent with the findings in rats and is thought to 
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possibly result due to a higher bioavailability of phosphate (Neven & D’Haese 
2011). 
4.4 Summary 
A novel mouse model of CKD-associated AC has been developed based on a 
modified adenine-containing diet. Unfortunately at present this model suffers from a 
high level of inconsistency and proved to be unhelpful in addressing the primary 
question of whether P2X7R deficiency attenuates disease. To try and provide an 
answer to this an alternative in vivo system was sought and is the focus of the work 
described in Chapter 5. 
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CHAPTER 5 – EXPERIMENT TO ASSESS THE INFLUENCE OF A 
SELECTIVE P2X7R ANTAGONIST ON CHRONIC KIDNEY DISEASE-
ASSOCIATED ARTERIAL CALCIFICATION IN RATS 
5.1 Introduction 
The experiments described in Chapter 4 were ultimately unhelpful for assessing the 
effect of P2X7R deficiency on AC due to the low number of mice exhibiting arterial 
calcium deposition. It was therefore necessary to find an alternative method of 
examining the influence of in vivo receptor ligation on disease progression.  
Although adenine diet-based models are infrequently used in mice, they have 
successfully been employed to induce the combination of CKD and aortic 
calcification in rats for several years (Katsumata et al 2003). The P2X7R antagonist, 
AZ11657312, has previously been administered to rats in other disease models 
(AstraZeneca unpublished data) and was available for use in this work. Thus, this 
agent along with the rat adenine model provided the necessary experimental tools to 
test the hypothesis that P2X7R blockade could ameliorate CKD-associated AC in 
vivo. 
5.2 Results 
5.2.1 Optimisation of the rat adenine model. 
It was first necessary to confirm that feeding an adenine-containing diet to rats 
would lead to AC and CKD, as is described in the literature (Shobeiri et al 2010, 
Neven & D’Haese 2011). In addition, it was important to ascertain what degree of 
consistency of AC would be achieved using this model and whether it would 
therefore be a suitable model with which to assess the impact of a pharmacological 
agent. 
5.2.1.i The addition of 0.75% adenine to a high phosphate diet leads to AC and 
marked renal impairment in rats by 4 weeks. 
A high phosphate diet (Diet D, Table 2.1) was administered to 8 male Wistar rats for 
4 weeks. In the case of 4 of these 8 rats, the diet was supplemented with 0.75% 
adenine. Rats fed the high phosphate control diet gained 1.2 ± 4.5% body weight, 
whereas those on the adenine diet lost 25.9 ± 3.4% by the end of 4 weeks. Despite 
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the weight loss, those in the adenine group continued to display normal activity and 
social interaction. No animals died during this experiment. 
Quantitative and qualitative assessment (von Kossa staining) of aortas from control 
rats revealed complete absence of calcification (Figure 5.1A). In contrast, all aortas 
from rats fed the adenine-containing diet had at least some calcium deposition. The 
degree of calcification within vessels was extremely variable, ranging from 
circumferential calcium deposition of the entire vessel, essentially dividing the 
medial layer in half (Figure 5.1B), to smaller, scattered, linear deposits along 
sections of elastin within the media (Figure 5.1C-E). No staining was detected along 
the internal elastic lamina (IEL). Calcification was detected in the abdominal aortas 
from all adenine-fed rats with a mean of 13.6 ± 11.0µg/mg. However, calcium was 
only detected in the thoracic aorta and aortic arch in one (the same) animal. 
Kidneys from control rats looked normal both macroscopically and histologically 
(Figure 5.2A and B). In contrast, kidneys from adenine-fed rats appeared grossly 
enlarged and ‘sandy’ coloured (Figure 5.2A). The mean kidney weight from control 
rats was 2.77 ± 0.21g compared with 9.57 ± 1.40g in the adenine fed cohort (p < 
0.001). The respective kidney to body weight ratios were 0.006 ± 0.000 vs 0.030 ± 
0.004 (p < 0.001). H & E staining of kidneys from adenine-fed rats showed 
morphologically normal glomeruli but marked abnormalities in the tubulointerstitial 
compartment (Figure 5.2C). Many tubules appeared dilated with epithelial flattening, 
and many contained green-brown crystals, consistent with 2,8-dihydroxyadenine 
deposition (Monico & Milliner 2012). Interstitial fibrosis was apparent as evidenced 
by expansion of the tubulointerstitium and ECM accumulation (Norman & Fine 
1999). 
Serum biochemical results were in keeping with these histological findings, with the 
adenine-fed rats having significantly higher levels of urea, creatinine and phosphate 
compared with controls (Table 5.1). 
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Figure 5.1. Aortic Calcium Deposition in Rats. Aortic sections were stained with 
silver nitrate (von Kossa stain) for calcification (stained black). A: Negative 
calcium staining in an aorta from a control rat. B-D: Positive staining in aortas 
from 3 different adenine-fed rats showing varying extents of mineral deposition. E: 
Higher magnification (x63) image showing calcification along elastin fibres 
running between intact VSMCs. All sections counterstained with aluminium red. 
A-D magnification x10. 
A B 
C D 
E 
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Group 
 
Urea mmol/l Creatinine µmol/l Phosphate mmol/l 
Control (n=4) 1.32 ± 0.35 31.7 ± 5.7 1.72 ± 0.14 
Adenine (n=4) 33.8 ± 13.1 441.6 ± 79.8 6.68 ± 0.7 
Table 5.1. Serum Biochemistry from Rats in First Pilot Experiment. Data are presented as mean ± 
SD. 
 
Control             Adenine-fed 
Figure 5.2. Macro- and Microscopic Appearance of Kidneys from Rats. A: 
Macroscopic appearance of kidneys from control and adenine-fed rats. Control 
kidneys appeared normal whereas those from adenine-fed animals were grossly 
dilated and ‘sandy’ coloured. H & E stain of B: control kidney with essentially 
normal morphology; C: a kidney from an adenine-fed rat exhibiting tubular 
dilation with epithelial flattening. Interstitial inflammation and fibrosis is evident. 
Some tubules contain green-brown material (arrows) consistent with 2,8-
dihyroxyadenine crystals. B and C magnification x20. 
A 
B C 
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5.2.1.ii Reduction of the dietary adenine content to 0.25% does not increase the 
consistency of AC when administered for 6 weeks. 
Given that the extent of calcification was not uniform in the aortas of the 0.75% 
adenine-fed rats in the initial pilot experiment, a second diet was trialled, containing 
0.25% adenine (Diet E, Table 2.1). This was administered to 4 rats for a longer 
period (6 weeks). The rationale behind this was a report suggesting that more 
consistent aortic calcification could be achieved by lowering the adenine content of 
the diet to this level and administering for an extended time-course (Shobeiri et al 
2013). A 6 week feeding period was selected for this experiment, representing the 
greatest length of time that it would have been practically possible to conduct twice 
daily oral gavages of P2X7R antagonist to rats. 
Despite being housed in the same cage, after 6 weeks on Diet E (Table 2.1), 2 rats 
had extensive calcification of their entire aorta whereas the other 2 had no detectable 
calcification whatsoever. Those with calcified aortas lost more weight, had larger 
kidneys and worse renal impairment than the 2 without (Table 5.2). 
AC present? %Weight loss Kidney to body wt  
ratio 
Urea 
mmol/l 
Creatinine  
µmol/l 
Phosphate 
mmol/l 
 
YES -25.6 0.020 35.9 482.0 5.84 
YES -20.9 0.019 15.0 395.7 5.80 
NO -14.3 0.013 7.2 80.3 3.52 
NO -11.1 0.016 6.3 81.3 3.53 
Table 5.2. Kidney Parameters and Serum Biochemistry from Rats (n=4) in Second Pilot 
Experiment. 
 
5.2.2 Experiment to assess the influence of a selective P2X7R antagonist on AC. 
5.2.2.i Selection of diets. 
In the pilot studies, although the first trial diet (Diet D, Table 2.1) did not induce a 
uniform degree of calcification between animals, all rats that received it did exhibit 
some aortic calcium deposition. In contrast, AC was much more variable with the 
second diet (Diet E, Table 2.1) as no calcification was detected in some animals. 
Therefore, the 0.75% adenine-containing high phosphate diet (Diet D, Table 2.1) 
was selected to be administered to the vehicle (V), low-dose P2X7R antagonist-
treated (20mg/kg, LD) and high-dose P2X7R antagonist-treated (60mg/kg, HD) 
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groups. Control groups ‘N’ and ‘A’ were fed a diet containing normal phosphate 
without or with 0.75% adenine (Diets F and G, respectively, Table 2.1) (see Chapter 
2, section 2.7). 
5.2.2.ii Survival and tolerability of oral gavage. 
There was no mortality in the N, A or V groups. In contrast, 4/7 rats in the LD and 
2/8 in the HD groups died. Three of these deaths were due to immediate 
complications of the gavage procedure itself. The other 3 rats had a more insidious 
onset of morbidity. One lost an excessive amount of weight, one exhibited a sub-
acute onset of respiratory distress, and the other displayed an unacceptably high 
degree of agitation.  
The extent to which each individual animal tolerated the oral gavage procedure was 
variable, with some remaining calm and un-fazed, and others showing varying 
degrees of agitation. Whilst difficult to objectively measure, it was noted throughout 
the experiment that rats receiving vehicle alone seemed to be more tolerant of the 
procedure than those receiving the study drug. On isolated occasions, due to either 
encountering severe resistance at the level of the proximal oesophagus when 
attempting to pass the gavage cannula, or the rat displaying severe agitation, the dose 
could not be administered. Of the surviving animals, the V group received 89.5% of 
scheduled doses, the LD group received 79.2% and the HD group 88.4% (p = 0.39 
for V vs HD). Only 4 rats (all in the V group) received all of the scheduled doses. 
The rats in the N group all gained weight, whereas all those in the other 4 groups lost 
weight to a similar degree (Table 5.3). 
Group 
 
% Weight change 
N (n = 10) +11.2 ± 5.9 
A (n = 6) -29.2 ± 2.8 
V (n = 9) -28.5 ± 2.6 
LD (n = 3) -33.4 ± 3.8 
HD (n = 6) -28.9 ± 2.8 
Table 5.3. Weight Changes. Percent weight changes from baseline after 4 weeks. Data are presented 
as mean ± SD. 
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Due to the low final numbers of LD rats, this group was excluded from subsequent 
statistical analysis of biological parameters. 
5.2.2.iii Serum levels of P2X7R antagonist. 
The mean serum concentration of AZ11657312, taken 2 hours after the first dose 
(peak level) in 4 HD rats was 4039 ± 2486 ng/ml. The corresponding concentration 
immediately before the second dose (trough level) was 1926 ± 1297 ng/ml. After 2 
weeks of study, another trough level was taken which was 1785 ± 662 ng/ml. Only 
2/4 of these rats survived to the end of the study. A final serum sample was taken at 
sacrifice with drug levels of 29 and 200 ng/ml detected in these 2 animals. The other 
4 rats in the HD group had a peak drug level taken at 2 weeks to confirm absorption 
of the compound. This was measured at 3005 ± 1432 ng/ml. 
5.2.2.iv P2X7R expression in normal and calcified aorta. 
The absolute mRNA copy numbers for P2X7R for each group are given in Table 5.4 
(p = 0.046). The mean copy number in the 3 adenine-treated groups was higher than 
controls without reaching statistical significance following post hoc testing. There 
was no significant difference between the A, V and HD groups.  
N  
(n=10) 
 
A  
(n = 6) 
V  
(n = 9) 
HD  
(n = 6) 
607 ± 379 1,114 ± 308 989 ± 292 1,191 ± 747 
Table 5.4. Corrected Absolute mRNA Copy Numbers for P2X7R. Post hoc testing compared all 
groups to N and V as initial KW test indicated p<0.05. Following this, no significant differences were 
detected. Data are presented as mean ± SD. 
 
P2X7R protein expression in normal and calcified aorta was assessed by Western 
blotting. Protein lysates from the A group were excessively haemorrhagic, so to 
avoid potential contamination from blood proteins, the N group was compared to the 
V and HD groups only. A blot was run using the 3 samples in each group with 
calcification closest to the respective group mean (Figure 5.3). By densitometry the 
mean band intensity between the 3 groups was very similar suggesting equivalent 
protein expression (p = 0.19). 
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5.2.2.v P2X7R antagonism does not influence the development of AC in adenine-fed 
rats. 
The differences in arterial calcium deposition between the V and HD groups, and the 
V and A groups were not statistically significant (Table 5.5 and Figures 5.4 and 5.5). 
As expected, no calcification was detected in the aortas from control rats. In the 
other 4 groups, calcium was present in all but 2 aortas (both from HD rats) when 
analysed colourimetrically. Of note, these 2 rats missed the most doses of those in 
the HD group (8 and 13 doses missed). In addition, the rat with the lowest aortic 
calcium content in the V group was the one with the greatest number of missed doses 
(24 doses missed). For the V and HD groups together, there was a strong negative 
correlation between doses missed and aortic calcification (Spearman rho = -0.62; p = 
0.013) (Figure 5.6). 
                       N                                  V                                HD 
P2X7R 69kDa 
α-tubulin 55kDa 
Figure 5.3. P2X7R Protein Expression in Control and Calcified Rat Aorta. 
Western blot of protein lysates from aorta taken from 3 rats in each of the N, V and 
HD groups shown with the corresponding band densitometry below. Error bars 
represent mean ± SD. 
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Group 
 
Aortic calcium content (µg/mg tissue) 
N (n = 10) 0 ± 0 
A (n = 6)     46.2 ± 31.0** 
V (n = 9)      35.7 ± 34.2 ** 
LD (n = 3) 41.8 ± 30.4  
HD (n = 6)    35.0 ± 28.5 * 
Table 5.5. Aortic Calcification. Quantification of total aortic calcium content in each group. Post 
hoc testing compared all groups (except LD) to N and V as initial KW test indicated p<0.05. *p<0.05; 
**p<0.01 all compared to N. Data are presented as mean ± SD. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.4. Quantification of Aortic Calcium Deposition. Quantification of total 
aortic calcium content in each rat in the indicated groups. Post hoc testing 
compared all groups (except LD) to N and V as initial KW test indicated p<0.05. 
*p<0.05; **p<0.01 all compared to N. Each symbol represents one animal. 
Horizontal bars represent group means. 
    
A B 
Figure 5.5. Calcium Deposition in Adenine-Fed Rat Aortas. Representative 
images of von Kossa stained rat aortas. Extensive, heavy calcification (stained 
black) is seen throughout the arterial media in both vessels shown. A: Vehicle-
treated. B: High-dose P2X7R antagonist-treated. Counterstained with aluminium 
red. Magnification x10. 
    **    **     * 
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As was seen in the first pilot experiment, the extent of calcification between aortas 
was extremely variable. Once again the most consistently calcified segment was the 
abdominal aorta. Calcification of the aortic arch and thoracic aorta was not seen 
unless abdominal aortic calcium deposition was present. Three aortas, all from the V 
group, had calcification of the abdominal portion in isolation, and a further aorta, 
taken from an LD rat, had calcification in all but the thoracic segment. It was notable 
that pan-aortic calcification was seen in all rats in the A group. 
The majority of aortas had such extensive calcification that when histological 
sections were cut, the tissue ‘fractured’ making assessment of both calcification 
localisation and morphology of surrounding tissue and cells extremely difficult 
(Figure 5.5). However, in samples where calcification was not so severe, early 
calcium deposition could clearly be seen ‘tracking’ along the elastin layers between 
VSMCs within the arterial media in an identical fashion to the observations made in 
the pilot study.  
5.2.2.vi Analysis of mRNA expression of molecules implicated in AC pathways. 
Although the overall extent of aortic calcification was not modified by treatment 
with AZ11657312, it was conceivable that P2X7R blockade might confer subtle 
influences on one or more pathogenic pathways thought to be involved in AC. To 
investigate this possibility aortic mRNA expression was assessed for a number of 
Figure 5.6. Correlation of Aortic Calcium Content and Number of Missed 
Gavages. Spearman’s rank correlation of aortic calcification and number of missed 
gavages from rats in the V and HD groups combined. 
Spearman rho = -0.62 (p = 0.013) 
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molecules implicated in disease progression (Table 5.6 and Figure 5.7). The 
A260/280 ratios of all RNA samples were above 1.7 and all RIN values exceeded 8, 
indicating high levels of purity and integrity, respectively.  
The stability of five housekeeping genes was assessed (β-actin, HPRT, 28S, SDHA 
and YWHAZ) with β-actin found to be the least stable. Final absolute mRNA copy 
numbers were calculated by correcting for the combination of HPRT, 28S, SDHA 
and YWHAZ, as determined by the GeNorm programme (see Chapter 2, section 
2.16.9). These 4 housekeeping genes had mean absolute copy numbers of 16,040 ± 
3,678, 43,565 ± 14,847, 31,914 ± 22,249 and 188,593 ± 151,961, respectively. 
A significant reduction in mRNA expression of the VSMC-specific markers α-SMA, 
SM-22 and smoothelin (Proudfoot & Shanahan 2012) was seen in the A, V and HD 
groups compared with controls. However, no difference was seen in expression 
between these 3 groups. The absolute mRNA copy numbers for these 3 genes were 
in the order of several tens of thousands, and several million in the case of α-SMA, 
indicating abundant expression relative to the housekeeping genes (Figure 5.7A-C, 
Table 5.6). 
To assess for osteogenic transformation of VSMCs, mRNA expression of the 
osteogenic transcription factors runx-2 (Komori et al 1997, Ducy et al 1997) and 
osterix (Nakashima et al 2002), along with a key regulator of their induction, BMP-2 
(Celil et al 2005, Hruska et al 2005), was measured (Figure 5.7D-F). A significant 
increase was seen in runx-2 expression in the A, V and HD groups compared with 
the controls, but there was no difference between these 3 groups. No differences 
were detected between any groups for osterix or BMP-2 mRNA expression. 
Absolute copy numbers for BMP-2 were of the order of a few thousand in all groups, 
however, the copy numbers for runx-2, even in the calcified groups, were very low, 
and in the case of osterix, mRNA expression was barely detectable (Table 5.6). 
Copy numbers of mRNA for the apoptotic marker caspase-3, and the NLRP3 
inflammasome, both showed a significant up-regulation in calcified vessels 
compared with controls but no difference in the HD group compared with V. 
Absolute copy numbers for both were in the order of several thousand (Figure 5.7G 
and H, Table 5.6). 
             
 
       
1
3
7
 
Gene  N 
(n=10) 
A 
(n=6) 
V 
(n=9) 
HD 
(n=6) 
p value 
(KW) 
 
α-SMA 
 
10,068,417 ± 3,888,662 2,473,818 ± 1,142,494* 2,805,836 ± 2,116,936** 2,909,573  ± 2,572,880** <0.001 
SM-22 
 
3,727,314 ± 1,599,672 696,480 ± 452,396** 904,225 ± 668,699** 947,389  ± 819,106** <0.001 
Smoothelin 
 
231,679 ± 84,502 68,785 ± 28,359** 80,379 ± 35,659** 95,306 ± 58,678* <0.001 
Runx-2 35 ± 21 
 
294 ± 156 * 446 ± 518 * 744 ± 718 * 0.003 
Osterix 9 ± 5 
 
6 ± 4 9 ± 9 10 ± 6 0.582 
BMP-2 
 
2,073 ± 889 1,985 ± 845 2,726 ± 1,229 2,038 ± 398 0.277 
Caspase-3 
 
5,318 ± 4,120 19,293 ± 5,362* 22,794 ± 5,378** 19,514  ± 9,762* <0.001 
NLRP3 
 
2,313 ± 1,348 9,786 ± 1,598 13,813 ± 2,408*** 10,089 ± 3,478* <0.001 
Table 5.6. Corrected Absolute mRNA Copy Numbers. RNA was extracted from rat aortas and qPCR assays performed for the genes indicated. Post hoc testing compared 
all groups to N and V if initial KW test indicated p<0.05. This condition was met for all genes except osterix and BMP-2. *p<0.05; **p<0.01; ***p<0.001 all compared to N. 
Data are presented as mean ± SD. 
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Figure 5.7. Expression of Molecules Implicated in AC. RNA was extracted from rat 
aortas and qPCR assays performed for the genes indicated. Post hoc testing compared 
all groups to N and V if initial KW test indicated p<0.05. This condition was met for 
all genes except osterix and BMP-2. *p<0.05; **p<0.01; ***p<0.001 all compared to 
N. Each symbol represents one animal. Horizontal bars represent group means. 
A B 
C 
D 
E 
G 
F 
H 
α-SMA SM-22 
Smoothelin Runx-2 
Osterix BMP-2 
Caspase-3 NLRP3 
* ** ** ** ** ** 
 * ** **  *  *  * 
 *  *  **  * *** 
             
139 
       
5.2.2.vii P2X7R antagonism does not impact on the degree of renal impairment 
observed in the adenine nephropathy model. 
Histologically, kidneys from adenine-fed rats were grossly different from controls, 
with similar changes seen to those observed in the pilot experiments. The amount of 
interstitial fibrosis in V and HD kidney sections was assessed using Picrosirius red 
staining (Figure 5.8). The mean fibrosis score in kidneys from V rats was 21.6 ± 
6.7% compared with 21.8 ± 8.1% in HD rats (p = 0.936). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A 
C 
B 
Figure 5.8. Picrosirius Red Staining of Rat Kidney Tissue. Representative 
Picrosirius red stained kidney sections. A: Vehicle-treated (V) group. B: High-dose 
antagonist-treated (HD) group. C: Control (N) group. 2,8-dihydroxyadenine crystals 
stain as black (arrow in A). Quantitative analysis of collagen staining (see text) 
showed no significant difference between the V and HD groups. Magnification x40. 
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Adenine-fed rats had a significantly greater kidney-to-body weight ratio, 24 hour 
urine output and daily water intake compared with controls. No differences for these 
3 parameters were noted between the A, V and HD groups (Table 5.7 and Figure 
5.9). 
 N 
(n=6) 
A 
(n=5) 
V 
(n=9) 
HD 
(n=6) 
p value 
(ANOVA) 
 
Kidney:Body weight 
ratio 
0.006 
± 0.000 
0.033 *** 
± 0.004 
0.031*** 
± 0.004 
0.031 *** 
± 0.010 
<0.001 
24 hr urine output 
(ml/kg/hr) 
2.0 
± 0.8 
4.4 *** 
± 1.3 
3.8 ** 
± 1.1 
4.6 *** 
± 0.9 
<0.001 
24 hr water intake  
(ml) 
26.8 
± 10.8 
39.3 
± 11.6 
42.6 * 
± 13.3 
43.2 
± 11.1 
0.022 
Table 5.7. Kidney:Body Weight Ratio and Fluid Balance. Post hoc testing compared all groups to 
N and V as initial ANOVA indicated p<0.05. *p<0.05; **p<0.01; ***p<0.001 all compared to N. 
Data are presented as mean ± SD. 
 
 
 
 
 
 
 
 
 
 
 
 
 
A 
C 
B 
Figure 5.9. Kidney:Body Weight Ratio and Fluid Balance. A: Kidney:Body 
weight ratios. B: 24 hour urinary output (ml/kg/hr). C: 24 hour oral water intake (ml). 
Post hoc testing compared all groups to N and V as initial ANOVA indicated p<0.05. 
*p<0.05; **p<0.01; ***p<0.001 all compared to N. Each symbol represents one 
animal. Horizontal bars represent group means. 
*** *** *** ***   ** *** 
  * 
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Serum biochemistry was assessed at 2 weeks in V and HD rats (Table 5.8 and Figure 
5.10) and in all animals following sacrifice (Tables 5.9 and Figures 5.11). 
Additionally, Table 5.10 and Figure 5.12 summarise the results from analysis of 
urine (samples collected during the 24 hours prior to tissue harvest).  
At 2 weeks there was no significant difference in any serum analyte between the V 
and HD groups except for ALP which was increased in V rats (Table 5.8, Figure 
5.10). However, the ALP concentration measured at the end of the experiment did 
not differ. There was no significant difference in any other serum parameter 
measured at the end of the experiment between these 2 groups (Table 5.9, Figure 
5.11), although HD rats had a significantly higher 24 hour protein excretion (Table 
5.10, Figure 5.12).  
Compared with N rats, those in groups A, V and HD had increased serum 
concentrations of creatinine, urea, phosphate and PTH and decreased levels of 
corrected calcium, albumin, ALP and ALT. All differences were statistically 
significant except those for urea, corrected calcium and PTH for HD animals (Table 
5.9, Figure 5.11).  
A, V and HD rats had significantly lower creatinine clearances and significantly 
higher 24 hour urinary protein excretion compared with the N group. The 24 hour 
urinary phosphate excretion was also lower in these 3 groups compared with N rats 
and this was statistically significant except for in HD animals. No differences were 
seen in urinary calcium excretion across all 4 groups (Table 5.10, Figure 5.12). 
Comparisons between the V and A groups were also non-significant in most cases. 
Of note, the serum concentrations of both creatinine and urea were significantly 
greater in the A group Table 5.9, Figure 5.11), however the creatinine clearance was 
similar in both cohorts (Table 5.10, Figure 5.12). Urinary protein excretion was 
significantly increased in the A group (Table 5.10, Figure 5.12). 
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V 
(n=9) 
HD 
(n=8) 
P value 
(t-test) 
Creatinine (µmol/l) 126.6 ± 29.3 119.1 ± 22.5 0.566 
Urea (mmol/l) 7.9 ± 2.8 8.0 ± 2.2 0.914 
Phosphate (mmol/l) 3.4 ± 0.5 3.0 ± 0.6 0.139 
Corrected Calcium (mmol/l) 2.6 ± 0.1 2.6 ± 0.2 0.920 
Albumin (g/l) 29.2 ± 1.6 30.0 ± 1.7 0.302 
Alkaline Phosphatase (U/l) 174.6 ± 25.3 138.6 ± 29.7 0.017 
ALT (U/l) 58.3 ± 37.7 43.3 ± 15.3 0.308 
 
Table 5.8. Serum Biochemistry Measured at 2 Weeks in V and HD Groups. Measurement of indicated serum parameters at 2 weeks from V and HD rats. Data are 
presented as mean ± SD. 
 
 N 
(n=10) 
A 
(n=6) 
V 
(n=9) 
HD 
(n=6) 
P value 
(ANOVA) 
Creatinine (µmol/l) 32.7 ± 4.3 633.9 ± 153.8
c,e 
404.8 ± 103.6
c
 318.4 ± 106.8
c
 <0.001 
Urea (mmol/l) 1.7 ± 0.8 54.4 ± 24.1
c,d
 28.2 ± 12.5
c
 18.8 ± 8.4 <0.001 
Phosphate (mmol/l) 4.4 ± 0.6 8.0 ± 0.9
c
 7.0 ± 0.9
c
 6.8 ± 1.5
c
 <0.001 
Corrected Calcium (mmol/l) 3.3 ± 0.1 3.0 ± 0.2
b
 3.1 ± 0.2
a
 3.2 ± 0.2 0.005 
PTH (pg/ml) 1013 ± 379 2203 ± 1047
b
 2003 ± 362
b
 1736 ± 493 0.001
 
Albumin (g/l) 33.2 ± 1.8 28.7 ± 2.2
c
 28.9 ± 1.5
c
 28.1 ± 1.1
c
 <0.001 
Alkaline Phosphatase (U/l) 288.2 ± 81.8 108.5 ± 31.7
c
 147.4 ± 47.0
c
 166.7 ± 33.5
c
 <0.001 
ALT (U/l) 56.3 ± 25.4 30.0 ± 7.9
a
 30.0 ± 8.7
b
 28.3 ± 9.5
a
 0.003 
 
Table 5.9. End-Point Serum Biochemistry. Measurements of indicated serum parameters at the time of sacrifice. Post hoc testing compared all groups to N and V as initial 
ANOVA indicated p<0.05. 
a 
p<0.05; 
b 
p<0.01; 
c 
p<0.001 (all compared to N). 
d
 p<0.05, 
e
 p<0.01 (all compared to V). 
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Figure 5.10. Serum Biochemistry Measured at 2 Weeks in V and HD groups. 
Measurements of indicated serum parameters taken at 2 weeks from V and HD rats. 
Each symbol represents one animal. Horizontal bars represent group means. 
Significant results are indicated (evaluated by unpaired t-test). 
  ALT 
  ALP   Albumin 
Corrected 
Calcium   Phosphate 
Urea   Creatinine 
  p=0.017 
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Figure 5.11. End-Point Serum Biochemistry. Measurements of indicated serum 
parameters taken at the time of sacrifice. Post hoc testing compared all groups to N 
and V as initial ANOVA indicated p<0.05. 
a 
p<0.05; 
b 
p<0.01; 
c 
p<0.001 (all 
compared to N). 
d
 p<0.05, 
e
 p<0.01 (all compared to V). Each symbol represents 
one animal. Horizontal bars represent group means. 
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 N 
(n=10) 
A 
(n=5) 
V 
(n=9) 
HD 
(n=6) 
P value 
(ANOVA) 
Creatinine Clearance 
(ml/min) 
2.07 ± 0.37 0.08 ± 0.03
c 
0.13 ± 0.04
c
 0.20 ± 0.08
c
 <0.001 
Phosphate Excretion 
(mmol/day) 
0.85 ± 0.27 0.28 ± 0.11
c
 0.53 ± 0.11
b 
0.63 ± 0.10 <0.001 
Calcium Excretion 
(mmol/day) 
0.04 ± 0.01 0.03 ± 0.02 0.03 ± 0.01 0.04 ± 0.02 >0.05 
Total Protein Excretion 
(mg/day) 
6.1 ± 2.2 15.7 ± 3.8
c,d 
10.2 ± 1.6
a 
16.2 ± 4.6
c,e 
<0.001 
 
Table 5.10. End-Point Creatinine Clearance and Urine Biochemistry. Measurements of indicated 
parameters quantified in urine taken during the final 24 hours of the experiment. Post hoc testing 
compared all groups to N and V if initial ANOVA indicated p<0.05. This condition was met for all 
parameters except urinary calcium. 
a 
p<0.05; 
b 
p<0.01; 
c 
p<0.001 (all compared to N). 
d
 p<0.05, 
e
 
p<0.01 (all compared to V). 
Figure 5.12. End-Point Creatinine Clearance and Urine Biochemistry. Measurements of 
indicated parameters quantified in urine collected during the final 24 hours of the experiment. Post 
hoc testing compared all groups to N and V if initial ANOVA indicated p<0.05. This condition was 
met for all parameters except urinary calcium. 
a 
p<0.05; 
b 
p<0.01; 
c 
p<0.001 (all compared to N). 
d
 
p<0.05, 
e
 p<0.01 (all compared to V). Each symbol represents one animal. Horizontal bars 
represent group means. 
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5.2.2.viii P2X7R antagonism does not influence changes in bone induced by adenine 
feeding. 
Given the proposed inverse relationship between bone health and AC (Persey & 
D’Haese 2009), and reports linking P2X7R to bone homeostasis (Grol et al 2009), 
the femurs of animals from this study were analysed using micro-CT. During the 
harvesting process 4 femurs from the N group were damaged but all those intact 
were included in the subsequent analyses. Representative images from the 4 groups 
are shown in Figure 5.13. The results are summarised in Figure 5.14 and Table 5.11. 
There was no statistically significant difference in any parameter for the HD group 
compared with V animals. However, there appeared to be a trend towards decreased 
trabecular separation in HD rats. There was a statistically significant difference in 
percentage trabecular bone volume by KW test, with post hoc testing indicating a 
significant difference between the N and V groups. Similar results were obtained for 
trabecular separation but no differences between groups were detected for either 
trabecular number or thickness. The A group had significantly less cortical bone 
volume compared with controls (Figure 5.14). 
For each parameter, the overall spread of data was wide. In order to try and gain a 
clearer insight into the influence of renal impairment in this context, given the lack 
of difference between A, V and HD rats, these 3 groups were combined to form a 
‘CKD’ group and compared with the controls (Figure 5.15). This CKD group 
showed a significant decrease in both percentage trabecular bone (17.1 ± 6.6 v 11.0 
± 3.2%; p = 0.039) and cortical bone volume (6.7 ± 0.4 v 6.2 ± 0.5 mm
3
; p = 0.033). 
Another question was whether there was any correlation between trabecular and/or 
cortical bone volume and aortic calcification. Assessing aortic calcification against 
percentage trabecular bone yielded Spearman’s rho -0.217 (p = 0.277). However, for 
cortical bone volume Spearman’s rho was -0.383 (p = 0.049). Trabecular thickness 
was also significantly correlated (negatively) with aortic calcification (Spearman’s 
rho = -0.424; p = 0.028), although there was no relationship between AC and either 
trabecular number or separation (not shown). 
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Cortical Bone 
Volume 
Trabecular Bone 
Volume 
Trabecular 
Separation 
Trabecular  
Number 
Trabecular  
Thickness 
Figure 5.14. Micro-CT Analysis of Bone. Measurement of indicated bone parameters 
by micro CT-scanning. Post hoc testing compared all groups to N and V if initial KW 
test indicated p<0.05. This condition was met for all parameters except trabecular 
number and thickness. Each symbol represents an individual rat and horizontal lines 
represent group means. *p<0.05 compared with N. 
    *     * 
 * 
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 N 
(n=6) 
A 
(n=6) 
V 
(n=9) 
HD 
(n=6) 
p value 
(KW) 
 
Trabecular bone volume 
(%) 
17.1  
± 6.6 
11.9  
± 1.4 
9.4 * 
 ± 3.3 
12.6  
± 3.5 
0.042 
Trabecular separation 
(mm) 
0.39 
 ± 0.13 
0.50 
 ± 0.06 
0.59 * 
± 0.06 
0.47 
 ± 0.11 
0.019 
Trabecular number 
(1/mm) 
2.19  
± 0.79 
1.64  
± 0.26 
1.30 
 ± 0.45 
1.64  
± 0.47 
0.089 
Trabecular thickness 
(mm) 
0.078  
± 0.003 
0.073 
 ± 0.004 
0.072  
± 0.006 
0.077  
± 0.005 
0.071 
Cortical bone volume 
(mm
3
) 
6.7  
± 0.4 
5.9 * 
± 0.6 
6.2  
± 0.5 
6.4  
± 0.2 
0.047 
Table 5.11. Micro-CT Analysis of Bone. Measurement of indicated bone parameters by micro CT. 
Post hoc testing compared all groups to N and V if initial KW test indicated p<0.05. This condition 
was met for all parameters except trabecular number and thickness. Data are presented as mean ± SD. 
*p<0.05 compared with N. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cortical Bone 
Volume 
Trabecular Bone 
Volume 
p=0.033 p=0.039 
Figure 5.15. Comparison of Bone Volume Between Control and CKD Rats. 
Rats in groups A, V and HD were combined to form a ‘CKD’ cohort. This group 
was compared with controls (N) to evaluate the influence of renal impairment on 
cortical and trabecular bone volumes (as indicated). Each symbol represents one 
animal and horizontal bars represent group means. Groups compared using MWU 
test. 
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5.3 Discussion 
Pharmacological blockade of P2X7R had no effect on the degree of AC seen in this 
experiment. The high dose of 60mg/kg antagonist employed here was selected based 
on unpublished data (held by AstraZeneca) showing it to be effective in rat models 
including the streptococcal cell wall model of rheumatoid arthritis in which it 
significantly reduced ankle swelling. Pharmacokinetic studies (AstraZeneca, 
unpublished observations) had demonstrated that this dose, administered twice daily, 
maintains serum levels above 10 x pA2 (reported to be 225 ng/ml). The pA2 value is 
the concentration of antagonist required to necessitate a doubling of the agonist 
concentration to elicit the original response (Schild 1947) and ten times this value 
are frequently targeted in pre-clinical studies. Serum levels measured in HD rats 
demonstrated that adequate trough concentrations were obtained during this study 
and although on average animals received approximately 90% of the originally 
intended doses it can be reasoned that sufficient receptor antagonism was achieved 
for the majority of the experimental period and that sub-therapeutic dosing is 
therefore unlikely to account for the lack of effect on AC. However, tissue levels of 
antagonist were not quantified and therefore inadequate cellular uptake of drug 
cannot be excluded although there is no obvious reason to suggest that this should 
have occurred. 
The qPCR experiments described in this chapter were primarily performed because 
although overall calcification was not affected by P2X7R blockade, it was possible 
that cellular pathways thought to be involved in AC, such as VSMC osteogenic 
transformation and/or apoptosis (Shanahan et al 2011, Shanahan 2013, Shroff et al 
2013), were still being influenced. The qPCR experiments described in Chapter 3 
suggested that in the ring culture model of AC these mechanisms may not even 
occur, thereby going some way to explain the lack of effect of P2X7R ligation on 
arterial calcium deposition in vitro. It was therefore also clearly relevant to assess 
whether they could be demonstrated at all in vivo and specifically under uraemic 
conditions. 
Expression of mRNA for all 3 VSMC-specific markers studied, α-SMA, SM-22 and 
smoothelin, significantly decreased in calcified tissue, suggesting that in 
calcification-promoting conditions in vivo, VSMCs do undergo a change of 
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phenotype. These changes were not, however, influenced by P2X7R blockade. Most 
reports in the literature assign this change in phenotype to cells taking on 
characteristics of ‘bone-like’ cells and show a concurrent up-regulation in osteogenic 
markers (Shroff et al 2010). In the current work, mRNA for the osteogenic 
transcription factor osterix (Nakashima et al 2002) was essentially absent in all 
samples. Furthermore, expression of mRNA for BMP-2, a key regulator of osterix 
(Celil et al 2005, Hruska et al 2005) was unchanged in calcified vessels compared to 
controls. Although the osteogenic transcription factor runx-2 (Komori et al 1997, 
Ducy et al 1997) was up-regulated in calcified vessels, the mRNA copy numbers 
were extremely low, even in the arteries containing mineral deposition. Its functional 
significance is therefore doubtful. These findings, like those in Chapter 3, challenge 
the relevance of osteogenic transformation in the development of CKD-associated 
AC and are in agreement with some previous work. 
Of particular note is a recent study which employed a well-controlled 
immunohistochemistry protocol to stain normal and calcified arteries of varying 
sizes from humans with and without CKD (O’Neill & Adams 2014). Staining for 
both osterix and osteocalcin (bone gla protein) was absent. A number of reports 
using the rat adenine model have also failed to detect any significant increase in 
mRNA for osteogenic markers in calcified tissue (O’Neill et al 2008, Lomashvili et 
al 2011). One group have suggested that VSMCs undergo chondrocytic rather than 
osteogenic transformation in the adenine model (Neven et al 2010) associated with 
an up-regulation of sox9. There is minimal evidence linking P2X7R with cartilage 
formation and hence this possibility was not examined in this thesis.  
In contrast to the in vitro findings in Chapter 3, an increase in mRNA expression of 
the apoptosis marker, caspase-3, was seen in calcified vessels compared with 
controls. This suggests that a factor present in the uraemic environment is required to 
induce VSMC apoptosis in this model. In keeping with this theory, increased 
apoptosis has been demonstrated in arterial tissue from dialysis patients as compared 
with healthy controls (Shroff et al 2008). It is unclear from the current work whether 
apoptosis is a causative phenomenon, occurring prior to the onset of calcification as 
suggested by some groups (Shroff et al 2010), or a late, consequence of tissue 
damage as suggested by others (O’Neill & Adams 2014). It is also possible that the 
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increased apoptosis is unrelated to calcification and is the effect of another toxin. In 
this regard, and as discussed below, it is unknown whether adenine exerts any direct 
effects on vascular cells. P2X7R inhibition did not influence the expression of 
caspase-3 mRNA suggesting that the receptor does not mediate apoptosis in this 
context. 
The ability of P2X7R to activate the NLRP3 inflammasome is well described (Di 
Virgilio 2007) and one recent report suggested that NLRP3 is involved in AC (Wen 
et al 2013). In keeping with this study, calcified aorta had significantly greater levels 
of inflammasome mRNA in the present work, however this was not altered by 
P2X7R blockade. One possible explanation for these apparently paradoxical findings 
is that inflammasome activation in calcified arteries might be P2X7R-independent, 
as has been described in adipose tissue (Sun et al 2012). 
The expression of P2X7R at both the mRNA and protein level was unchanged in 
calcified vessels compared with controls. This is consistent with the results from 
Chapter 3 and the data taken together indicate that expression of P2X7R in rat aorta 
is not affected by the presence of calcium deposition either alone or in the presence 
of a uraemic environment. At present it is unclear what functional role the receptor 
plays in arterial tissue. 
As emphasised in the KDIGO guidelines for CKD-MBD (Kidney Disease: 
Improving Global Outcomes (KDIGO) CKD–MBD Work Group 2009) (see Chapter 
1, section 1.5.2), a spectrum of bone disturbances can occur in CKD. These include 
abnormalities in turnover, mineralisation and volume. Compared with traditional 2-
dimensional (2D) histomorphometric-based procedures and with relevance to CKD-
MBD, because micro-CT gives a 3D view, it is superior for measuring bone volume 
(Bouxsein et al 2010). Indeed, micro-CT is now considered the ‘gold-standard’ 
method of assessing small rodent bone morphology and microstructure under 
experimental conditions and the results generated by this technique have been shown 
to correlate very well with those obtained from histomorphometry (Bouxsein et al 
2010).  
As outlined in Chapter 1 (section 1.9.4.i), the exact role of P2X7R in bone biology is 
a point of controversy with 2 strains of P2X7
-/-
 mice reported to show opposing 
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changes in bone volume compared with WT controls (Ke et al 2002, Gartland et al 
2003a) and different groups using cultured bone cells reporting either positive 
(Panupinthu et al 2008) or negative effects (Orriss et al 2012) of the receptor on 
bone formation. This study is the first to examine the effect of pharmacological 
P2X7R blockade on CKD-related bone disease and overall, receptor antagonism 
failed to exert a significant impact on any parameter measured by micro-CT. 
Assuming that adequate uptake of antagonist into bone was achieved, the implication 
is that any effect of P2X7R blockade on bone remodelling was outweighed by the 
influences of other factors, which probably include increased PTH (which was 
shown to occur in the present study), and suppressed vitamin D, which is also known 
to occur in this model (Neven et al 2010). 
Investigators that have used histomorphometry to assess bone from adenine-fed rats 
have consistently demonstrated features consistent with a high-turnover state such as 
increased osteoid and osteoblast parameters (Henley et al 2009, De Schutter et al 
2011, O’Neill et al 2011). Micro-CT cannot be used to directly assess bone turnover, 
as histological assessment of cell-types is required. However, previous studies have 
demonstrated that on micro-CT imaging, high-turnover disease associates with loss 
of trabecular bone volume and increased trabecular separation (De Schutter et al 
2011, Hopper et al 2007). These findings are consistent with those presented here.  A 
decrease in cortical bone volume was also seen in adenine-fed animals in the present 
study which is consistent with a previous report (De Schutter et al 2011).  
No correlation was found between final trabecular bone volume and AC in this work, 
although a negative correlation was found with final cortical bone volume and 
trabecular thickness. One previous study (De Schutter et al 2011), correlated changes 
in cortical bone volume, as measured on micro-CT, with the magnitude of aortic 
calcification. For practical reasons scanning could only be performed post-mortem in 
this study. Change in bone volume is likely to better represent uraemia-induced bone 
disease compared with just a final reading, however, the findings in the present work 
are in keeping with this study by De Schutter et al (2011) and suggest that cortical 
bone volume is related to AC. 
Serum biochemistry cannot definitively predict the degree of bone turnover (Kidney 
Disease: Improving Global Outcomes (KDIGO) CKD–MBD Work Group 2009), 
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however, elevated PTH, ALP and phosphate are usually observed in high-turnover 
disease whilst PTH and ALP are often normal or decreased in low-turnover states. 
The serum biochemistry from the adenine-fed rats in the current work is mainly 
consistent with high bone turnover with the exception of ALP, which was, 
surprisingly, suppressed compared with controls. Most studies that have employed 
the rat adenine model have not specifically measured serum ALP. A recent study 
(Sun et al 2013) found no difference in ALP in adenine-fed rats compared with 
controls and an older report (Okada et al 1999) compared results after 2 and 6 weeks 
of adenine feeding, (there was no control group) and again found no difference. Of 
note an increase in ALP with this model has not been reported. Serum albumin levels 
were found to decline in adenine-fed animals in this work and this is often reported 
(Yokozawa et al 1986, Price et al 2006). It is therefore possible that synthetic liver 
function is suppressed with this model and the ALP is a reflection of this, rather than 
indicating bone disturbances. In keeping with this is the fact that ALT was also 
decreased in the adenine groups in the current study.  
In both the initial pilot experiment and the main study, the abdominal aortic segment 
was the most consistently calcified region. Most other studies examining AC in vivo 
have not specifically looked at each aortic segment individually however this 
observation is in keeping with one previous report (Shobeiri et al 2013). It is also 
consistent with the in vitro work described in Chapter 3 in which abdominal aortic 
segments calcified to a greater extent than those from more proximal regions. 
Differences in AC between vascular beds has rarely been studied in man, although 
one report found a greater incidence of AC in the abdominal aorta compared to the 
thoracic region in obese patients (Jensky et al 2011). Although not widely studied, 
potential reasons to account for the regional differences include maladaptive 
responses to haemodynamic changes in the abdominal aorta compared with the 
thoracic region (Ameer et al 2014) and differences in embryological origin of cells 
from each anatomical site which has been shown to influence the propensity to 
calcify (Leroux-Berger et al 2011). 
The magnitude of renal impairment, AC and other associated clinical features seen 
with the adenine model is unquestionably related to dietary intake and therefore any 
factor that suppresses the ability or willingness of an animal to eat will potentially 
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attenuate development and progression of disease. This issue is perhaps the greatest 
limitation of this experiment. Although not statistically significant, for some 
outcome measures, particularly biochemical markers of renal function, there were 
arguably trends towards a more favourable outcome for the HD group compared 
with the V controls. Despite these results, the overall subjective impression 
throughout the experiment was that HD rats, whilst not sick, were not faring as well. 
These apparent paradoxical observations are probably best explained by considering 
the negative correlation between the number of missed gavages and aortic 
calcification. Rats did not receive a dose of antagonist on a particular occasion if 
either the gavage cannula could not be passed due to resistance at the level of the 
oesophagus, or there were other concerns over an animal’s condition. Thus the 
number of missed doses is in effect a surrogate marker of poorer animal health and 
likely to reflect a suppressed dietary intake of adenine. The implication of this is that 
the likelihood of any one animal developing AC is intimately linked to how well it 
tolerates the oral gavage procedure, with those less tolerant more likely to sustain 
oesophageal trauma during dosing with the knock-on effect of decreasing oral intake, 
thereby confounding any real pharmacological effect of the substance being 
administered. Rats in the HD group (and in fact the LD group too) subjectively 
seemed to tolerate the gavage procedure less well than V controls and a subtle 
influence conferred by the smell or taste of the antagonist cannot be excluded as a 
contributing factor to this. The fact that these two groups were less tolerant of the 
procedure probably also explains, to a large extent, why they both suffered from a 
higher mortality rate compared with the V group as the procedure itself was made 
more difficult in these situations. 
The adenine rat model is commonly used for investigating AC in vivo. The rates of 
calcification reported with this model vary widely and can be enhanced by reducing 
the protein content of the diet to 2.5% (Price et al 2006). The protein content of all 
diets administered in this chapter was set to this level and of those rats fed 0.75% 
adenine, aortic calcification occurred in all but 2. It was notable that calcification 
occurred in all rats fed the diet containing 0.75% adenine and normal phosphate 
(Diet G, Table 2.1). The original rationale for including this group was to try and 
obtain a control cohort that had uraemia without AC. The adenine diet is almost 
always used in combination with high (usually 0.9%) phosphate (Shobeiri et al 2010, 
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Neven et al 2011), however one previous study (Lomashvili et al 2008) had 
employed a 0.75% adenine diet combined with normal (0.4%) phosphate to 
successfully induce renal impairment alone. This report was the basis for employing 
Diet G (Table 2.1) in the current work.  In retrospect, the disparity in calcification 
described in the study by Lomashvili et al (2008) and this chapter is almost certainly 
down to the protein content of the respective diets. This was not specifically stated in 
the work by Lomashvili et al and it is likely that normal dietary protein was given 
rather than the 2.5% utilised here.  
The fact that calcification occurred in all rats in the A group meant it was not 
possible to determine whether any particular biological effect observed in adenine-
fed rats, (when compared with controls), was specifically due to calcification, or 
secondary to uraemia per se. There are also other factors, unrelated to the degree of 
CKD, which could have contributed to the differences observed between control rats 
and those fed adenine. It is unknown whether the AC seen in adenine-fed animals is 
only attributable to the uraemic state invoked, or whether adenine itself is a direct 
vascular toxin. A large proportion of adenine within the intestinal lumen has been 
shown to be taken up into the circulation un-metabolised (Salati et al 1984) and the 
free base has been shown to be directly toxic to some cell types including human 
lymphoblasts (Snyder et al 1978). Work performed over 50 years ago, when the 
effects of adenine-feeding to rodents were just beginning to be described, suggested 
that the clinical manifestations are purely attributable to renal impairment (Philips et 
al 1951), however, until proven otherwise a direct effect on the vasculature cannot 
be excluded particularly considering the increased expression of the apoptosis 
marker caspase-3 in calcified vessels seen here.  
Adenine-fed animals also lost a considerable amount of weight compared with 
controls (in which there was mild weight gain) and this is another potentially 
confounding factor. The weight loss of approximately 30% seen in this study is in 
keeping with most other reports using this model (Price et al 2006) and is likely due 
to both the adenine diet being less palatable and also the increased catabolism known 
to occur in advanced renal disease (Slee 2012). Some groups have tried to control for 
the weight loss by adopting a paired-feeding strategy (Lomashvili et al 2009) 
however a lot of wastage of dietary pellets was seen in this study, which makes 
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accurate monitoring of oral intake very difficult. In addition, because much of the 
weight loss seen is almost certainly a consequence of uraemia, rather than 
suppressed intake (although this unquestionably does occur), it can be argued that 
limiting the availability of diet for non-CKD animals in effect adds another variable 
into the experiment rather than acting as a control procedure. 
Given the number of limitations with this experiment it is worthwhile considering 
whether either an alternative experimental model and/or method of drug delivery 
could have been employed. As discussed in Chapter 1, there are 2 other rat models of 
CKD-associated AC described – the 5/6th nephrectomy model (Chauntin & Ferris 
1932) and the Cy/+ rat model (Kaspareit-Rittinghausen et al 1990). AC in the 5/6
th
 
model is much less consistent than with adenine, often reported to be less than 50% 
(Shobeiri et al 2010, Neven & D’Haese 2011). In addition, both of these alternative 
models require a number of months for AC to develop which make them impractical 
from the point of view of drug delivery by oral gavage. The potential options for 
administration of the antagonist were extensively discussed prior to commencing the 
experiment. More convenient methods such as integration of the compound into feed 
or drinking water, or the use of an implantable drug delivery system were not viable 
due to issues surrounding drug stability (AstraZeneca personal communications). 
Twice daily ip administration has been used by some, including others in our group 
(Booth et al unpublished observations), however not without adverse effects. In 
addition, the strongest pharmacokinetic data was obtained using oral dosing 
(AstraZeneca personal communications). It was therefore felt that overall, this model 
and method of dosing were the best available options. 
5.4 Summary 
Pharmacological P2X7R blockade failed to influence the extent of CKD-associated 
AC in the rat adenine model and did not appear to modulate any of the biological 
pathways to which it might be linked that are thought to mediate this disease. The 
work in this chapter further challenges the relevance of osteogenic transformation to 
the aetiology of AC but suggests that apoptosis may occur, although the timing of 
this is unclear. This work has also demonstrated that both trabecular and cortical 
bone loss occur in this in vivo model although again, this was not influenced by 
ligation of P2X7R.  
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CHAPTER 6 – ATP METABOLIC PATHWAYS IN ARTERIES FROM 
RODENTS AND HUMANS WITH CHRONIC KIDNEY DISEASE 
6.1 Introduction 
The results of the work described in Chapters 3-5 did not provide any significant 
indication that P2X7R is implicated in the pathogenesis of CKD-associated AC. 
Therefore for the latter part of this thesis the focus switched from investigating 
P2X7R in isolation to considering more broadly the potential involvement of ATP in 
the calcification process.  
As discussed in detail in Chapter 1 (section 1.10), there is increasing interest in the 
importance of ATP metabolism in the evolution of AC. In particular, the role of ATP 
as a substrate for the enzyme ENPP-1, which catalyses the conversion of ATP to 
AMP and (more relevantly) the calcification inhibitor, PPi, (Figure 1.2, re-printed as 
an aide memoire on the following page), has received attention (Persy & McKee 
2011, O’Neill et al 2011, Villa-Bellosta & Sorribas 2013, Lomashvili et al 2014). 
PPi can directly inhibit hydroxyapatite formation (Fleisch et al 1965), however 
conversely, it can be metabolised by TNAP to generate phosphate, thereby 
promoting calcification (Murshed et al 2005). Genetic deficiency of ENPP-1 causes 
extensive AC in both mice (Sakamoto et al 1994) and humans (Rutsch et al 2003) 
leading to premature death. Increased arterial TNAP expression and activity have 
been demonstrated in uraemic rats (Lomashvili et al 2008) and in patients with CKD 
(Shroff et al 2008), possibly contributing to AC, however it is unknown whether 
there are also changes in ENPP-1 in this clinical setting. Other components of the 
ATP-metabolising system present in the vasculature might also play a role in the 
calcification process but have not been studied in the context of renal impairment. 
These include the enzymes CD39 and CD73 and the putative PPi transporter, ANK 
(Figure 1.2). 
The primary objective of the work described in this chapter was to determine, with 
an emphasis on ENPP-1, whether the expression of enzymes involved in ATP 
metabolism is altered in calcified arteries from subjects with CKD. The rodent tissue 
collected during the work performed in previous chapters provided the necessary 
resources to address this question in an in vivo model. In addition, segments of 
inferior epigastric artery from patients undergoing renal transplantation were 
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available for study. This provided the opportunity to not only assess some facets of 
vascular ATP metabolism but also the histological appearance of CKD-associated 
AC in man which has only rarely been previously described (Shroff et al 2008, 
Shlieper et al 2010, O’Neill & Adams 2014). 
 
Figure 1.2 (re-printed with abbreviated legend). The Purinergic System and its 
Regulation of AC in VSMCs. 
 
ATP and other ligands for P2X and P2Y receptors gain access to the extracellular space in a 
number of ways (see text). ATP is hydrolysed by either CD39  (ecto-nucleoside triphosphate 
diphosphohydrolases (NTPDases)) into AMP plus 2 phosphates (Pi), or by ecto-nucleotide 
pyrophosphatase/phosphodiesterases (ENPPs) into AMP plus inorganic pyrophosphate 
(PPi). AMP is hydrolysed into adenosine (Ad) and Pi by CD73 (ecto-5’-nucleotidase). PPi 
can also reach the extracellular space from within the cell through the putative membrane 
transporter ANK (ankylosis) protein. PPi is subsequently hydrolysed into Pi by tissue non-
specific alkaline phosphatase (TNAP). 
 
PPi is a potent inhibitor of calcification, however it is also the substrate for generation of Pi 
by TNAP and subsequent hydroxyapatite formation. The balance between ENPP1 and 
TNAP activity is therefore critical in determining whether calcification pursues. Autosomal 
recessive mutations in ENPP1 cause arterial calcifications in infancy and autosomal 
recessive mutations in CD73 cause arterial calcifications in adulthood. 
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6.2 Results 
6.2.1 Studies in rodent arteries. 
6.2.1.i ENPP-1 mRNA expression and enzyme activity are increased in calcified 
rodent arteries. 
The expression of mRNA for ENPP-1 was quantified in abdominal aortic tissue 
collected from rats fed the control (N), adenine/normal-phosphate (A) and 
adenine/high phosphate (V) diets (Chapter 5). AC of the abdominal aorta and 
advanced renal impairment were present in all animals in the latter 2 groups. 
Compared with control rats, ENPP-1 mRNA expression was significantly increased 
in both the A and V groups with no significant difference in expression seen between 
these 2 cohorts (Table 6.1 and Figure 6.1). Absolute copy numbers were relatively 
low in the N group but rose to the order of several thousand in both A and V 
animals. The data for the 9 V animals seemed to divide into 2 distinct clusters, one 
well above (n=4) and the other well below (n=5) the overall group mean (Figure 
6.1). Of note, the 4 V rats with the highest mRNA expression were also the 4 with 
the greatest amount of abdominal aortic calcium deposition. The magnitude of 
calcification was significantly higher in these 4 rats compared with the other 5 in this 
group (66.3 ± 27.6 vs 14.2 ± 12.8 respectively; p = 0.016). 
Gene  
 
N 
(n=10) 
 
A 
(n=6) 
V 
(n=9) 
p value 
(KW test) 
ENPP-1 571 ± 716 4,765 ± 1,614** 6,284 ± 3,767*** <0.001 
CD39 157,304 ± 70,884 66,718 ± 23,572** 90,041 ± 27,617   0.006 
TNAP 12,072 ± 4,553 4,027 ± 3,663* 7,321 ± 4,957   0.018 
CD73 4.495 ± 4,787 19,674 ± 4,227** 20,833 ± 7,488*** <0.001 
ANK 68,245 ± 28,845 143,392 ± 37,120** 146,468 ± 49,990**   0.001 
Table 6.1. mRNA Copy Numbers for ATP-Metabolism Related Molecules in Rat Aorta. RNA 
was extracted from rat aortas and qPCR assays performed for the genes indicated. As initial KW test 
indicated p<0.05 post hoc testing compared all groups with N and A with V. *p<0.05; **p<0.01; 
***p<0.001 all compared to N. Data are presented as mean ± SD. 
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To assess whether ENPP-1 was also increased at the protein level in arteries from A 
and V rats several efforts were made to perform Western blots of aortic protein 
lysates. Unfortunately despite trialling several commercially-available primary 
antibodies these attempts proved unsuccessful with no bands of appropriate 
molecular weights ever being detected. 
Although ENPP-1 protein expression could not be evaluated, it was possible to 
quantify actual enzyme activity by measuring the metabolism of the synthetic 
substrate pNP-TMP (Nam et al 2011, Lomashvili et al 2011). Using this method, 
ENPP-1 activity was assessed in segments of aortic arch obtained from 7, 6 and 7 
rats in the N, A and V groups, respectively. In keeping with the mRNA results, a 
significant increase in activity was detected in arteries from A and V rats compared 
with controls, with both groups exhibiting an approximate doubling in enzyme 
function (Figure 6.2A). Three aortic arch segments from the V group had no 
detectable calcification when analysed colourimetrically. Therefore in order to 
ascertain the effect of uraemia alone, the enzyme activity in these 3 samples was 
compared with the N group. A significant increase was detected in these non-
calcified, uraemic vessels which had a mean change in optical density (enzyme 
activity) of 0.74 ± 0.16 arbitrary units/mg tissue compared with 0.47 ± 0.10 in 
controls (p = 0.012) (Figure 6.2B). 
 
Figure 6.1. ENPP-1 mRNA Expression in Rat Aorta. RNA was extracted from 
rat aortas (abdominal aorta) and a qPCR assay performed for ENPP-1. Post hoc 
testing compared all groups with N and compared A with V. **p<0.01; 
***p<0.001 all compared to N. Each symbol represents one animal. Horizontal 
bars represent group means. 
** *** 
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6.2.1.ii Serum PPi measurements in rodents with and without CKD. 
To assess whether greater aortic ENPP-1 activity resulted in an increase in 
circulating PPi, the relative serum concentrations of this molecule were compared 
between groups (Figure 6.3A). Overall there were no significant differences 
detected. Given the comparable results for A and V rats the data from these 2 groups 
were combined. The mean change in optical density (relative PPi concentration) was 
less in this ‘CKD group’ compared with controls but it did not reach statistical 
significance (Figure 6.3B).  
 
 
 
 
 
 
 
A B 
* ** p = 0.012 
Figure 6.2. ENPP-1 Activity in Rat Aorta. Activity was measured in segments of 
aortic arch as the change in optical density following a 1 hour incubation of each 
vessel with the synthetic enzyme substrate pNP-TMP. A: Comparison of enzyme 
activity between all groups. Post hoc tests were performed as initial KW test 
showed p<0.05 and compared all groups with N and compared A with V. *p<0.05; 
**p<0.01 all compared to N. B: Comparison of enzyme activity in non-calcified 
vessels from rats with CKD (CKD (Cal Neg)) with controls (MWU test). Each 
symbol represents one vessel segment. Horizontal bars represent group means. 
A B 
Figure 6.3. PPi Content of Rat Serum. The fluorescence of serum from each rat 
was measured following the addition of a proprietary PPi sensor and compared 
between groups to assess for relative differences. A: Comparison of all groups. B: 
Comparison of control animals with all rats with CKD (A and V groups 
combined). Each symbol represents one animal. Horizontal bars represent group 
means. 
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6.2.1.iii Analysis of mRNA expression for other ATP metabolism-related molecules. 
Following the findings for ENPP-1 expression and activity, other components of the 
ATP-metabolising system were assessed in rodent vessels. Quantification of mRNA 
expression for the enzymes CD39, TNAP and CD73, along with the ANK protein, 
was performed (Table 6.1 and Figure 6.4). 
In the case of CD39, mRNA expression was reduced in calcified arteries compared 
with controls. This only reached statistical significance for the A group following 
post hoc testing although there was also a marked decrease in the V group. It was 
notable that the magnitude of CD39 mRNA expression was in the order of several 
tens of thousands.  
A decrease in mRNA expression for TNAP was also seen in calcified vessels, 
although once again only reaching statistical significance in the A group after post 
hoc analysis. The level of TNAP mRNA expression was much lower than CD39 
being present in the order of only a few thousand copies. 
In contrast to the findings for these 2 enzymes, a statistically significant increase in 
mRNA expression for both CD73 and ANK were seen in both the A and V groups 
compared with controls. Orders of magnitude of expression were several thousands 
and tens of thousands respectively.  
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Figure 6.4. Expression of ATP-Metabolism Related Molecules in Rat Aorta. RNA 
was extracted from rat aortas and qPCR assays performed for the genes indicated. Post 
hoc testing compared all groups with N and A with V as initial KW test indicated 
p<0.05. *p<0.05; **p<0.01; ***p<0.001 all compared to N. Each symbol represents 
one animal. Horizontal bars represent group means. 
CD39 
CD73 
TNAP 
ANK 
 **  * 
** *** ** ** 
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6.2.1.iv Analysis of ATP metabolism-related molecules over time using an ex vivo 
model of AC. 
To try and begin to understand the factors governing these altered expression 
profiles, the ex vivo ring culture model (described in Chapter 3) was used to 
investigate the changes over time in vessels exposed to an elevated phosphate 
concentration. Analysis was conducted using the samples obtained from the time-
course experiment detailed in Chapter 3, section 3.2.5 – ‘Expression of mRNA for 
P2X7R, markers of VSMC phenotype and caspase-3’, in which cultured rings, 
obtained from 3 rats, were distributed evenly between control and high phosphate 
groups for each time-point (baseline and 3, 7 and 10 days). The results are 
summarised in Table 6.2 and Figure 6.5. 
For ENPP-1 there was a general trend towards an increase in mRNA expression in 
the control samples compared with baseline with increasing time in culture - this was 
statistically significant at days 7 and 10. At each time-point there was no significant 
difference between ENPP-1 expression in control rings and those exposed to high 
phosphate. In the case of CD39, mRNA expression was suppressed in control rings 
compared with baseline and this was statistically significant at days 3 and 7. Again 
no differences were detected between control and corresponding high phosphate 
samples at any time-point. TNAP mRNA expression was markedly suppressed in all 
control ring groups compared with baseline, reaching statistical significance at day 3 
and day 10 (a clear trend was also evident at day 7). No differences were detected in 
phosphate-treated rings compared with their time-point controls. Expression of 
mRNA for CD73 was elevated in all control rings compared with baseline vessels 
with statistically significant differences detected at all time-points. High phosphate 
conditions again did not exert any significant impact. Results for ANK mRNA 
expression were much more equivalent between groups and although the initial KW 
test indicated significant differences overall, none were detected with post hoc tests 
comparing control samples to baseline and groups matched for time-point (control vs 
high phosphate). 
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Gene  
 
 
Baseline 
n=7 
Day 3 – Control 
n=5 
Day 3 -  HP 
n=5 
Day 7 – Control 
n=5 
Day 7 - HP 
n=5 
Day 10 – Control 
n=5 
Day 10 – HP 
n=6 
p value 
(KW test) 
ENPP-1 770 ± 175 
 
1,277 ± 176 1,059 ± 154 1,731 ± 906* 1,906 ± 649 2,426 ± 539*** 1,353 ± 424 <0.001 
CD39 88,995 ± 7,878 
 
26,021 ± 4,558** 22,336 ± 6,148 33,457 ± 9,162* 38,060 ± 10,050 57,598 ± 24,905 31,409 ± 14,754 <0.001 
TNAP 11,589 ± 5,541 
 
971 ± 1,164* 857 ± 864 493 ± 356 352 ± 335 221 ± 119** 346 ± 285   0.007 
CD73 3,367 ± 814 
 
14,713 ± 1,720** 9,651 ± 1,287 13,914 ± 2,928* 15,251 ± 5,666 12,575 ± 3,344* 15,377 ± 4,013   0.001 
ANKH 41,071 ± 4,814 
 
33,145 ± 1,324 31,072 ± 5,512 45,486 ± 23,615 48,745 ± 20,102 92,199 ± 29,848 45,132 ± 14,610   0.008 
 
Table 6.2. mRNA Copy Numbers for ATP Metabolism-Related Molecules in Cultured Rat Aortic Rings Over Time. Quantification of mRNA copy numbers for 
indicated genes in rat aortic rings cultured in either control or 3mM (high) phosphate-containing (HP) Medium-199 over time. As initial KW test indicated p<0.05 for all 
genes post hoc tests compared all control groups with baseline and control with HP at each time-point. *p<0.05; **p<0.1; ***p<0.001 (all compared with baseline). Data are 
presented as mean ± SD. 
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ENPP-1 
Figure 6.5. mRNA Copy Numbers for ATP Metabolism-Related Molecules in 
Cultured Rat Aortic Rings Over Time. Quantification of mRNA copy numbers for 
indicated genes of interest in rat aortic rings cultured in either control or 3mM (high) 
phosphate-containing (HP) Medium-199 over time. Initial KW test indicated p<0.05 
for all genes. Post hoc tests compared all control groups with baseline and control 
with HP at each time-point. *p<0.05; **p<0.1; ***p<0.001 all compared with 
baseline. ‘D’ designates number of days in culture. Error bars represent mean ± SD.  
Number of rings per group from left to right = 7,5,5,5,5,5,6.  
 *  *** 
CD39 
 **  * 
CD73 TNAP 
ANK 
 * ** ** * * 
    D3     D7   D10 
    D3     D7   D10     D3     D7   D10 
    D3     D7   D10     D3     D7   D10 
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6.2.2 Studies in human arteries. 
6.2.2.i Clinical characteristics. 
A total of 15 inferior epigastric artery segments were available for study. Table 6.3 
summarises the clinical characteristics for these 15 patients. The average patient age 
was 47 ± 15 years (range 19-71) and the cohort contained 8 males. All except one 
patient (patient 2) received a live-donor TP. No patients were diabetic and 3 had a 
known history of ischaemic heart disease (IHD). In terms of renal replacement 
therapy, 4 patients were transplanted pre-emptively (including one with a failing 
graft which had originally been placed before the requirement for dialysis). One 
further patient was transplanted with their first, failing graft in situ having originally 
received peritoneal dialysis (PD) for a year. Four patients were on HmD and 6 were 
receiving PD. At the time of transplantation 6 patients were taking phosphate 
binders, 2 of which were calcium-based compounds. No patients were taking 
warfarin. 
6.2.2.ii Calcification in arteries from patients with ESRD. 
Calcium deposition was detectable with von Kossa staining in 12 out of the 15 
samples (80%). Calcification, when present, was most frequently seen as speckled 
deposits, scattered throughout the medial layer of the vessel wall. Calcification 
predominantly localised to the outer region of the media with relative sparing of the 
medial tissue proximal to the arterial lumen. The specks of calcification were 
associated with ECM fibres rather than with cells (Figure 6.6). In the 12 vessels with 
positive von Kossa staining, calcification was detectable in at least 50% of the 
section circumference in 4 samples, 5 arteries had 25-50% of the circumference 
affected, with the other 3 exhibiting small clusters of speckled calcification in a few 
discrete areas (Figure 6.6 and Table 6.3). Calcification of the IEL was mainly seen in 
vessels exhibiting the greatest degree (>50% circumference effected) of medial 
deposition (Figure 6.6). One sample (patient 8) was an exception to this with only 
IEL staining detectable. Of note, the cause of ESRD in this patient was enteric 
hyperoxaluria and nephrocalcinosis necessitating the use of calcium carbonate as 
treatment.  
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Patient no. 
 
Gender Age Cause of ESRD RRT 
modality 
Time on RRT IHD Phosphate 
binder 
Circumference 
Calcified 
IEL 
calcification 
1 M 46 IgA nephropathy HmD 1 month N N >50% Y 
2 M 45 IgA nephropathy TP 14 yr N N >50% N 
3 F 57 unknown PD 4 yr N Sevelamer 25-50% N 
4 F 19 Bilateral nephrectomy for NS PD/TP 1yr/15yr N N 25-50% N 
5 F 60 ADPKD PD 2yr N Lanthanum 0 N 
6 M 31 ANCA vasculitis HmD 1yr N N 25-50% N 
7 F 67 Renovascular disease PD 6 months N Lanthanum >50% Y 
8 F 49 Enteric hyperoxaluria/nephrocalcinosis HmD 2 yr N Calcium 25-50% Y 
9 M 54 IgA nephropathy PD 2 yr Y N 25-50% N 
10 F 33 IgA nephropathy PD 6 months N N 0 N 
11 M 61 Membranous nephropathy N/A N/A Y N >50% Y 
12 F 45 IgA nephropathy PD 6 months N N 0 N 
13 M 35 Renal dysplasia N/A N/A N Sevelamer <25% N 
14 M 27 Fabrys disease N/A N/A N N <25% N 
15 M 71 Renal tuberculosis HmD 1 yr Y Calcium <25% N 
 
Table 6.3. Summary of Patient Characteristics. NS: nephrotic syndrome; ANCA: anti-neutrophil cytoplasmic antibody. 
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A B 
E F 
D C 
Figure 6.6. Calcium Deposition in Arteries from Patients with ESRD. Sections of 
human inferior epigastric artery taken at time of kidney transplantation stained with von 
Kossa reagent to visualise calcium deposits (stained black). A: Extensive calcification 
involving >50% vessel circumference. B: Digitally magnified image of the luminal 
surface of the vessel in A showing calcium deposits on the IEL (arrows). C: Higher 
magnification of the boxed region in A demonstrating the speckled pattern of 
calcification. D: Digitally magnified image of the boxed region in C demonstrating the 
association of calcium deposits with ECM. E: A vessel containing less extensive 
calcification. F: A vessel without calcification. A, E and F: magnification x10. C: 
magnification x63 (boxed region cropped using Microsoft Office 2010 for image D). 
All sections counterstained with aluminium red. 
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The patients without AC were all female. Neither renal replacement therapy vintage 
or patient age were related to AC in this small cohort - all 4 patients receiving pre-
emptive TPs had detectable AC whereas the 3 patients without any vascular calcium 
deposition had all been on dialysis for at least 6 months. The mean age of the 
patients without AC was almost identical to those with disease (46 ± 14 vs 47 ± 16 
years respectively; p = 0.936). The 3 patients with known IHD all had detectable 
calcification. 
6.2.2.iii Analysis of arterial mRNA expression for ENPP-1 and ANK. 
Owing to limited tissue availability, the yield of RNA extracted from human arteries 
was low. It was therefore only possible to reverse transcribe 100ng for each sample 
and to evaluate ENPP-1 and ANK mRNA expression. The expression of three 
housekeeping genes, SDHA, HPRT and RPL13a was quantified and mean copy 
numbers were 22,280 ± 8161, 18,143 ± 9346 and 871,779 ± 463,771 respectively. 
RPL13a was the least stable and was therefore not used to generate final corrected 
copy numbers. In the case of HPRT, 3 technical replicates displayed a standard 
deviation exceeding 2 cycles, raising concern about the validity of using it as a 
calibrator gene for this work. It was therefore decided to correct the copy numbers 
for all genes of interest in 2 ways: using the combination of SDHA/HPRT and 
SDHA in isolation. One sample (a calcified vessel) showed copy numbers very much 
lower than the overall mean for all 3 housekeeping genes (e.g. a factor of 10 lower 
for HPRT) and was excluded from the analyses. Comparisons were made between 
the 3 un-calcified vessels and all those with calcium deposition. 
For quantification of ENPP-1 mRNA expression, one sample from a calcified vessel 
failed to amplify leaving n=10 in this group. Using the HPRT/SDHA combination to 
correct copy numbers, mRNA expression in calcified vessels showed a non-
significant increase compared with un-calcified tissue (1579 ± 401 vs 3306 ± 3013 
for un-calcified vs calcified respectively; p = 0.077). When corrected for SDHA 
alone, the increase in expression in the calcified samples became statistically 
significant (1594 ± 513 vs 3526 ± 3025 for un-calcified vs calcified respectively; p = 
0.049) (Figure 6.7). There appeared to be 2 outliers in the calcified group – one well 
above and one well below the group mean (Figure 6.7). Both results were included in 
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the analysis described above however their exclusion only strengthened the 
significance of the result (p = 0.012 following removal of these 2 data points). 
In contrast to the findings for ENPP-1, expression for ANK mRNA was similar 
between groups (Figure 6.7). When corrected for HPRT/SDHA mean copy numbers 
were 86,832 ± 43,301 vs 77,323 ± 19,437 for un-calcified compared with calcified 
vessels respectively (p = 0.350). Using SDHA alone as the calibrator gene, the 
corresponding corrected copy numbers were 85,548 ± 41,233 vs 83,000 ± 21,693 (p 
= 0.436). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.7. Expression of ENPP-1 and ANK mRNA in Arteries from Patients 
with ESRD. RNA was extracted from segments of inferior epigastric artery 
obtained at the time of kidney transplantation from patients with ESRD. qPCR 
assays were performed for the genes indicated Copy numbers of mRNA for each 
gene were corrected for both the combination of HPRT/SDHA and SDHA alone 
(see text). Groups compared with MWU test. Each symbol represents one vessel. 
Horizontal bars represent group means. 
ENPP-1 (HPRT/SDHA corrected)  ENPP-1 (SDHA corrected)  
ANK (HPRT/SDHA corrected)  ANK (SDHA corrected)  
p = 0.077 p = 0.049 
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6.3 Discussion 
The most notable findings from the rat in vivo work described in this chapter were 
that ENPP-1 mRNA expression increased in calcified arteries taken from rodents 
with CKD and that functional enzyme activity was also elevated in aortas from these 
animals. As discussed in Chapter 5, because all adenine-fed animals developed 
calcification of the abdominal aorta, (the section harvested for qPCR experiments), it 
was impossible to determine whether this increase in mRNA expression was related 
to the presence of uraemia or the calcium deposition itself. However, the fact that the 
aortic arch did not calcify in all rats made it possible to evaluate the effect of uraemia 
in isolation. The results suggest that arterial ENPP-1 activity increases in the setting 
of CKD even in the absence (or presumably prior to the onset of) calcification.  
No up-regulation of ENPP-1 mRNA was seen in calcified rings in vitro indicating 
that under these conditions calcification per se does not induce expression and 
neither does the presence of an elevated phosphate concentration. However, ENPP-1 
mRNA expression did increase in calcified human vessels which were all taken from 
patients with ESRD suggesting that in the presence of uraemia, calcification is 
associated with an increase in ENPP-1. A link between ENPP-1 mRNA expression 
and arterial calcium deposition in the setting of CKD was also suggested by the rat in 
vivo data which implied that the magnitudes of each were directly related. The 
results from the human tissue analysis are consistent with the rat in vivo findings and 
therefore confirm that the results from the animal experiment are related to 
calcification rather than a ‘model-specific’ factor such as adenine. 
As ENPP-1 is heavily expressed in bone cells (Johnson et al 2000) the increase in 
expression and activity seen in calcified vessels could be a reflection of VSMC 
osteogenic transformation. However, given the findings in Chapters 3 and 5, which 
suggested that this process may not occur to any major extent during the 
development of AC, it seems an unlikely explanation for the increased ENPP-1 
expression. Based on current understanding (Mackenzie et al 2012), the main role of 
ENPP-1 appears to be the generation of PPi and it therefore seems likely that the 
changes in expression seen in the current work are related to this biological function. 
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Serum PPi concentrations were not elevated in rodents with AC despite the increase 
in arterial ENPP-1 activity. In fact, although not statistically significant, if anything a 
reduction was apparent in CKD animals. This is consistent with the suppressed 
serum PPi that has been detected in patients with renal impairment (Lomashvili et al 
2005, O’Neill et al 2010). At present the tissue source of systemic PPi is unclear but 
some authors have suggested that bone is likely to be the major contributor 
(Lomashvili et al 2014). The vasculature undoubtedly produces PPi as shown by its 
presence in medium following aortic ring culture (Lomashvili et al 2004). However, 
whether in vivo it is released to a sufficient degree to contribute to systemic levels or 
only utilised locally is unknown. The results from the current study would suggest 
that arterial production does not influence serum levels. Whilst impossible to 
measure, presumably the increase in arterial ENPP-1 activity did result in a greater 
amount of local PPi production and a fundamental question is therefore what was the 
fate of this PPi? Potentially it may have been metabolised by TNAP, which would 
favour the development of calcification, or alternatively perhaps it was generated in 
an attempt to directly inhibit hydroxyapatite growth, as part of a protective response 
by the vasculature against ensuing AC. 
Which of these 2 apparently opposing hypotheses is more likely has been 
unwittingly evaluated, albeit under non-uraemic conditions, in a recent report 
(Lomashvili et al 2014). In this study, aortas from WT (calcification-resistant) mice 
were transplanted into ENPP-1 KO recipients, (which have minimal circulating PPi 
and therefore develop spontaneous AC) thereby modelling increased arterial ENPP-1 
expression in a ‘pro-calcification’ systemic environment. Whilst the grafted (WT) 
aortic segments did calcify, the surrounding vessel (ENPP-1-deficient aorta) 
calcified to a much greater extent. TNAP activity was equal in both genotypes so 
could not explain these findings. The data imply that an increase in arterial ENPP-1 
(PPi generation) will attenuate local calcium deposition rather than promote it and 
therefore suggest that the greater enzyme activity detected in calcified vessels in the 
current study arises as part of a protective response by the vasculature against the 
calcification-inducing factors present in the uraemic circulation. 
CD39 activity results in the formation of 2 phosphate ions (along with AMP) (Figure 
1.2) and therefore seemingly provides conditions to favour calcification. Expression 
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was significantly decreased in adenine-fed rats theoretically limiting the availability 
of phosphate whilst increasing PPi, both of which also seem to be in keeping with an 
‘anti-calcification’ response. Clearly this increased PPi could be hydrolysed by 
TNAP and therefore enhance calcification, however if this does represent a 
pathogenic mechanism it would appear to be a rather redundant and complex way of 
generating, in effect, the same end-product i.e. phosphate from PPi. 
Mutations of the NT5E gene, which encodes the CD73 enzyme, have been shown to 
be associated with calcification of distal arteries in humans (St Hilaire et al 2011) 
although, as discussed in Chapter 1 (section 1.10.2.ii), the mechanism underlying 
this finding is not completely understood. CD73 catalyses the conversion of AMP 
into phosphate and adenosine (Figure 1.2) and it is most plausible that the latter 
product is the key regulator of calcification in this context (St Hilaire et al 2011). 
Vascular CD73 expression in the setting of CKD-associated AC has not been 
previously described. However, the increase in CD73 mRNA seen in the current 
work coupled with the known deleterious effect of genetic deficiency would also be 
consistent with an adaptive, protective response by arterial cells.  
Previous studies have demonstrated an increase in TNAP activity in arteries from 
both rats (Lomashvili et al 2008) and patients (Shroff et al 2008) with CKD and so it 
seems surprising that expression of TNAP mRNA was decreased in calcified rodent 
vessels in the present work. The study by Lomashvili et al (2008) used 2 rodent 
models of CKD (adenine and 5/6
th
 nephrectomy) and notably AC was not present in 
any animal. TNAP protein expression and activity were increased in aortas from 
these rats however mRNA levels were no different from controls indicating that 
regulation of TNAP is probably mainly post-transcriptional. In the study by Shroff et 
al (2008) examining human tissue, only TNAP activity (not mRNA expression) was 
measured and notably, in patients with CKD not yet on dialysis, no increase in 
arterial TNAP activity was apparent despite the presence of early calcium deposition. 
Activity was increased in patients that were on dialysis. The findings from these 2 
studies seem to differ somewhat and the exact role for this protein in the 
pathogenesis of AC therefore remains to be fully elucidated. Limited tissue 
availability meant that TNAP activity could not be measured in the present work and 
because mRNA expression may not reflect functional enzyme activity it is difficult 
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to interpret the data obtained here. If in fact arterial TNAP activity does reduce in 
this setting it should result in an elevated local PPi concentration (Figure 1.2) and 
protect against calcification. 
The expression of mRNA for ANK was increased in calcified rodent, but not human 
vessels. Differences in species and/or the small number of non-calcified human 
samples are 2 immediately obvious potential reasons for this. However, the changes 
in expression of the other proteins examined in calcified arteries all seem to favour 
an elevation in extracellular PPi and so an increase in ANK expression would be 
consistent with this. Just one previous study (Zhao et al 2012) has assessed ANK 
specifically in the setting of CKD and the authors of this paper concluded that 
expression of the protein was decreased in rodents and patients with renal 
impairment. However, it is unclear in this report how many human samples were 
assessed and the rodent model differed significantly from that used in the current 
study, involving extensive surgical manipulation of the aorta in order to deliberately 
induce inflammation. 
The results from the ring culture experiment, like those described in Chapter 3, 
indicated that time in culture alone can significantly influence the mRNA expression 
profiles for a number of genes in arterial tissue. Again wide standard deviations were 
seen in most groups, especially for the samples cultured for 10 days, further limiting 
interpretation. However, it was notable that the presence of an elevated phosphate 
concentration did not influence the expression of any molecule either before (day 3) 
or after (days 7 and 10) the appearance of overt calcification. This implies that the 
alterations in expression seen in calcified vessels in vivo are mediated by ‘uraemic-
specific’ factors.  
The histological appearance of AC in humans with CKD has only been examined in 
a small number of previous reports (Shroff et al 2008, Shlieper et al 2010, O’Neill & 
Adams 2014). These studies, in keeping with the findings in this chapter, have all 
reported a speckled, punctate pattern of calcium deposition within the arterial media. 
Calcification has consistently been shown to be associated with ECM, as was 
observed in the current work, with variable involvement of the IEL. A notable 
difference in the present work however was the apparent relative sparing of the inner 
media from mineral deposition. There is no immediately obvious explanation for this 
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and in fact some previous studies have specifically commented that, in complete 
contrast to the findings here, the sub-intimal region of the media was predominantly 
effected (O’Neill & Adams 2014). This is the first study to analyse inferior epigastric 
artery specimens in patients with CKD with previous work examining vessels of 
larger or smaller calibre. It is possible, as suggested by some authors (Schliper 
2014), that the mechanisms contributing to AC along with how the disease manifests 
differ depending on the anatomical site of the vascular bed. 
There are a number of limitations to the work reported in this chapter. Owing to 
limited tissue, with the exception of ENPP-1, protein expression and/or enzyme 
activity could not be assessed for any of the other molecules examined. In the case of 
CD39, mRNA expression has been shown to correlate well with enzyme activity in 
other contexts (Liao et al 2010), although whether this holds true for CD73 and 
ANK is less clear. As discussed above, this does not seem to be the case for TNAP. 
The number of human samples available for study was low, making it difficult to 
draw comparisons between calcified and non-calcified vessels. Furthermore, the 
calcification ‘status’ of each patient was assessed in a single histological section and 
it is possible that the staining pattern seen was not representative of the whole vessel. 
The lack of a non-CKD control group is a further limitation. The low yield of RNA 
from human tissue made qPCR experiments technically challenging. In particular it 
was not possible to obtain an RNA integrity number (RIN) for many samples.  
6.4 Summary 
The work in this chapter has shown for the first time that ENPP-1 expression and 
activity are increased in calcified arteries from rodents and humans with CKD. This 
increase appears to begin prior to the onset of calcification but seems to continue as 
disease progresses and may well be part of a vascular defence mechanism against, as 
yet unidentified, uraemic-specific factors which induce mineral deposition. Other 
vascular proteins involved in ATP metabolism also appear to be regulated in this 
context, possibly in order to protect against increasing calcification. Manipulating 
certain components of this pathway may potentially offer therapeutic benefit. This 
concept is expanded upon as part of the general discussion in Chapter 7. 
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CHAPTER 7 – GENERAL DISCUSSION 
7.1 Summary Of Key Findings 
The main aim of the work described in this thesis was to answer a fundamental 
research question: ‘Is P2X7R involved in the pathogenesis of CKD-associated AC?’. 
With respect to addressing this aim the following key findings have emerged: 
1. P2X7R is expressed in human and rodent vascular smooth muscle with 
expression remaining unaltered in the presence of calcification (Chapters 3 & 
5). 
2. Neither pharmacological blockade nor genetic deletion of P2X7R influence 
AC in vitro (Chapter 3). 
3. Pharmacological blockade of P2X7R does not influence AC in vivo using the 
adenine nephropathy model (Chapter 5). 
The hypothesis that P2X7R might participate in the pathogenesis of AC was based 
upon studies linking it, in non-vascular-related contexts, to mechanisms thought to 
be important in the aetiology of disease (Figure 1.3, re-printed on the following page 
as an aide memoire). Whilst not a primary aim of this thesis, the work conducted 
here has made some intriguing observations in regard to some of these previously 
described ‘disease-mediating’ pathways: 
1. The VSMC-specific markers α-SMA, SM-22 and smoothelin are down-
regulated at the mRNA level in calcified arteries in vivo (Chapter 5). 
2. Arterial expression of mRNA for some classic markers of osteogenic 
transformation is absent in both in vitro and in vivo models of AC (Chapters 
3 & 5). 
3. Expression of mRNA for the apoptosis marker caspase-3 is up-regulated in 
calcified arteries in vivo but not in vitro (Chapters 3 & 5). 
4. None of these changes in mRNA expression are influenced by P2X7R 
blockade in vivo. 
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Studies in the latter parts of this thesis (Chapter 6) moved away from P2X7R directly 
to focus on arterial ATP-metabolic pathways. Time constraints permitted some 
preliminary studies to be conducted to assess whether there are changes in 
expression profiles of components of this system associated with AC. The following 
novel findings emerged: 
1. ENPP-1 mRNA expression and activity are increased in vivo in calcified 
rodent arteries. 
2. ENPP-1 mRNA expression is increased in calcified arteries from patients 
with ESRD. 
3. Calcified rodent arteries in vivo have increased expression of CD73 and ANK 
mRNA while expression of mRNA for CD39 and TNAP decreases. 
4. Phosphate and/or the presence of calcification per se do not appear to 
mediate the changes in gene expression profiles observed in vitro. 
7.2 P2X7R And Arterial Calcification 
The overarching impression from the work conducted in this thesis is that P2X7R is 
not involved in the pathogenesis of AC. A number of diverse experimental systems 
were used to evaluate the receptor in this context but none of the data obtained 
suggested that it participates in mediating disease. However, to our knowledge, this 
work represents the first set of experiments specifically designed to assess the role of 
P2X7R in AC and therefore before concluding that the receptor is not involved in the 
evolution of disease, whether or not the original hypothesis has been adequately 
tested needs to be considered.  
The potential relationship between P2X7R and AC was investigated robustly in 
vitro.  Ex vivo studies in which rodent vessels were treated with high-dose, receptor-
specific pharmacological agents (antagonists and agonists) in the presence/absence 
of calcification-promoting medium, culture of arteries from receptor-deficient mice 
and in vitro studies with primary VSMCs were performed, representing a 
comprehensive array of experimental strategies. Cellular deficiency of P2X7R could 
also have been assessed using interfering RNA methodology but as discussed in 
detail in Chapter 3, experiments using primary VSMCs in culture were abandoned 
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early on in favour of the ring culture model and the studies on cultured tissue from 
P2X7
-/-
 mice should have achieved the same objective. 
Although the majority of available in vitro methods were used in this thesis to try 
and address the primary research question, whether these models are actually 
suitable for examining the pathogenesis of CKD-associated AC is debatable. Failing 
to mimic a uraemic milieu and, as demonstrated here with the ex vivo model and 
previously with cultured VSMCs (Nakano-Kurimoto et al 2009), the induction of 
changes in gene expression with or without the addition of ‘calcification-enhancing’ 
reagents, are major disadvantages common to both primary cell- and arterial ring-
based systems. The absence of intact elastin fibres, the initial sites of calcium 
deposition (Lanzer et al 2014, O’Neill & Adams 2014), is another major limitation 
of studies using cultured VSMCs. How translatable any findings from experiments 
using these models are to human disease therefore remains uncertain. 
From these perspectives it might be seen that in vivo experiments are preferable. As 
discussed in Chapter 5, to investigate AC in vivo, especially when assessing a 
potential therapeutic intervention, the adenine nephropathy model is superior to the 
alternative options of using either the Cy/+ rat or 5/6
th
 nephrectomy as calcification 
is much more consistent and develops over weeks rather than months (Shobeiri et al 
2010, Neven & D’Haese 2011). However, the question remains, how closely does 
this adenine-based system really resemble the human disease it is trying to mimic? 
In general, the main benefits of animal work in this context are that calcified arteries 
will have been exposed to circulating ‘uraemic toxins’ and vessels are surrounded by 
their usual biological environment. Other relevant biochemical disturbances such as 
elevated PTH and FGF-23 and decreased vitamin D will also be present (Neven et al 
2010). In terms of the renal lesion, adenine overload in rats results in a similar 
histological appearance to that seen in patients with APRT deficiency, the enzyme 
responsible for adenine metabolism (Hori & Henderson 1966). This rare condition is 
associated with renal calculi, interstitial fibrosis and progression to ESRD if 
untreated (Bollee et al 2010, Monico et al 2012). However, whether mineral-bone 
disorder is particularly severe in these patients is unknown. 
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One notable feature of the rat experiment described in Chapter 5 was the extremely 
high serum concentration of phosphate in most animals. The normal serum 
concentration of phosphate in Wistar rats is reported to be around 2mmol/l (Baxter et 
al 2000, Tripathi et al 2013). In rats treated with adenine in this thesis, serum 
phosphate concentrations were often in the order of 7-8mmol/l and occasionally as 
high as 9mmol/l i.e. over 4 times the normal value. Serum phosphate levels of this 
relative order are never seen in man. In clinical practice the highest serum 
phosphates generally occur in acute settings, typically within the contexts of tumour 
lysis syndrome (McBride & Westervelt 2012) or rhabdomyolysis (Efstratiadis et al 
2007). For illustrative purposes, possibly the highest serum phosphate on record was 
documented by Bywaters & Beall (1941) when describing the clinical progression of 
traumatic crush injuries during the Blitz. The serum phosphate at the time of death in 
one patient is recorded at just over 4mmol/l (about 3 times the upper limit of 
normal).  
As continually referred to throughout this work, the current conceptualisation of AC 
(and indeed the fundamental principle on which this thesis is centred), is that it does 
not occur simply due to the passive deposition of mineral in the arterial wall. In 
further support of this theory, calcium and phosphate, when added simultaneously to 
human plasma even at the upper limit of concentrations seen in acute disease states, 
do not precipitate out (O’Neill 2007). This study by O’Neill suggested that a calcium 
x phosphate product of above 16mmol/l
2
 would be required for mineral to become 
insoluble in human serum - this is still around double the level of what might 
possibly be seen in patients with profoundly disturbed calcium and phosphate 
homeostasis i.e. this situation is unlikely to ever occur in man and therefore other 
mechanisms must be in play for AC to develop. Whether the findings in this study 
are translatable back to rodents is uncertain, however it seems plausible that 
elevations in calcium and in particular phosphate, to the extent seen in rat models of 
CKD, could result in extensive ‘passive’ arterial mineral deposition. Clearly ‘non-
passive’ mechanisms (e.g. changes in VSMC gene expression profiles and levels of 
calcification inhibitors) will be present concurrently, as shown by the current work 
and numerous previous studies (Price et al 2006, Lomashvili et al 2009, Neven et al 
2010), thereby still permitting inferences to be made about mechanistic pathways 
involved in the development of disease. However, a substantial calcification burden 
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resulting from passive mineral precipitation could well overwhelm and mask the 
effect of any intervention targeting ‘cell-mediated’ pathological pathways. 
When considering how well the role of P2X7R was assessed in this work, it also 
needs to be evaluated how well receptor ligation was achieved in the studies 
performed. No firm conclusions could be drawn from the experiments with P2X7
-/- 
mice due to a surprisingly low number of animals developing AC. This meant that 
the only available way to practically examine the effect of suppressed receptor 
activity in vivo was to pharmacologically block it, in the rat adenine model. 
Although the result of this study strongly suggested that P2X7R blockade does not 
impact on the pathogenesis of AC there were, as discussed extensively in Chapter 5, 
a number of limitations to the experiment. It could therefore be argued that there 
remains an element of uncertainty relating to the involvement of the receptor in this 
disease process and it is worth considering how the negative findings relating to 
P2X7R and AC described in this thesis might be confirmed. 
P2X7R KO rats are not currently available but would be a useful tool in the future 
should they be developed. In the meantime, if using a rat model, receptor ligation 
would need to be achieved by pharmacological blockade. Probably the most obvious 
refinement to the experiment conducted in this thesis (Chapter 5) would be to 
administer the drug by a different route e.g. an implantable delivery system. This 
method of dosing would also open up the option of employing the 2 alternative (5/6
th
 
nephrectomy and Cy/+) rat CKD-AC models, as long term administration of the drug 
would be possible (AC takes months to develop in these two models (Neven et al 
2011)). However, as alluded to in Chapter 5, this would require extensive 
optimisation of the drug for it to become feasible. 
The mouse 5/6
th
 nephrectomy model (El-Abbadi et al 2009) could be employed to 
examine WT and KO mice but is likely to need an extended operator training period 
and result in a high loss of animals. An alternative would be to attempt further 
refinement of the adenine mouse model developed in this thesis (Chapter 4) in order 
to obtain more consistent disease and less animal morbidity. Potential modifications 
might include titration of the adenine, protein, phosphate and calcium contents of the 
diet and/or changing the mode of adenine administration – both ip injection and 
delivery in an oral suspension have been described in rat studies (Forbes 1971, Terai 
               
 184   
        
et al 2009). In addition, this thesis focussed mainly on DBA/2 mice as this strain was 
employed by the Giachelli lab in their description of the 5/6
th
 nephrectomy model 
(El-Abbadi et al 2009). However, the C3H strain is also described to be prone to 
ectopic calcification (Eaton et al 1978) and it would be interesting to assess the 
effect of these interventions in animals on this background. Finally, the work in this 
thesis examined the propensity of 2 agents, folic acid and adenine, to induce CKD 
and AC but there are numerous other ‘chemical’ agents available which can cause 
marked renal fibrosis in mice. Examples include cyclosporine (Bing et al 2006) and 
aristolochic acid (Huang et al 2013) and it would therefore be informative to 
combine these agents with high phosphate feeding to assess whether AC develops. 
Given the limitations of the animal models, it might be preferable to directly assess 
P2X7R within the context of human CKD-associated AC. Unfortunately the number 
of human vessels available for study in this thesis was low (n=15), thereby limiting 
the number of experiments that could be undertaken with them. With a larger sample 
size and tissue yield it would become possible to perform a range of complementary 
laboratory techniques, to examine receptor expression in calcified and non-calcified 
vessels. It would clearly also be advantageous to obtain control tissue from healthy 
donors for comparison. However, whilst studies of this nature can be useful, they 
cannot provide information concerning causality of a particular disease or the 
chronology of contributing biological processes. 
One method of investigating a potential link between P2X7R and AC in humans 
with CKD might be to assess whether SNPs that alter receptor function associate 
with disease severity. Whilst possible, major barriers would need to be overcome 
before performing such an analysis. Firstly, whilst a number of P2X7R SNPs are 
described, many have minor allele frequencies of less than 5% (Wiley et al 2011, 
Gartland et al 2012). Therefore a large patient cohort would be required to detect any 
association with disease. Secondly, one would need to consider how to detect arterial 
calcium deposition within the vessel media in these subjects. In practical terms this 
would probably need to be achieved using radiological methods, however plain X-
rays and CT scanning cannot reliably discriminate between intimal and medial 
calcification (Sigrist et al 2007, Marinelli et al 2013). Newer generation ultrasound 
machines can distinguish between the two locations in superficial vessels such as 
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femoral, carotid and brachial arteries (Coll et al 2011) but evaluating calcification in 
more central sites such as the abdominal aorta or coronary arteries may be less 
straightforward. Finally, coronary artery calcification is now usually measured in 
terms of an Agatston score (Agatston et al 1990). This is a well-validated clinical 
tool permitting a quantifiable assessment of disease progression. However at present, 
and as commented on by some authors (Vezzoli et al 2014), no such method exists 
for gauging the extent of ultrasonically detected calcification in peripheral arteries. 
Defining ‘progression of AC’ in this setting therefore becomes problematic. 
In summary, the results in this thesis do not support a role for P2X7R in the 
pathogenesis of CKD-associated AC. The role of the receptor in mediating disease 
has been evaluated rigorously within the limitations of the available experimental 
models. Optimisation and/or development of superior experimental systems to study 
this disease process will be required in order to definitively confirm redundancy of 
P2X7R in this clinical context. Studies in man are feasible but may first require 
resolution of some logistical, practical and technical issues. 
7.3 Vascular ATP Metabolic Pathways And Arterial Calcification 
Whilst the work described in Chapters 3-5 was aimed at testing a central hypothesis 
(i.e. that P2X7R mediates AC), the work in Chapter 6 was more ‘hypothesis 
generating’, as it was conducted as a preliminary exercise to assess the expression of 
enzymes involved in ATP-metabolism in normal and uraemic, calcified arteries. The 
findings from these experiments are both novel and intriguing, possibly in keeping 
with an adaptive, defensive response by the vasculature against persistent uraemia 
and subsequent calcium deposition. It should therefore now be considered what steps 
are required to prove or refute this hypothesis and, in addition, what the future 
implications may be. 
The most relevant function of the ATP-metabolising system in relation to AC is the 
regulation of extracellular PPi. All components of this pathway can seemingly 
influence the level of this molecule either directly or indirectly – ENPP-1 and TNAP 
by direct generation and hydrolysis respectively (Terkeltaub 2001, Murshed et al 
2005), ANK by transmembrane transport (Terkeltaub 2001) and CD39 by regulating 
the amount of ATP available for ENPP-1 (Kaczmarek et al 1996) (Figure 1.2). The 
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relationship between ENPP-1, TNAP and ANK in determining local PPi 
concentration has been shown to be critically important in relation to skeletal bone 
formation (Harmey et al 2004) and a similar situation may well occur in the 
vasculature regarding AC. Given these observations, a key piece of information 
required is how the function of each of these proteins changes in CKD and 
moreover, how these changes relate to each other in terms of time and function. In 
the current work, the activity of only one enzyme, ENPP-1, was examined. Therefore 
the effect of both uraemia alone and subsequent calcification needs to be confirmed 
for all components of this pathway in a larger sample size. To this end it might be 
preferable to employ the 5/6
th
 nephrectomy model of disease as it is likely to result in 
a greater number of animals with renal impairment that do not develop AC as 
compared with the adenine model (Neven & D’Haese 2011) thereby permitting a 
better evaluation of the effect of uraemia in isolation. This would also serve to 
exclude any change in these enzymes specifically induced by adenine. Studies on 
human vessels will also be valuable in terms of establishing the net changes in 
expression but in practical terms are unlikely to be helpful in assessing the time-
course of events. When this information is obtained, future research aiming to 
examine any individual component of this system in the context of CKD will need to 
ensure that appropriate expression profiles of all other proteins in this pathway are 
present in order to draw translatable conclusions. 
ENPP-1 deficiency is unquestionably associated with arterial calcium deposition. 
Rare human conditions such as GACI (Rutsch et al 2003), Pseudoxanthoma 
elasticum (Nitschke et al 2012) and Cole disease (Eytan et al 2013), all of which 
have ectopic calcification as part of the disease phenotype, can arise due to mutations 
in the ENPP-1 gene. It might therefore intuitively seem that an increase in enzyme 
activity, as observed in this work in uraemic subjects, would be protective. However, 
mutations in this gene can also cause ARHR (Levy-Litan et al 2010), a disease of 
deficient skeletal mineralisation, so the situation is far from straightforward. Very 
few studies have examined the expression of ENPP-1 in relation to AC, but those 
that have been published differ somewhat in their findings. Nitschke et al (2011) 
found decreased expression in human carotid artery calcified atherosclerotic plaques, 
whereas Cote et al (2012a) reported an increased expression in human calcified 
aortic valves. These studies examined pathologies slightly removed from medial AC 
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and were performed in non-uraemic patients. However, taken together all these 
observations illustrate the complexity of ENPP-1 in this clinical context and 
emphasise the need for further work to better understand its exact role, especially in 
relation to CKD. 
How might the functional effect of increased ENPP-1 activity be investigated 
experimentally? One approach might be to compare arterial ENPP-1 overexpression 
with WT tissue in uraemic, pro-calcifying conditions. ENPP-1 has been successfully 
overexpressed in a number of sites in mice including liver, muscle, brain and adipose 
tissue (Maddux et al 2006, Pan et al 2011). Arterial expression was not commented 
on in these reports. The obvious barrier to overcome in employing this methodology 
in vivo is finding a suitable CKD-AC model, the potential options for which have 
been discussed above. As an alternative, it would be interesting to assess whether in 
the ex vivo model, the addition of uraemic serum to the culture medium might better 
simulate in vivo conditions compared with just the addition of supplementary 
phosphate as used in this thesis. Supplementing culture medium with uraemic serum 
has been previously employed to examine other factors thought to influence AC in 
the context of uraemia (Lomashvili et al 2008, Kramann et al 2011).  
There are currently limited alternative options for directly examining the effect of 
increased ENPP-1 activity. In man, SNPs of the ENPP-1 gene are generally ‘loss-of 
function’ and although putative ‘gain-of-function’ mutations are described these are 
thought not to interfere with the catalytic site of the protein (Terkeltaub 2006). 
Pharmacological activators of the enzyme are not yet available as the molecular 
structure has only recently been determined (Kato et al 2012). Primary cells could be 
directly genetically manipulated to overexpress the protein but subsequent 
experiments will be limited and their translational relevance questionable, as alluded 
to throughout this thesis. As an indirect strategy, the response of increasing the 
substrate (i.e. ATP) for the enzyme could be examined, although it would need to be 
confirmed that subsequent metabolism of the nucleotide was occurring via ENPP-1 
and not via alternative pathways (such as CD39). Possibly the easiest way to ensure 
these criteria are met would be to conduct experiments using CD39-deficient vessels, 
in parallel with suitable control tissue.  
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If ENPP-1 is up-regulated as a protective response against uraemic toxins and 
ensuing arterial calcium deposition it might point towards CKD being a state of 
‘relative PPi deficiency’. This concept is supported by in vivo studies which have 
prevented the development of AC in uraemic animals by direct administration of PPi 
(O’Neill et al 2011, Riser et al 2011). However, there is a question as to whether this 
relative deficiency is because PPi is all hydrolysed by TNAP or because it is all 
incorporated into the expanding hydroxyapatite. Alternatively, do uraemic conditions 
perhaps render ENPP-1 less efficient at producing PPi or even cause PPi to be less 
efficient at preventing calcification? It is also unclear what exactly is regulating the 
altered expression and activity of ENPP-1 (and other enzymes). Answering these 
questions may provide insight into the regulation of the calcification process overall 
and indicate some potential therapeutic targets.  
If the aim of future therapy does prove to be attenuating a relative deficiency of PPi, 
it is worth speculating on the potential options. Bisphosphonates, which are 
analogues of PPi, prevent AC in uraemic rodents (Price et al 2006) and improve the 
prognosis in GACI (Rutsch et al 2008). However, these agents are likely to result in 
disrupted bone homeostasis in the setting of CKD (Lomashvili et al 2009) and are 
also directly nephrotoxic (Perazella & Markowitz 2008) thus limiting their use in 
this setting. PPi itself reduces AC in rodents, but has a very short half-life if given 
orally (Schibler et al 1968) and this would seem to restrict its use clinically. 
However, it is unknown how much PPi is deposited within the vessel wall (the actual 
target site) and, in addition, the bioavailability of PPi can be increased by ip 
administration (O’Neill et al 2011). Further research into the pharmacology of this 
agent is therefore needed but there is reason to be optimistic about its potential 
therapeutic use in the future. Some work has been conducted in vitro to determine 
whether TNAP inhibitors might be a useful treatment strategy by minimising PPi 
breakdown (Narisawa et al 2007). These drugs were effective at attenuating 
calcification in these models but in vivo analysis is clearly required as there may well 
be undesired side-effects of these agents, particularly relating to bone homeostasis.  
Might increasing PPi production be an option? An inhibitor of CD39 would 
theoretically increase the available ATP for ENPP-1 production of PPi. Of interest, 
the ecto-ATPase inhibitor ARL67156, which has been shown to suppress the activity 
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of both CD39 and ENPP-1 (Levisque et al 2007), attenuated aortic calcification in 
warfarin-treated rats (Cote et al 2012b). However, this study by Cote et al is 
intriguing in that it failed to detect expression of CD39 mRNA in the vasculature (in 
complete contrast to the present study and others (Behdad et al 2009, Villa-Bellosta 
et al 2011a) where this enzyme was found to be extremely abundant). These findings 
therefore clearly need to be confirmed with a detailed assessment of the mechanisms 
involved. Finally, as a speculative and theoretical concept, enzyme replacement 
therapy is used in conditions such as Fabry’s disease to correct deficiencies of 
proteins vital to maintain normal physiology (Rozenfeld & Neumann 2011). Perhaps 
in the future, if supported by research, it might be possible to develop and administer 
recombinant ENPP-1 in the hope of preventing, or slowing the progression of, AC in 
patients with CKD.  
7.4 Conclusion 
Arterial calcium deposition occurring in the setting of CKD is a complex, likely 
multifactorial process. Current experimental models to study the pathophysiology of 
this condition have a number of limitations and may not closely simulate human 
disease, making it difficult to draw consistent conclusions. P2X7R does not appear 
to be a mediator of CKD-associated AC however improved models are required to 
confirm this. The arterial expression of enzymes involved in the metabolism of ATP 
does seem to change in AC and future work should focus on gauging the clinical 
relevance of this in order to better understand the mechanisms underlying the disease 
and potentially develop new therapeutic interventions. 
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